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I  GENERAL INTRODUCTION 
Chapter 1 Background 
 1.1 Overall objectives of thesis 
The successful completion of the human genome project has created an enormous 
amount of information and also generated many scientific insights about future drug 
therapy. One major interest that has risen over the years is the possibility of 
personalized medicine. Pharmacogenomics is the driving force of personalized 
medicine that uses genetic analysis to understand the interaction between drug therapy 
and the genetic makeup of an individual (Evans and McLeod 2003). This information 
may allow us to design individual-based medicine to increase efficacy, reduce side 
effects and avoid adverse drug reactions (ADR). 
One of the most significant works to date in the area of pharmacogenomics is the 
discovery of Single Nucleotide Polymorphisms (SNPs). There is limited sequence 
variation between any two individuals so there is great interest in identifying these 
unique genetic differences. Of these genetic differences, over 90% are single 
nucleotide polymorphisms (Deloukas and Bentley 2004). A SNP is a single base 
substitution of one nucleotide with another, and is observed in the population at a 
frequency of at least 1%. There are concerted efforts to genotype all human variations, 
especially SNPs across the human genome in large populations. By studying SNP 
profiles, genes associated with any human trait such as disease susceptibility or 
aberrant drug response can be revealed. Association studies can detect and indicate 
which particular SNP profile is most likely to be associated with the genes of interest. 
Eventually, panels of SNP profiles that are characteristic of a variety of diseases will 
be established and therefore be used for screening individuals for susceptibility to 
disease or drug sensitivity by analyzing their DNA. It is envisaged that 
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pharmacogenomics has the potential to predict interindividual pharmacokinetic 
differences by genetic polymorphisms of drug transporters/enzymes or 
pharmacokinetic changes by transporter-mediated drug interactions (Evans and 
McLeod 2003). By predicting the bioavailability profiles based on this genomic 
information, drug toxicity such as adverse drug reactions (ADRs), and loss of drug 
efficacy due to underdosage, would be prevented. 
While SNPs are abundant in the human genome, the majority of these SNPs may be 
neutral or benign variations. Therefore the next challenge is to search for the causal 
variants responsible for inter-individual variability in drug response or disease 
susceptibility. This can be facilitated by rudimentary knowledge of target genes and 
the discovery of novel technology for mapping genetic variation in individuals. 
Keeping in view that SNP profiles of drug transporters in individuals and populations 
are variable, this thesis has 2 main objectives: 
1. To develop a cost-effective SNP genotyping method for the purpose of mid- to 
high-throughput analysis of multiple SNPs; 
2. To characterize the haplotype and linkage disequilibrium profiles of 2 
nucleotide analog transporters, ABCC4 and ABCC5, for future gene-based 
association studies; 
As the objectives of this thesis cover a wide spectrum, at least one chapter is devoted 
to each objective in the sections on Methods and Materials, Results and Inferences. 
The final section of General Discussion closes this thesis with an overall discussion 
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1.2 SNP genotyping strategies  
Single nucleotide polymorphisms are by far the most abundant form of genetic 
variation (about 90% of all human genetic variation), occurring every 100 to 300 
bases along the 3-billion-base human genome (Cargill et al. 1999). Although more 
than 99% of human DNA sequences are the same across the population, it is thought 
that many complex human phenotypes have a significant genetic component and the 
variability is likely to be a result from differences in SNP genotypes (Meyer 2004). 
Given the importance of SNPs in pharmacogenetics and pharmacogenomics, it is no 
small wonder that there has been an impressive development in SNP genotyping 
technologies over the past few years, especially the push for more cost-effective high-
throughput assays. DNA microarrays and mass spectroscopy are still too expensive 
for the average laboratory, so other alternative methods, preferably scalable, liquid-
based and amenable for multiplexing have to be developed. 
A genotyping strategy typically consists of 3 main components: target DNA 
amplification, followed by allelic discrimination and signal detection (Chen and 
Sullivan 2003). Most current methods are assortments of different methods of allelic 
discrimination and signal detection (Gray et al. 2000; Kwok 2001; Chen and Sullivan 
2003). 
Target DNA amplification is a critical step to generate enough copies of specific 
amplicons containing the SNP of interest. Most genotyping methods therefore begin 
with the Polymerase Chain Reaction (PCR). The Invader® technology marketed by 
Third Wave Technologies (Hsu et al. 2001) is currently the only method which is able 
to eliminate the need for amplification of sample DNA by genotyping directly from 
the human genome. Therefore the total cost of PCR can be of significance to most 
genotyping methods (Chen and Sullivan 2003). One way to increase efficiency is to 
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amplify several amplicons, each containing SNPs of interest, in a single reaction 
(Henegariu et al. 1997). Multiplex PCR is not without its problems. With multiple sets 
of primers, there may be nonspecific or uneven amplifications (Henegariu et al. 1997). 
The presence of gene families such as the ATP-Binding Cassette (ABC) Superfamily 
of transporters, as well as pseudogenes and other conserved sequences in the genome 
can give rise to false genotypes.  
In some genotyping methods such as those that involve primer extension, a clean-up 
step needs to be performed to free the products of the PCR reaction from excess 
dNTPs and PCR primers. Generally, there are three ways to do a post-PCR cleanup 
for genotyping purposes. Extracting desired products via electrophoresis on an 
agarose gel is not considered a viable method here as quantity loss from small 
volumes of PCR reaction is not acceptable and this would also run contrary to the 
benefits of multiplex PCR. The first method of PCR clean-up is the use of magnetic 
beads for DNA binding and elution of PCR products after washing away primers. The 
second method uses ultrafiltration to retain PCR products via a spin column while 
primers and excess dNTPs are removed. The PCR products can be eluted off the 
membrane after washing. The last method, is to enzymatically cleave excess dNTPs 
and PCR primers using shrimp alkaline phosphatase (SAP) and E.coli exonuclease I 
(Exo I) respectively.  
Allelic discrimination can be divided into 2 categories: sequence non-specific or 
sequence specific (Kwok 2001). Sequence non-specific methods of allelic 
discrimination such as heteroduplex analysis and Denaturing High-Performance 
Liquid Chromatography (dHPLC), make use of the different electrophoretic ability or 
molecular sizes of either heteroduplexes or single-stranded DNA molecules. Unless 
modified, they are not useful in genotyping known variants. 
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The assay chemistry of sequence-specific allelic discrimination methods includes 
allele specific hybridization, polymerase extension, oligonucleotide ligation, and 
enzymatic cleavage (Syvanen 2001). A different enzyme is used in each of these 
methods, namely DNA polymerases, DNA ligases, and structure-specific enzymes. 
Allele specific hybridization makes use of two allele-specific probes, each designed to 
anneal to the target sequence only if the both sequence and probe are perfectly 
complementary.  In allele-specific extension (ASE) and allele-specific PCR (AS-
PCR), DNA polymerases extend far more efficiently in matched sequences than 
unmatched ones. The allele-specific primers are differentially labeled with tags for 
determination of genotype. In Single-Base Extension (SBE) or minisequencing, DNA 
polymerase extends one base pair 3’ of a probe designed to anneal immediately 
upstream of a polymorphic site. Differentially labeled ddNTP are used instead of 
dNTP to label and terminate the extension. In pyrosequencing, detection is based on 
the formation of pyrophosphate as a byproduct of DNA polymerization. DNA 
polymerase catalyzes the incorporation of the deoxynucleotide triphosphate into the 
DNA strand, if it is complementary to the base in the template strand. Each 
incorporation event is accompanied by release of pyrophosphate (PPi) in a quantity 
equimolar to the amount of incorporated nucleotide. The addition of dNTPs is 
performed separately so that signals can be correlated to calling of genotype. The 
ability of DNA ligases to repair minor nicks in DNA is made used of in 
Oligonucleotide Ligation Assays (OLA). Ligation of two adjacent oligonucleotides 
annealed on target DNA only occurs in the presence of DNA ligase and only if the 
oligonucleotides perfectly match the template at either end of the ligation sites. Lastly, 
enzymatic cleavage by specific enzymes can also be used for allelic discrimination. 
The 5’ nuclease activity of DNA polymerases can cleave a probe annealing at a SNP 
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site. If the probe is not perfectly annealed to the template, it will not be cleaved. In the 
Taqman assay, two dually labeled probes are used for allele discrimination. Some 
DNA polymerases with endonuclease activity can cleave complexes formed from the 
hybridization of overlapping oligonucleotide probes. The probes are designed so that 
the polymorphic site is at the point of overlap. When there is no overlap as in the case 
of a primer with a one-base mismatch, there is no cleavage. The Invader assay makes 
use of 2 allele-specific oligonucleotides such that one of the two would be cleaved 
and release a 5’ arm. The released 5’ arm can be used in a secondary reaction for 
greater signal amplification (Hsu et al. 2001).    
While a definite genotype of a known SNP variant can be ascertained with any of the 
methods, each of them has its own advantages and disadvantages. Various detection 
methods such as fluorescence, colorimetry, chemiluminiscence and mass 
spectrometry also influence choice of a genotyping platform (Kwok 2001; Chen and 
Sullivan 2003). All methods can be fairly robust. SBE or minisequencing is almost as 
specific as DNA sequencing because the chemistry is the same in both cases except 
that the products of SBE are only one base longer than the probes used. This means 
that both SBE and sequencing may be performed on the same automated platform. 
This can be extremely cost saving since an existing sequencing machine in a facility 
can also be used for genotyping SNPs as well as discovering new ones. SBE also 
requires the least number of probes and all probes used are normal or HPLC purified 
oligos that are by far cheaper than labeled probes. Pyrosequencing is quantitative and 
so may be used for pooling samples when analyzing genotypes in large populations 
(Sham et al. 2002). Furthermore, it is able to perform single-tube haplotyping and 
thereby genotype multiple close SNPs (Pati et al. 2004). OLAs are potentially highly 
specific but the slow rate of reaction and the large numbers of modified probes 
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required are two of its disadvantages. The Invader assay is able to genotype an SNP 
directly from genomic DNA without prior amplification. On the other hand, the 
Invader assay requires more DNA than most genotyping methods and the design and 
purity of the probes is crucial (Kwok 2001). Pati et al., 2004, have compared SBE, 
pyrosequencing and the Invader assay and found them all favorable for the use in high 
throughput genotyping with minor differences in accuracy, cost and throughput (Pati 
et al. 2004). Lee et al., compared 4 methods of SNP genotyping (ASE, SBE, OLA, 
and direct hybridization) objectively by using the same flow cytometer as platform. 
They found that SBE is the most robust assay but is also comparatively more 
expensive, due to its inability to genotype both alleles in a single reaction (Lee et al. 
2004b). The ASE assay was both cheaper and simpler than SBE.  
The choice of a genotyping strategy is affected by many considerations, amongst 
which are accurate results, cost per SNP/sample and ease of optimization/use. In this 
thesis, SBE or minisequencing was adopted as the genotyping strategy based on 
previous reports for its high accuracy (Syvanen 2001). Its ability to genotype multiple 
SNPs in a single reaction, scalability to 96 samples, robustness and cost-effectiveness 
were deemed critical for haplotype and linkage disequilibrium studies of moderate 
sample sizes. There is no need for the purchase of a dedicated machine for genotyping 
as the same platform was also used for dideoxy sequencing (still the ‘gold standard’ 
for verifying sequences). The laboratory was therefore able to perform sequencing for 
novel SNP discovery as well as SBE for large-scale genotyping of these SNPs using a 
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1.3 Population-based genetic association studies 
Complex genetic diseases are familial disorders that are not attributable to a single 
dominant or recessive gene but to several genes contributing to the disease in a 
multiplicative or additive fashion. Polygenic inheritance also plays a significant role 
in the display of inter-individual variability in the therapeutic response to current 
clinical medicine. The genes involved in complex genetic diseases and variable drug 
responses are therefore harder to detect due to the small effects of each of the multiple 
component genes involved. There has been a shift in recent years to meet these 
challenges from linkage analysis to population-based genetic association studies. 
(Reich et al. 2001; Goldstein et al. 2003). While linkage analysis studies have been 
successful for rare single-gene defects, they have not been equally adept at locating 
causal variants responsible for complex gene diseases.  
The approach to designing a population-based genetic association study is remarkably 
simple. Allele frequencies of a genetic variation (e.g. Single Nucleotide 
Polymorphism or Haplotype) in a candidate gene are compared between 2 groups of 
individuals, affected cases and unaffected controls. By testing candidate variations, it 
is theoretically possible to identify all the variants responsible for complex genetic 
diseases or variable drug responses. However, it would be both time-consuming and 
expensive to make an exhaustive and comprehensive comparison of all SNP sites, 
even with today’s technology and corroborative electronic databases. One of the 
advantages of using population-based genetic association studies is that individuals 
can be selected to match the study e.g. for age and gender. Risks of contribution from 
the environment or non-genetic background can be assessed (Goldstein 2001; 
Goldstein and Weale 2001). Small genotypic effects from a relatively modest 
collection of cases and controls can be detected. By and large, unrelated individuals 
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are easier to obtain in numbers compared to families, trios (father-mother-child), 
siblings or twins.    
 
1.4 SNPs and Haplotypes 
Haplotypes are defined as specific combinations of alleles on an individual 
chromosome (Hoehe 2003). Traditionally, SNPs within and around genes were tested 
to correlate candidate genes with disease. Doubts concerning single SNP approaches 
have recently surfaced with studies demonstrating better correlation of complex 
phenotypes with haplotypes rather than with single SNP variants (Davidson 2000; 
Drysdale et al. 2000; Hoehe 2003). The argument for the use of haplotypes over SNPs 
is based on the evidence that single SNP-based candidate gene studies may be 
statistically weak in complex phenotypes. True associations may not be reflected due 
to low significant power and negative correlation with a single SNP does not exclude 
a positive correlation with the gene of interest. 
 
1.5 Haplotypes and linkage disequilibrium 
Linkage disequilibrium occurs when the observed frequencies of haplotypes in a 
population deviate from the haplotype frequencies predicted by multiplying together 
the frequency of individual genetic markers in each haplotype (Zondervan and Cardon 
2004) (Figure 1). When there is no such deviation, then the population is said to be in 
linkage equilibrium. This observation that there is non-random association of alleles 
at different loci is of importance. The basis of using LD mapping relies on the fact 
that haplotypes are often associated with reasonably common diseases that have 
complex genetic origins. Identifying haplotypes may therefore make it easier to link 
them to specific complex diseases.  
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Figure 1.  Linkage Disequilibrium and Linkage Equilibrium. Loci 1 and 2 are marker 
SNPs in close proximity. Panel A: When one allele (e.g. red) of Locus 1 is completely 
linked to another allele (e.g. yellow) of Locus 2, they are in complete linkage 
disequilibrium (i.e. LD = 1). Panel B: When the alleles of the two loci are completely 
unlinked, then complete equilibrium has occurred. Panel C: Alleles of the two loci are 
linked by different degrees, giving rise to a measurable LD value between 0 and 1.  
 
The extent of LD is dependent on several factors both on the molecular level such as 
recombination and mutation rate as well as demographic and evolutionary factors 
such as migration, population growth and admixture between populations.  
There are two main measures of LD, |D’| and r2. Both are based on the Lewontin’s D. 
The first measure is derived from D, which measures the difference between the 
observed haplotype frequency and the expected haplotype frequency if the alleles are 
randomly segregating. D’ is obtained by dividing D over Dmax, the maximum D 
possible for a given set of allelic frequencies at any two loci. When |D’| is null, there 
is linkage equilibrium. When |D’| equals to one, there is complete linkage 
disequilibrium (Zondervan and Cardon 2004). The main disadvantage of using |D’| is 
that it can get highly inflated, especially in small sample sizes. It is also sensitive to 
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allele frequencies and can be inflated in SNPs with rare allele frequencies (Zondervan 
and Cardon 2004). The ‘half length’ LD is the distance at which the average D' value 
drops below 0.5 (Zondervan and Cardon 2004). 
The next measure of LD, r2, determines the correlation of alleles at two loci. When r2 
=0 there is perfect linkage equilibrium. When r2=1 there is perfect linkage 
disequilibrium. r2 has the advantage over |D’| in that it does not get inflated in small 
sample sizes and/or when the loci have rare alleles (Shifman et al. 2003). r2 is 
therefore more appropriate when association studies are of interest. For pairs of 
biallelic markers, D' will be equal to 1.0 when one or two out of the four possible 
haplotypes are missing from the population, while r equals to 1.0 when there are only 
two haplotypes (Zondervan and Cardon 2004). When recombination does not occur 
between two markers, D' will be 1.0 (in the absence of mutation or genotyping error), 
while r will be dependent on allele frequencies of both markers. D' is therefore used 
as a model for recombination rates and r or r2 as a model for association power. 
The degree of LD between 2 alleles is dependent on how old the two polymorphisms 
are i.e. when they appeared in the populations and the degree of recombination 
between them. Reich et al., estimated the D’ in the genome to be 60 kb by studying 
unrelated individuals in a United States population of north-European descent (Reich 
et al. 2001). The authors measured LD between two SNPs using the classical statistic 
D' as 'half length' LD. A study by Gabriel et al., estimated that half the human genome 
exists in blocks of 22 kb or larger in African and African American populations and 
44kb or larger in European and Asian populations (Gabriel et al. 2002).  
Markers that are in close proximity generally have stronger LD than those located far 
apart. Whilst there is some correlation of LD with genomic distance, it has been 
recently shown that there is also variation in the extent of LD. Demographic processes 
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can also affect LD. Population expansion can decrease LD (Kruglyak 1999) while 
population bottlenecks and population structure tend to increase LD. 
 
1.6 Gene-based versus genome-based approaches  
One of the famous Mendelian laws of inheritance states that hereditary factors are 
inherited independently (Independent Assortment). Therefore the presence of having 
one type of gene should not be influenced by the presence of another gene. In reality 
genes are often linked and thereby inherited together as a unit. As such, individuals 
often inherit stretches of DNA from their parents.  The genome can therefore be 
segregated into segments of chromosomal sequence within which sets of common 
SNPs exist in high LD. Apparent sites of recombination called “recombination 
hotspots” punctuate these segments or “blocks” (Zhang and Jin 2003). This suggests 
that there is a haplotype block structure in the human genome. These haplotype blocks 
can thus serve as organization units to establish genome-wide LD mapping. 
The length of each haplotype is of interest as it reflects the extent of LD. LD has been 
found to extend to 60-100 kbs in European populations as compared to a few kbs in 
African populations (Abecasis et al. 2001; Daly et al. 2001; Goldstein 2001; Patil et al. 
2001; Reich et al. 2001; Rioux et al. 2001; Bonnen et al. 2002; Dawson et al. 2002; 
Gabriel et al. 2002). Within these haplotype blocks, there are a limited number of sets 
of observed haplotypes. Because of the limitation of genetic diversity withi each block, 
a small subset of common SNPs might be sufficient to define the majority of the 





Genetic Characterization of Nucleotide Analogue Transporters ABCC4 and ABCC5 Gene Loci 
1.7 Gene-based haplotypes 
Just as genome-based haplotypes are based on combinations of alleles at sites across a 
chromosomal segment, gene-based haplotypes represent combinations of alleles at 
markers in a gene. These markers may be SNPs, Restriction Fragment Length 
Polymorphisms (RFLPs), Short-Tandem-Repeats (STRs) or microsatellites. 
Regardless of allele frequency, any causative allele in strong LD with any of the 
selected markers will be represented in the haplotypes. Gene-based haplotypes are 
much more precise than single SNP markers as they represent more heterozygosity 
and contain the entire LD structural information. As such, they will have greater 
power in elucidating the unobserved causative allele (Judson and Stephens 2001). 
 
1.8 Haplotype reconstruction 
To unambiguously determine haplotypes, one could either directly genotype pedigrees 
or use molecular methods in conjunction with genotyping individual samples if 
pedigrees are not available. Directly genotyping pedigrees relies on the fact that 
closely-located markers (as haplotypes) will be inherited as a unit unless separated by 
recombination events. Assigning haplotypes to pedigrees is laborious and expensive 
as well as increasingly difficult as the number of loci increases. Molecular and 
experimental methods are unambiguous methods for constructing haplotypes if 
pedigrees are not available. These methods include the allele-specific polymerase 
chain reaction (AS-PCR) and the use of somatic cell hybrids (Zhang et al. 2005). 
These techniques are used in small populations, as they are also laborious and 
expensive to perform on large number of loci or large sample pools.  
Statistical inference of haplotypes from genotype data in large population studies thus 
remains the most viable method. To date, there are three principal computational 
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methods that haplotype inference software can be categorized into: parsimony, 
maximum-likelihood, and Bayesian (Lin et al. 2002; Crawford and Nickerson 2005). 
The Clark statistical algorithm utilized in the software programs HAPINFERX and 
HAPINF is based on parsimony. Clark's method (Clark 1990) first lists known 
haplotypes from unambiguous genotypes i.e. haplotypes in homozygous individuals 
and individuals with no more than one heterozygous locus. The algorithm then 
attempts to resolve ambiguous genotypes into one of the known haplotypes until they 
are inconsistent with any inferred haplotypes.  It is not popular even though it is 
relatively fast and does not assume Hardy-Weinberg Equilibrium (HWE), because the 
level of ambiguity increases with the number of polymorphic sites considered or at 
which an individual is heterozygous (Niu 2004). The maximum likelihood is 
implemented via the expectation-maximization (EM) algorithm (Excoffier and Slatkin 
1995; Hawley and Kidd 1995; Long et al. 1995) in the software programs Arlequin 
[http://lgb.unige.ch/arlequin/], HAPLO [http://krunch.med.yale.edu/haplo], and many 
others. These programs make use of the EM algorithm to optimize the probability of 
finding the sample of observed genotypes by calculating the frequency of possible 
haplotypes (Excoffier and Slatkin 1995; Fallin and Schork 2000). Each genotype is 
thus assigned the haplotype pair with the highest frequency amongst all other 
haplotype pairs. The EM algorithm is arguably the most popular statistical algorithm 
of all three methods, because it is easy to interpret, is fairly stable, and is based on 
well-established statistical properties (Qin et al. 2002).  Its performance is also not 
much affected by deviation from HWE although the EM algorithm makes an explicit 
assumption of HWE (Niu et al. 2002; Niu 2004). One of the caveats in using the EM 
algorithm is that the results are dependent on the initial value of haplotype frequencies 
being reasonably close to the true population frequencies. The existence of local 
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maxima can result in a false maximum-likelihood estimate and this problem can be 
elevated as the number of polymorphisms increases (Niu 2004). Most EM-based 
approaches are best restricted to analysis of less than twenty loci (Zhang et al. 2005), 
because they are too computationally intensive and cannot handle very large numbers 
of potential haplotypes. The partition-ligation (PL) algorithm as in the PL-EM 
software [http://www.people.fas.harvard.edu/~junliu/plem/] is a derivative method 
incorporating Bayesian Monte Carlo statistics into the basic expectation-maximization 
(EM) model to increase input capacity (Niu et al. 2002). It first divides the region into 
artificial blocks and uses the EM algorithm to construct haplotypes within each block. 
The haplotypes are then ligated via the EM algorithm. Another recently developed 
program, SNPHAP [http://www-gene.cimr.cam.ac.uk/clayton/software/snphap.txt] 
adopts a progressive-extension technique to handle large numbers of linked loci. SNPs 
are added progressively as haplotype frequencies are estimated and low-frequency 
ones are discarded (Qin et al. 2002). Both the partition-ligation and progression-
extension derivative methods give consistent results but handle only biallelic SNPs. 
Lastly in software programs such as PHASE 
[http://www.stat.washington.edu/stephens/software.html] and HAPLOTYPER 
[http://www.people.fas.harvard.edu/~junliu/Haplo/docMain.htm], the approach is 
based on a Bayesian framework calculated via the Markov chain–Monte Carlo 
(MCMC) technique. Both methods implement a Gibbs sampler for construction of a 
Markov chain for haplotype frequencies. Unknown haplotypes are regarded as 
unobserved random quantities and are sampled by consideration of the conditional 
distribution of the genealogy that underlie the genotype data of randomly sampled 
individuals, as described by coalescence theory (Stephens et al. 2001). These 
Bayesian-based methods are relatively fast, handle large numbers of loci (in the 
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hundreds) and also allow missing genotype data. However, as PHASE imposes a 
coalescent assumption model on the distribution of unknown haplotypes (as opposed 
to PL-EM), it would perform better than PL-EM when the assumption is valid and 
worse than PL-EM when the assumption is not (Zhang et al. 2005).  
The main disadvantage of using statistical inference programs is that there is a 
likelihood that a proportion of inferred haplotypes may be incorrect. The uncertainty 
in constructing haplotypes will lead to a loss of power in testing for an association 
with a disease and therefore should be kept to as low as possible. Lin et al., 2002 
showed that using a modified Stephens-Smith-Donnelly (SSD) algorithm in a Markov 
chain–Monte Carlo technique, accuracy of haplotype inference is higher using only 
common polymorphic sites rather than including all loci (Lin et al. 2002). It is 
reassuring to note that any of EM or Bayesian-based haplotype inference methods 
performed almost equally well in both real and simulated studies, resolving 
haplotypes of at least 1% frequency (Adkins 2004; Xu et al. 2004), although Niu 
highlighted the sensitivity of these programs to haplotype diversity (Niu 2004). There 
is therefore a high probability that any of these methods would be able to detect a 
haplotype that carries a disease risk or phenotypic trait in a significant proportion of 
the population. 
In this study, two programs based on EM, Arlequin, and SNPHAP for haplotype 
inference were chosen. For data sets less than 20 polymorphic sites, Arlequin was 
implemented. For data sets more than 20 polymorphic sites and only if these sites are 
biallelic markers, SNPHAP was more suitable. For data sets of approximately 20 
polymorphic sites and requiring analysis of trio data, the Bayesian-based program 
TAGIT [http://popgen.biol.ucl.ac.uk/people/mw/mike_home.html] was more adept at 
handling multiple SNP loci in a short time.  
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1.9 Haplotype tagging  
Whilst the costs of genotyping have gone down considerably with the advent of high-
throughput techniques, the number of markers to analyze for any candidate gene or a 
specific region of interest is still too overwhelming to perform for the average 
laboratory. The presence of LD patterns offers a possibility to select a smaller subset 
of markers by discarding those markers that are in high LD. Haplotype tagging is a 
means of selecting a set of non-redundant markers from an initial given set of densely 
spaced SNPs to retain the most information about the dense map. These markers have 
variously been called “haplotype-tagging SNPs”, “htSNPs”, “tagSNP”, “tagging 
SNPs”, or “tSNPs”. Tagging SNPs (tSNPs) are therefore particularly useful in 
association studies as they explain the majority of LD patterns within the markers and 
reduce genotyping effort significantly without reducing resolution (Johnson et al. 
2001). 
Several statistical methods have been developed for the identification of tSNPs. In 
general, these SNPs can be determined via haplotype-based or linkage disequilibrium-
based methods. At present it is unknown which of these methods are truly superior 
(Halldorsson et al. 2004b). Haplotype-based methods select tSNPs through optimizing 
resolution of existing haplotypes and are therefore reliant on correctly inferred 
haplotypes (Zhang et al. 2002; Sebastiani et al. 2003).  Furthermore the generation of 
large numbers of haplotypes from highly-dense sets of markers within most candidate 
genes and genomic regions mean that the most common haplotype may not have a 
population frequency of more than 5% (Crawford and Nickerson 2005). Incorrectly 
inferred and large number of haplotypes may therefore potentially reduce the 
efficiency and accuracy in which tSNPs can be inferred. The earliest method by 
Johnson 2001 simply resolves haplotypes generated while recent and more complex 
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haplotype-based algorithms construct haplotype blocks as part of their algorithm 
(Zhang et al. 2002; Ke and Cardon 2003). This assumption of haplotype blocks within 
the genomic area under study may limit haplotype-based algorithms to be performed 
on genes with simple haplotype architecture.  In LD-based algorithms (Ke and Cardon 
2003; Stram et al. 2003; Wang and Xu 2003; Weale et al. 2003; Carlson et al. 2004; 
Halldorsson et al. 2004a), a quality measure is used to define a set of tagging SNPs 
that can capture the variance observed. Most of these LD-based methods set a 
minimum arbitrary threshold of a pair-wise LD measure such as r2>0.85 (Wang and 
Xu 2003; Weale et al. 2003; Carlson et al. 2004) so that the selected tSNPs resolve the 
majority of the haplotypes. While some groups elected to select tSNPs based on pair-
wise r2 values with the tagged SNPs, Weale et al., 2003 used a multilocus linkage 
disequilibrium measure, haplotype r2, as a metric of information to select minimum 
informative subsets of tSNPs (Goldstein et al. 2003; Weale et al. 2003). Using a 
simplistic LD measure as r2 is easy to interpret but may be inefficient due to the 
generation of large numbers of tSNPs (Goldstein et al. 2003). Linkage-disequilibrium-
based methods do not rely on haplotype block definition and may therefore be more 
suitable for genes or genomic regions with complex haplotype architectures. Without 
prior information about the LD structure inherent in the study, we adopted the use of 
TAGIT as outlined in Weale’s paper for the construction of tSNP sets (Weale et al. 
2003).  
However several groups have reported that sets of tSNPs differ across different 
populations (Weale et al. 2003). In studying specific genes that may be involved in 
predisposition to complex disease or aberrant drug response, LD patterns need to be 
defined at a finer scale in order to obtain accuracy in candidate gene association 
 18
Genetic Characterization of Nucleotide Analogue Transporters ABCC4 and ABCC5 Gene Loci 
studies (Tishkoff and Verrelli 2003). This suggests that additional studies in specific 
ethnically diverse populations and individual candidate genes are still necessary.  
 
 1.10 International Hapmap Project 
The goal of the International Hapmap Project [http://www.hapmap.org/] is to 
determine the common patterns of DNA sequence variation in the human genome 
(The International Hapmap Consortium 2003; Deloukas and Bentley 2004). These 
patterns will be useful in identifying genes that contribute to disease and drug 
response. Sequence variants will be characterized with their frequencies, and LD data 
between them. While the most common sequence variations can be obtained in any 
population, samples from four large populations at different ancestral geographical 
locations would be included to ensure that allele frequency changes, if any, can be 
observed amongst populations. Thirty sets of trios from a US Utah population with 
Northern and Western European ancestry (collected by the Centre d’Etude du 
Polymorphisme Humain (CEPH)), thirty sets of trios from a Yoruban population in 
Ibadan, Nigeria, 45 unrelated Japanese in Tokyo, Japan, and 45 unrelated Han 
Chinese in Beijing, China constitute the 270 samples in this project. To adequately 
describe the genetic variation across the entire genome, SNP density must be high. 
The initial intention of the project was to genotype successfully 600,000 SNPs spaced 
at approximately 5-kilobase intervals, each having a minor allele frequency of at least 
5%. Choice of SNPs was to be based on previous validation and distance between 
consecutive markers. Associations between these SNPs are to be analyzed and in 
genomic regions where associations are weak, additional SNPs will then be genotyped 
to increase the SNP density.  Today, the number of validated SNPs has risen to more 
than a million in each of the 4 populations. Still, there are several spare regions where 
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SNP coverage is still poor. As a result of the Hapmap Project, cross-validation of 
SNPs from different genotyping platforms results in better corroboration of data. Five 
genotyping platforms are used: MassExtend (Sequenom, Invader (Third Wave), 
Acycloprime-FP (Perkin-Elmer), Golden Gate-BeadArray (Illumina) and ParAllele 
BioScience (Deloukas and Bentley 2004) and may pave the way for the use of large-
scale genotyping for future genetic studies (Deloukas and Bentley 2004). The 
International Hapmap Project holds much promise as a publicly available resource to 
enable investigators around the world to discover genetic factors that contribute to 
disease susceptibility or therapeutic response. This scientifically ambitious project 
will supplement the Human Genome Project and is more than just a catalogue of 
common genetic variants. The determination of common haplotypes generated from 
the LD map of the genome serves as a powerful tool for pharmacogenetic and 
pharmacogenomic studies. Firstly, candidate gene approaches can rely on this 
resource to look for rare variants that are not genotyped but in LD with underlying 
common haplotypes found. Secondly, data generated can be extrapolated to common 
complex diseases throughout the world for populations with similar SNP associations. 
For populations with ancestry and geographical locations clearly distinct from the 
samples used in the Project, its data would still serve a basis for comparison. Whole 
genome–based approaches are then able to seek new targets of functional importance 
without knowledge of biochemical pathways and gene interaction a priori. Lastly, the 
Hapmap also drives the generation of tagging SNPs in the identification of human 
variants that alter function. Other tools based on present knowledge of demographic 
history of different human populations to screen such potential variants for further 
studies would also greatly reduce the amount of work and time.  
 
 20
Genetic Characterization of Nucleotide Analogue Transporters ABCC4 and ABCC5 Gene Loci 
 1.11  Detection of positive selection 
Various forces such as genetic drift, mutation, recombination and natural selection can 
influence patterns of genetic diversity. Of particular interest to population and 
evolutionary geneticists is the inference of past selection events (Altshuler and Clark 
2005). Genes under the influence of recent positive selection can be reasonably 
assumed to evolve as a result of local adaptation to environmental changes (Altshuler 
and Clark 2005). These changes may be the cause of interindividual variability to 
disease susceptibility and drug response seen in modern humans. For example, 
variants that increase the ‘fitness’ of the population will increase in frequency over 
time while deleterious mutations at functionally important sites will decrease in 
frequency (Rebbeck et al. 2004). Researchers have begun looking at patterns of 
natural selection in the human genome for the purpose of correlating genes to human 
traits (Fay et al. 2001; Akey et al. 2004). As polymorphisms are the footprints of past 
genetic events, many methods have been designed to track selection through 
polymorphisms. Various aspects using polymorphism data can be used to test for 
selection, including allelic frequency spectrum, nucleotide diversity, 
polymorphism/divergence, linkage disequilibrium and comparison of the rates of 
substitution dN/dS (Table 1). Most tests detect selection by rejecting the assumption 
of neutrality, i.e. the observed data deviates significantly from what is expected under 
neutrality. Therefore the null model is one in which natural selection is absent. It 
should be noted that a deviation from neutrality could also be due to other 
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Comparison of the rates of substitution: the dN/dS ratio tests 
The presence of positive selection can be detected by simply comparing the number of 
nonsynonymous (dN) to the number of synonymous (dS) substitutions in a locus. 
Most nonsynonymous substitutions would be expected to be eliminated by purifying 
selection, but some might be retained under positive selection.  Investigating the 
number of synonymous and non-synonymous substitutions may therefore provide 
information about the degree of selection operating on a system. Under neutral 
evolution dN/dS would be equivalent to 1. A high (>1) dN/dS value suggests fixation 
of nonsynonymous mutations with a higher probability than neutral (synonymous) 
ones. The dN/dS ratio tests also take into account of other factors such as 
transition/transversion rate bias and codon usage bias. 
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Uses the Ewens sampling formula to compare the observed
homozygosity with the expected homozygosity and if the difference
between the two homozygosity values is larger than a critical value,
the neutral null hypothesis can be rejected.   
Vulnerable to deviation from allele frequency distribution
equilibrium and is limited in power to detect natural
selection.
Tajima D statistic
Compares the difference between the number of segregating sites
(S) and the average number of SNPs between sequences in a
sample (π). Under the neutral model, D value will be negative under
selective sweeps (and population growth) and positive under
balancing selection (or population substructure).
Fu and Li D statistic
Compares the number of derived mutations and the number of
ancestral mutations. Under a model of neutrality, the frequencies of
the derived and ancestral mutations should be the same. Under
balancing selection, the variation is maintained longer then expected
under a neutral model and results in more ancestral SNPs, thereby
giving a positive D value. Under positive selection, there are more
derived SNP branches, thereby giving negative D values.
Fay and Wu H 
statistic 
Compares the difference between the frequency distribution of
derived polymorphism in a sample and a unique distribution of
polymorphism that is primarily sensitive to the positive selection and
not population expansion. Under neutrality, the two test statistics
should be close to 0. In the presence of excess high frequency
alleles relative to neutral model, H is negative (Przeworski 2002).
(http://www.genetics.wustl.edu/jflab/htest.html) 




Detects whether there is a higher or lower number of haplotypes
than is expected given the number of segregating sites. When only
a few distinct haplotypes are obtained, balancing selection or
population structure might have occurred. On the other hand
excessive number of haplotypes might be indicative of selective
sweeps or population growth. 
Haplotype diversity 
(H)
Similar to the Watterson's Homozygosity test, but also uses
information derived from the number of haplotypes. Under balancing
selection, haplotype diversity is high. Under selective sweeps or
population growth, haplotype diversity is low.
Haplotype partition 
(HP)
Designed to detect a reduction in variation in a subset of sample as
compared to the total sample. This could be caused by an
incomplete selective sweep. 
Relies on observation of a strong haplotype structure for
a small subset of the sample. 
Tests for heterogeneity
The Hudson, 
Kreitman & Aguade 
(HKA) test
Compares the ratio of silent polymorphism and fixation at a gene
region of interest with the ratio of silent polymorphism and fixation at
a gene region that is considered neutrally evolving (i.e. the test
locus). If both are neutral, the ratio should be similar. Selection in
either locus will cause the variance of the ratio to increase.
Most well-known heterogeneity test in population




Relies on comparing the ratio of synonymous/silent and
nonsysnonymous/replacement polymorphisms with the ratio of
synonymous and nonsysnonymous fixations within a single gene.
Silent polymorphism and fixation reflect the neutral mutation rate
(i.e. 4Neμ). An excess of synonymous polymorphisms and fixations
indicates adaptative evolution. An excess of nonsynonymous
polymorphisms indicate purifying selection while an excess of
nonsynonymous fixations represent balancing selection.
However by pooling polymorphisms in categories, this
test (as well as the HKA test) does not take into account
of the frequency distribution of the segregating
polymorphisms and may therefore lose some power in




Compares the observed variance of the Wright’s fixation index Fst
among loci against the theoretical variance under a model of
geographical structure alone (Lewontin and Krakauer 1973). This is
based on the two assumptions that gene frequency of each
subpopulation is a random sample from a given frequency
distribution and that Fst is the same for all loci. If the ratio of
observed to expected variance is significantly large, the hypothesis
of neutral evolution at all loci in the sample must be rejected. That
infers that at least one locus within the set of loci is with unusually
high Fst and must be a result of a selective sweep. 
The validity of Lewontin-Krakauer test as a test of natural
selection was called into question when it was
discovered that several processes such as phylogenetic
history and migration could inflate the variance in Fst
(Robertson 1975b; Robertson 1975a). Despite this, Fst
has continued to be a popular choice of measuring
variation in allele frequencies among populations (Fst) as
an indirect estimator of gene flow and selection (see
section under New tests of selection).
Tajima's D and Fu & Li's statistics are based on allelic
variation and results may not clearly distinguish between
selection and demographic alternatives (bottleneck,
population subdivision). For example, a large negative
Tajima’s D value may be obtained if there is a recent
selective sweep, a recent population expansion possibly
out of bottleneck or the sample is made out of individuals
from several smaller subpopulations. On the other hand,
a large positive Tajima’s D value can be caused by old
balancing selection, recent population reduction or recent
admixture of two or more highly divergent
subpopulations. Both tests are robust to recombination.
Unlike frequency-distribution tests, haplotype tests uses
information not only from the frequencies of the
segregating sites, but also from the haplotype structure.
The 3 haplotype tests are correlated. A subset with low
number of haplotypes tends to have low haplotype
diversity and thus be of a "strong haplotype structure".
 
Table 1.  Summary of the major classes of tests for natural selection. (Adapted 
primarily from McVean [http://www.stats.ox.ac.uk/~mcvean/L4notes.pdf]) 
((Lewontin and Krakauer 1973; Lewontin 1974; Robertson 1975b; Robertson 1975a; 
Akashi 1999; Kreitman 2000; Przeworski 2002; Williamson et al. 2005) 
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1.12 New tests of selection 
Wright’s fixation index 
In addition to the previous traditional tests described, new strategies of detecting 
positive selection have been developed. Akey et al., 2002 examined variation in allele 
frequency using the Fst statistic by comparing the same loci in different test 
populations instead of amongst different loci (Akey et al. 2002). The Wright’s 
fixation Index Fst is the variance of the allele frequencies and is essentially a measure 
of population subdivision. It makes a comparison of the mean heterozygosity 
averaged over 2 or more test subpopulations and the heterozygosity calculated if these 
populations were to be pooled into a single pool. Simply put, Fst = (Ht - meanHs) / Ht, 
where Ht = 2 (pooled p) (pooled q) [note that pooled q = (1-pooled p)], and meanHs = 
the average of H values for each of the individual subpopulations (i.e., 2 p q for each 
subpopulation, averaged across all subpopulations).  
Under selective neutrality, Fst is null and populations have similar allele frequencies 
implying that there is no differentiation among populations due to genetic drift and 
therefore the populations are genetically indistinguishable.  As Fst increases toward 1, 
genetic drift is causing heterozygotes to be lost within populations, and populations 
are being fixed for different alleles. Previous tests using Fst such as the Lewontin-
Krakauer test rely on simulations to obtain expected Fst distribution under selective 
neutrality, but this method relies on prior assumptions on the population demographic 
history. To avoid this caveat and tap into the tremendous SNP information from The 
SNP Consortium, Akey et al., 2002 performed an analysis on more than 26000 SNPs 
in populations of African American, East Asian and European American descent and 
simply identified genes or loci under natural selection as extreme outliers in the Fst 
distribution (Akey et al. 2002).  
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Long-Range Haplotype (LRH) test 
Sabeti et al., 2002 introduced a novel method that relied on the length of linkage 
disequilibrium on one haplotype in relation to the frequency of that haplotype (Sabeti 
et al. 2002). Under neutral evolution, it is expected that the time taken for a newly 
introduced mutation to rise in allele frequency and accumulate in a population will be 
long. Due to recombination surrounding the variation, the LD between this variation 
and nearby variations will decay substantially during this time. If this newly 
introduced mutation were to be subjected to positive selection, its allele frequency 
would increase in such a short time that recombination did not substantially break 
down the haplotype on which the mutation occurred. Therefore an allele with 
unusually long-range haplotype (and therefore long flanking stretches of 
homozygosity) given its allele frequency would be an indication of recent positive 
selection. This method, named the Long-Range Haplotype (LRH) test examines 
multi-allelic associations using a statistic called relative extended haplotype 
homozygosity (rEHH), which is in turn derived from extended haplotype 
homozygosity (EHH). Haplotype homozygosity is the multilocus measure of linkage 
disequilibrium that calculates the probability of a particular haplotype in a population 
(Sabatti and Risch 2002). EHH is defined as the probability that two randomly 
selected chromosomes carrying the core haplotype of interest are identical by descent 
from the entire interval between the core locus to a distant point x. In simpler terms, it 
means that EHH represents the probability of two chromosomes that share the same 
core gene haplotype also share identical haplotypes in other SNPs surrounding the 
specified candidate core region (Brookfield 2003). As distance increases from the 
core region, it is expected that EHH will decrease and this rate of decay can be 
compared amongst core gene haplotypes. rEHH therefore is a comparison of EHH 
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values of the core haplotype of interest against other core haplotypes and can also be 
considered to be a measure of extended linkage disequilibrium. A core haplotype with 
both high frequency and high rEHH, as compared to another with a faster rate of 
decay in EHH for the same distance, would then be indicative of recent positive 
selection (Figure 2 Panel A). In Sabeti’s paper, he tested core haplotypes within 
different genes against markers at increasing distance away from the test core 
haplotype (Sabeti et al. 2002) (Figure 2 Panel B). The advantage of using this test is 
apparent. Since it compares core haplotypes against one another, it is less vulnerable 
to demographic changes, specifically the local recombination rate. Sabeti et al., 2002 
compared this method against traditional tests of selection (including Tajima’s D-test, 
Fu and Li’s D-test, Fay and Wu’s H-test, the Ka/Ks test, the McDonald-Kreitman test, 
and the McDonald-Kreitman-Aguade (HKA)) test in 3 genes, glucose-6-phosphate 
dehydrogenase (G6PD), and CD40 ligand gene (TNFSF5) and showed this test has 
greater power in detecting selection. The extended HH, with variances and core 
haplotype frequencies can be graphically represented using a web-based tool 
[http://ihg.gsf.de/cgi-bin/mueller/webehh.pl] (Mueller and Andreoli 2004). 
Nonetheless, this test has its own limitations. Firstly it detects only recent positive 
selection. For changes in allele frequency driven by selection early on in human 
history, recombination would have time to dissolve any linkage disequilibrium in 
flanking sequences (Brookfield 2003). Secondly it is also dependent on the 
assumptions that the human population is constant in size and contains no 
substructure (Brookfield 2003). Thirdly it might be subjected to sampling variations, 
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Figure 2.  Long-range haplotype test. 
Panel A: Extended haplotype homozygosity (EHH) as an LD measure. A high-
frequency haplotype that possesses long-range LD departs significantly from 
neutrality and thereby shows evidence of recent positive selection. Various coalescent 
models e.g. of constant size, expansion, extreme bottleneck and highly structured 
populations are simulated to test haplotypes for other demographic influences. Panel 
B:  Haplotype Branching Diagram (HBD). Closely-placed SNPs within genes are 
expressed as ‘core haplotypes’. Each of the core haplotypes serves as a core locus 
from which branches signifying the profile of LD decay appear. As LD decays from 
this core locus to consecutive markers placed further away, more branches appear. 
The thickness of each branch corresponds to the proportion of chromosomes within 
the haplotype. A predominantly thick LD branch is evidence of recent positive 
selection.   
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Pexcess test statistic 
Bersaglieri et al., analyzed the LCT gene, which encodes the enzyme lactase-phlorizin 
hydrolase in multiple populations for signature of positive selection using 3 different 
measures (Bersaglieri et al. 2004). In addition to the Fst and LRH tests, they described 
a novel test using the Pexcess statistic. This test calculates the probability P which 
represents the extent at which a haplotype is over-represented in the affected sample, 
and is analogous to Pexcess = (Ptest - Preference)/(1 - Preference), where Ptest and 
Preference denote allele frequency in chromosomes of population under study (test) 
and ancestral (reference) population, respectively. The ancestral allele frequency 
(Preference) is estimated by taking the average allele frequency in populations that 
have not experienced selection such as that of East Asian and African American 
populations (Bersaglieri et al. 2004). By observing consistently elevated Pexcess 
values that extend across multiple markers in a large region (>50kb), the increase in 
frequency of a single haplotype can be approximated. Looking for positive selection 
using elevated Pexcess values across multiple loci may be more informative than 
elevated Fst values in individual markers. However the Pexcess test is dependent on 
the assumptions of all allele frequency differentiation measures. In addition, using 
allele frequency of the African American or East Asian population as the ancestral 
allele frequency may be erroneous, even though Bersaglieri et al., showed that their 
results did not defer significantly whether 21% European admixture in the African 
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Chapter 2 The nucleotide analogue transporters 
2.1 Drug transporters  
While whole genome scanning is likely to be widely used in the future, candidate 
gene studies are, at present, more feasible. One of the key issues in performing a 
candidate gene case-control association study is the selection of candidate genes. 
Justifications are required for the choice of genes or genomic regions in which 
polymorphisms are to be analyzed. The number of genes or genomic regions may be 
numerous for complex diseases and drug response, hence it is important to prioritize 
these genes so that variations in them can be sequentially examined. Furthermore with 
the ever-expanding number of polymorphic sites discovered in disease- or drug-
related genes, it is important that the functional significance of the polymorphisms 
chosen for study and their reported allele frequencies are taken into account so that 
genuine associations are detected.  
Genetic variability can affect drug response in two ways, pharmacodynamically and 
pharmacokinetically. Most drugs act by interacting with target proteins such as 
receptors and if polymorphisms change the protein configuration of the target protein, 
drug response may be affected. Any genetic variability in genes involved in any one 
of the ADME (Absorption, Distribution, Metabolism, and Excretion) functions may 
also affect drug levels at target sites. Drug transporters are membrane bound proteins 
that actively export therapeutic drugs out of cells and are thus able to influence the 
pharmacokinetic characteristics of drugs (absorption, distribution, excretion). These 
transporters are also able to influence drug penetration into the brain and central 
nervous system. Some of them are also implicated as a mechanism of cancer 
multidrug resistance and linked to some genetic diseases. The energy-dependent 
efflux of drug from cells is a critical concept that first arose when a glycosylated 
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plasma membrane protein was detected in cells resistant to colchicine (Juliano and 
Ling 1976). The protein P-glycoprotein (P-gp), encoded by the MDR1 gene, was 
subsequently shown to impart resistance to a wide array of structurally and chemically 
unrelated compounds. Since then, other members of the ATP-binding cassette (ABC) 
superfamily of transporters have been identified. The multidrug resistance related 
proteins (MRPs), belonging to the ABCC subfamily, hold special interest as substrates 
range from a simple ion (ABCC7/MRP7/"cystic fibrosis transmembrane conductance 
regulator"/CFTR) to various anionic compounds (including large drug molecules) and 
have been linked to pathological states such as pseudoxanthoma elasticum 
(ABCC6/MRP6) and cystic fibrosis (ABCC7/MRP7). The analysis of the predicted 
structures show that ABCC4/MRP4, ABCC5/MRP5, ABCC11/MRP8 and 
ABCC12/MRP9 share structural similarity to MDR1 in having two nucleotide binding 
domains (NBDs) and two membrane spanning domains (MSDs), each composed of 
six transmembrane helices with a linker region (L1) connecting NBD1 to MSD2 
(Figure 3 Panel A) (Gottesman et al. 2002; Kruh and Belinsky 2003). The basic 
structure of other subfamily members such as ABCC1/MRP1, is composed of the 
same MDR1 core region, but has an additional N-terminal region composing of 
extracellular N-terminus, a membrane spanning domain MSD0, and an intracellular 
loop (L0) connecting MSD0 to MSD1 (Kruh and Belinsky 2003) (Figure 3 Panel B).  
The two cytosolic NBDs of about two hundred amino acids contain ATP-binding sites 
with three consensus sequences conserved among species (Efferth 2001; Gottesman 
and Ambudkar 2001; Lockhart et al. 2003). The Walker motifs A and B are involved 
in ATP binding and hydrolysis (Nikaido 2002), and are linked by a third consensus 
motif. This unique motif is called LSGGQ motif, C motif, or “signature motif S” as it 
is present in all ABC transporters (Figure 4) (Klein et al. 1999; Bodo et al. 2003). In 
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terms of amino acid identity, ABCC1/MRP1, ABCC2/MRP2, ABCC3/MRP3 and 
ABCC6/MRP6 proteins share 45-58% similarity whereas both the ABCC4/MRP4 and 
ABCC5/MRP5 share less similarity with ABCC1/MRP1 (36-39%) (Lee 2000) (Table 
2). As yet, no work has been published on the characterization of the promoter 
regulatory elements of the ABCC4 and ABCC5 loci (Bush and Li 2002).  
 
 
Protein Amino ABCC1 ABCC2 ABCC3 ABCC4 ABCC5 ABCC6
ABCC1 1531 aa  -
ABCC2 1545 aa 48.4 -
ABCC3 1527 aa 57.6 46.8 -
ABCC4 1325 aa 39.4 36.8 35.3 -
ABCC5 1438 aa 35.8 36.2 33.1 36.5  -
ABCC6 1503 aa 45.0 39.1 43.6 33.9 30.9  -
Overall percent amino acid identity
 
Table 2.  Overall amino acid identity amongst selected ABCC subfamily members. 
















Figure 3.  Structural illustration of selected members of ABC transporter superfamily. 
[Adapted from (Gottesman et al. 2002)] Panel A: Structural similarity of 
ABCC4/MRP4 and ABCC5/MRP5 to MDR1. Panel B: ABCC1, ABCC2, ABCC3 and 
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Figure 4.  Predicted secondary structures of ABCC4/MRP4 and ABCC5/MRP5 
proteins. The transmembrane topology schematic was rendered using a 
transmembrane protein display software available at TOPO2 
[http://www.sacs.ucsf.edu/TOPO-run/wtopo.pl]. Panel A: Prediction of 
transmembrane regions in ABCC4/MRP4 and ABCC5/MRP5 using TMHMM Server 
v. 2.0 [http://www.cbs.dtu.dk/services/TMHMM-2.0/] and "DAS" - Transmembrane 
Prediction server [http://www.sbc.su.se/~miklos/DAS/tmdas.cgi]. Panel B: 
Characteristic motifs within ABCC4/MRP4 and ABCC5/MRP5 proteins. Walker A 
and Walker B regions are linked by a ‘signature motif S’ (Gottesman and Ambudkar 
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2.2 ABCC4 and ABCC5 in antiretroviral and anticancer therapy 
ABCC4, ABCC5 and ABCC8 proteins are the only MRP isoforms shown to confer 
resistance to cyclic nucleotides (cAMP and cGMP), acyclic nucleoside phosphonates 
such as 9-(2-phosphonylmethoxyethyl)adenine (PMEA), and monophosphorylated 
nucleoside analogues such as azidothymidine-monophosphate (AZT-MP; 2’-azido-
2’,3’-dideoxythymidine monophosphate, zidovudine-monophosphate), thioxanthosine 
monophosphate, and thioinosine monophosphate (Schuetz et al. 1999; Jedlitschky et 
al. 2000; Wijnholds et al. 2000; Chen et al. 2002; Lai and Tan 2002; Wielinga et al. 
2002; Guo et al. 2003). The multidrug resistance protein 5 (MRP5/ABCC5) was the 
first ATP-dependent transporter identified for cyclic nucleotides with cGMP as a 
high-affinity substrate and cAMP as a low-affinity substrate (Jedlitschky et al. 2000) 
(Table 3). While ABCC4 has been recently shown to mediate efflux of cyclic 
nucleotides (van Aubel et al. 2002), its affinity for cGMP is lower than that of ABCC5 
(Adachi et al. 2002; Chen et al. 2002; Lai and Tan 2002) (Table 3). Despite these 
findings, Klokouzas et al’s (2003) vesicle uptake studies using MRP inhibitors 
suggested that the properties of a cGMP transporter in human erythrocytes was 
similar to those of  the ABCC4 transporter, and not those of the ABCC5 transporter 
(Klokouzas et al. 2003).  Interestingly, the affinity of cAMP for ABCC4 is at least 9 
fold higher than that for ABCC5.  
Nucleoside analogues are useful for both antitumour and antiviral therapies. Once 
taken up by cells, these analogues must be activated by phosphorylation, and 
incorporated into nucleic acids before exerting their cellular toxicity (Reid et al. 
2003a).  Both ABCC4 and ABCC5 transporters were shown to confer similar levels of 
resistance to unmodified PMEA, but not its phosphorylated form (Lee et al. 2000; 
Wijnholds et al. 2000; Lai and Tan 2002; Reid et al. 2003a). It was noted that 
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transport of both efflux pumps was limited to nucleoside monophosphates, but not the 
base, nucleoside, or di-phosphonate or tri-phosphonate derivatives of the nucleoside 
(Reid et al. 2003a; Wielinga et al. 2003; Borst et al. 2004). ABCC4 and ABCC5 
proteins do not confer resistance against typical substrates of ABCC1-3 anthracyclines 
(such as daunorubicin and doxorubicin), etoposide, vincristine, paclitaxel, cisplatin, 
heavy metals (cadmium chloride, potassium antimony tartrate and sodium meta-
arsenite) (McAleer et al. 1999; Lee et al. 2000; Wijnholds et al. 2000) and are 
therefore functionally distinct from these proteins. In fact, negative correlation of 
ABCC5 mRNA levels with the resistance of unselected lung cancer cell lines to 
etoposide (VP-16) and vincristine (VCR) had been reported (Young et al. 1999). 
High-level resistance against other acyclic nucleoside phosphonate drugs, such as cPr-
PMEDAP [cyclopropyl-PMEDAP] and PMEDAP [9-(2-phosphonomethoxyethyl)-
2,6-diaminopurine] was also observed for ABCC4 but not ABCC5 (Reid et al. 2003a) 
(Table 3). Low levels of resistance against purine-based carbocyclic nucleoside 
analogue abacavir (Reid et al. 2003a) as well as significant levels of thioguanine and 
6-Mercaptopurine have been observed for both transporters (Wijnholds et al. 2000; 
Reid et al. 2003a; Wielinga et al. 2003).  Some controversies regarding other 
substrates exist in literature. Chen et al., 2001 reported ABCC4 overexpression in 
NIH3T3 cells does not affect levels of cladribine (Chen et al. 2001), while Reid et al., 
showed some low levels of resistance by HEK293 cells expressing ABCC4 or ABCC5 
(Reid et al. 2003a). Davidson et al., 2002 reported substantial resistance to cytarabine, 
gemcitabine, and cladribine in HEK293 cells with overexpression of ABCC5 
(Davidson et al. 2002b; Ritter et al. 2005) while Reid et al., 2003 could not observed a 
significant level of resistance against gemcitabine, cytarabine, and fludarabine in 
HEK293 cells overexpressing either ABCC4 or ABCC5 (Reid et al. 2003a). Whereas 
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Jedlitschky et al., 2000 reported that the ABCC5-mediated vesicular transport of 
cGMP was sensitive to inhibitors of cGMP phosphodiesterase 5 such as trequinsin 
(Jedlitschky et al. 2000), Reid et al., 2003 observed only low levels of inhibition by 
sildenafil, trequisin, and zaprinast on MRP4- and MRP5-mediated PMEA efflux 
(Reid et al. 2003a). The repertoire of drugs transported by ABCC4 was also recently 
expanded when it was shown that overexpression of ABCC4 restricted accumulation 
of the topoisomerase inhibitor topotecan via vesicular transport assays and 
concentration of topotecan in the cerebrospinal fluid (CSF) of MRP4-/- mice was 
almost 10-fold that of MRP4+/+ mice (Leggas et al. 2004). In another publication by 
Norris et al., 2005, the in vitro accumulation of other topoisomerase inhibitors, 
namely irinotecan/CPT-11, and its metabolite, SN-38 in ABCC4-transduced cells but 
not ABCC5-transduced cells also proved that the expression of ABCC4 protein might 
have implications for the clinical use of camptothecin-based analogues which are now 
in clinical trials for the treatment of neuroblastoma (Norris et al. 2005). Norris et al., 
2005, were, however, unable to observed any significant resistance to either 
camptothecin or topotecan (Norris et al. 2005).  
While the substrate profiles of ABCC4 and ABCC5 for nucleoside-based molecules 
are remarkably similar, ABCC4 also has the ability to transport conjugates such as the 
estradiol glucuronide E217ßG and antimetabolite methotrexate (Lee et al. 2000; Chen 
et al. 2001; Chen et al. 2002; van Aubel et al. 2002). Other physiological substrates 
have also been found for ABCC4 such as steroid-glucuronides and sulfated steroid 
(Zelcer et al. 2003), monoanionic bile acid conjugates (in cotransport with reduced 
glutathione GSH) (Rius et al. 2003), dianionic bile acid conjugates (in absence of 
GSH) (Zelcer et al. 2003), prostaglandins PGE1 and PGE2 (Reid et al. 2003b) as well 
as urate at low affinities (van Aubel et al. 2005) (Table 3). The ABCC4 specific 
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bindings of p-aminohippurate and purine end metabolite urate as well as its transcript 
and protein expression on the brush border membrane of renal tubules suggest an 
excretory role for ABCC4 (Smeets et al. 2004; van Aubel et al. 2005). No 
physiological substrate has yet been found for ABCC5. Furthermore, cGMP transport 
by recombinant MRP4 can be inhibited by substances such as dipyridamole and the 
leukotriene analogue MK571 as well as the non-steroidal anti-inflammatory drugs 
(NSAIDs) such as indomethacin (Reid et al. 2003a; Reid et al. 2003b) while ABCC5-
mediated transport is inhibited by dipyridamole but not MK571 (Jedlitschky et al. 
2000; Reid et al. 2003a) (Table 4). Many of these inhibitors are assumed to be 
substrates as well (Table 4).  
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Substrate K m Reference Substrate K m Reference
Cyclic nucleotides Cyclic nucleotides
cAMP 44.5 uM Chen et al., 2001 cAMP 379 uM Jedlitschky et al., 2000
100 uM van Aubel et al., 2002
Weilinga et al., 2003
Lai and Tan, 2002
Sampath et al., 2002
cGMP 9.69 uM Chen et al., 2001 cGMP 2.1 uM Jedlitschky et al., 2000
1 uM van Aubel et al., 2002
Weilinga et al., 2003
8-Bromo-cGMP Jedlitschky et al., 2000
N 2,2'-O -Dibutyryl-cGMP Jedlitschky et al., 2000
Nucleoside analogues Nucleoside analogues
PMEA Reid et al., 2003a PMEA Wijnholds et al., 2000
Schuetz et al., 1999
Sampath et al., 2002
Lee et al., 2000
PMEG Reid et al., 2003a PMEG Reid et al., 2003a
Schuetz et al., 1999
PMEDAP Sampath et al., 2002 PMEDAP Reid et al., 2003a
Reid et al., 2003a
cPr-PMEDAP Reid et al., 2003a cPr-PMEDAP Reid et al., 2003a
bis-POM-PMEA Reid et al., 2003a bis-POM-PMEA Reid et al., 2003a
(S)-HPMPC Reid et al., 2003a (S)-HPMPC Reid et al., 2003a
Ganciclovir Adachi et al., 2002
AZT Schuetz et al., 1999
3TC Schuetz et al., 1999
Abacavir Reid et al., 2003a
Cladribine Reid et al., 2003a
Cladarabine Davidson et al., 2002*
Gemcitabine Davidson et al., 2002*
Cytarabine Davidson et al., 2002*
5-HP Wijnholds et al., 2000
5-FU 1.3 mM Dantzig et al., 2003*
5-Br-d-Urd Sampath et al., 2002
6-Mercaptopurine (6-MP) Reid et al., 2003a 6-Mercaptopurine (6-MP) Wijnholds et al., 2000
Chen et al., 2001 Reid et al., 2003a
Azathioprine (6-MP prodrug) Wijnholds et al., 2000
 6-Thioguanine Chen et al., 2001 Thioguanine Wijnholds et al., 2000
Reid et al., 2003a Dantzig et al., 2003*
Reid et al., 2003a
Methotrexate (MTX) 0.22 mM Chen et al., 2002
Lee et al., 2000
1.3 mM van Aubel et al., 2002
Sampath et al., 2002
Ribavirin Sampath et al., 2002
Adefovir Lee et al., 2000
Schuetz et al., 1999
ABCC 4 ABCC 5
 
Table 3.  Substrates of ABCC4 and ABCC5 proteins. 
*Data directly taken from Ritter et al., 2005 (Ritter et al. 2005) with references from 
Davidson et al., 2002a and Dantzig et al., 2003 (Davidson et al. 2002a; Dantzig et al. 
2003; Pratt et al. 2005). ABBREVIATIONS: cAMP, adenosine 3’,5’-cyclic 
monophosphate; cGMP, guanosine 3’,5’-cyclic monophosphate; PMEA, 9-(2-
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phosphonomethoxyethyl)adenine; PMEG, 9-(2-phosphonomethoxyethyl)guanine; 
PMEDAP, 9-(2-phosphonomethoxyethyl)-2,6-diaminopurine; cPr-PMEDAP, 
cyclopropyl-PMEDAP; bis-POM-PMEA, bis(pivaloyloxymethyl)-9-(2-
phosphonomethoxyethyl)adenine; (S)HPMPC, 1-(S)-3-hydroxy-2-
(phosphonomethoxy)propyl]cytosine; AZT, zidovudine (azidothymidine); 3TC, 2'-
deoxy-3'-thiacytidine (lamivudine); 5-Br-dUrd, 5-bromo-2'deoxyuridine; adefovir [9-
(2-phosphonylmethoxyethyl)-[2,8-3H]adenine; E217βG, estradiol 17-β-D-glucuronide; 
PG, prostaglandin; DNP-SG, S-(2,4-dinitrophenyl)-glutathione; NAc-DNP-Cys, N-
acetyl (2,4,-dinitrophenyl)-cysteine; Leucovorin (folinic acid, N5-formyl-THF, 
citrovorum factor); 5-HP, 5-hydroxypyridine-2-carboxaldehyde thiosemicarbazone; 5-
FU, 5-flurouracil.  
 
Substrate K m Reference Substrate K m Reference
Miscellaneous molecules Miscellaneous molecules
Glutathione (GSH) 2.7 mM Rius et al., 2003
S -methyl-glutathione (Me-SG) 1.2 mM Rius et al., 2004
cholyltaurine (C-tau) 3.8 uM Rius et al., 2005
E217betaG 30 uM Chen et al., 2001
Reid et al., 2003b
van Aubel et al., 2002
30 uM Zelcer et al., 2003
DHEAS 2 uM Zelcer et al., 2003
Sulfated bile acids Zelcer et al., 2003
Prostaglandin PGE1 2.1 uM Reid et al., 2003b
Prostaglandin PGE2 3.4 uM Reid et al., 2003b
Phosphonoformic acid (forscarnet; PFA) Sampath et al., 2002
Phosphonoacetic acid (PAA) Sampath et al., 2002
S-(2,4-dinitrophenyl)glutathione (DNP-SG) van Aubel et al., 2002 S-(2,4-dinitrophenyl)glutathione (DNP-SG) Wijnholds et al., 2000
NAc-DNP-Cys van Aubel et al., 2002
Leukotriene C4 van Aubel et al., 2002
alpha-Naphthyl-beta-D-glucuronide van Aubel et al., 2002
para-Nitrophenyl-beta-D-glucuronide van Aubel et al., 2002
Folic acid 0.17 mM Chen et al., 2002
Leucovorin 0.64 mM Chen et al., 2002
Cadmium chloride (CdCl2) McAleer et al., 1999
Potassium antimonyl tartrate McAleer et al., 1999
Wijnholds et al., 2000
5-chloromethylfluorescein
diacetate McAleer et al., 1999
Fluorescein diacetate Jedlitschky et al., 2000
ABCC 4 ABCC 5
 
Table 3  (continued). 
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Inhibitor IC50 (uM) Reference Inhibitor IC50 (uM) Reference
Uricosuric agents Uricosuric agents
Probenecid <100 van Aubel et al., 2002 Probenecid ~50 Jedlitschky et al., 2000
~100 Rius et al., 2003 200 Reid et al., 2003a
2300 Reid et al., 2003a
Sulfinpyrazone 420 Reid et al., 2003a Sulfinpyrazone 300 Reid et al., 2003a
Wijnholds et al., 2000
Benzbromarone 150 Reid et al., 2003a Benzbromarone 150 Reid et al., 2003a
Phosphodiesterase 5 (PDE5) Inhibitors Phosphodiesterase 5 (PDE5) Inhibitors
Zaprinast 250 Reid et al., 2003a Zaprinast Jedlitschky et al., 2000
250 Reid et al., 2003a
Trequensin 10 Reid et al., 2003a Trequensin Jedlitschky et al., 2000
30 Reid et al., 2003a
Sildenafil 20 Reid et al., 2003a Sildenafil Jedlitschky et al., 2000
80 Reid et al., 2003a
Leukotrienes Receptor Antagonists (LTRAs)
MK571 2 Rius et al., 2003 MK571 Jedlitschky et al., 2000
10 Reid et al., 2003a 40 Reid et al., 2003a
43 Jedlitschky et al., 2004
Nonsteroidal Anti-inflammatory Drugs (NSAIDs) Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
Dipyridamole 2 Reid et al., 2003a Dipyridamole 30 Reid et al., 2003a
12 Jedlitschky et al., 2004
<20 Rius et al., 2003
Indomethacin Reid et al., 2003a
~5 Reid et al., 2003b
22 Jedlitschky et al., 2004
Ibuprofen 20 Reid et al., 2003b
~50 Jedlitschky et al., 2004
Flurbiprofen ~5 Reid et al., 2003b
Indoprofen ~5 Reid et al., 2003b
Ketoprofen ~50 Reid et al., 2003b
Diclofenac poor Reid et al., 2003b
Celecoxib poor Reid et al., 2003b
Rofecoxib poor Reid et al., 2003b
Antiplatelet Drugs Antiplatelet Drugs
Dilazep 20 Reid et al., 2003a Dilazep >50 Reid et al., 2003a
Nucleoside analogues Nucleoside analogues
Methotrexate Rius et al., 2003
Nitrobenzylmercaptopurine riboside 75 Reid et al., 2003a Nitrobenzylmercaptopurine riboside >100 Reid et al., 2003a
ABCC 4 ABCC 5
 
Table 4.  Substrates of ABCC4 and ABCC5 proteins with inhibitory actions. 
ABBREVIATIONS: MK571, 3-[[3-[2-(7-chloroquinolin-2-yl)vinyl]phenyl]-(2-
dimethylcarbamoylethylsulfanyl)methylsulfanyl] propionic acid 
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Inhibitor IC50 (uM) Reference Inhibitor IC50 (uM) Reference
Miscellaneous molecules
Prostaglandin PGF1alpha Reid et al., 2003b
Prostaglandin PGF2alpha Reid et al., 2003b
Prostaglandin PGA1 Reid et al., 2003b
Thromboxane TXB2 Reid et al., 2003b
Folate Rius et al., 2003
Cholate 250 Zelcer et al., 2003
Glycocholate 400 Zelcer et al., 2003
Taurocholate 350 Zelcer et al., 2003
Taurodeoxycholate 60 Zelcer et al., 2003
Taurochenodeoxycholate 55 Zelcer et al., 2003
Taurolithocholate 20 Zelcer et al., 2003
Taurolithocholic acid sulphate 10 Zelcer et al., 2003
Glycolithocholic acid sulphate 10 Zelcer et al., 2003
Lithocholic acid sulphate 10 Zelcer et al., 2003
DHEAS 3 Zelcer et al., 2003
DHEA 3-glucuronide 80 Zelcer et al., 2003
Oestrone 3-sulphate 45 Zelcer et al., 2003
Oestradiol 3-sulphate 50 Zelcer et al., 2003
Oestradiol 3-glucuronide 120 Zelcer et al., 2003
Oestradiol 3,17-disulphate 2 Zelcer et al., 2003
ABCC 4 ABCC 5
 
Table 4  (continued). 
 
2.3 Tissue distribution of ABCC4 and ABCC5 proteins 
Expression of ABCC4 and ABCC5 in specific tissues may have an impact on 
therapeutic outcome by affecting nucleotide accumulation and determine their 
physiological roles in these tissues. Both nucleotide analogue transporters ABCC4 and 
ABCC5 are shown to have a widespread expression in a variety of tissues. ABCC4 
mRNA has been detected in several tissues: prostate, liver, testis, ovary, brain, kidney, 
and adrenal gland (Kool et al. 1997; Schuetz et al. 1999; Lee et al. 2000; Zelcer et al. 
2003). The expression of ABCC4 appears to be the highest in the prostate (Lee et al. 
1998), with primary localization in the basolateral membrane of the tubuloacinar cells 
(Lee et al. 2000). Immunoblotting studies have provided evidence for the expression 
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of ABCC4 and ABCC5 in erythrocytes (Klokouzas et al. 2003; Wu et al. 2005), and 
presence of ABCC4 in human platelets  (Jedlitschky et al. 2004). As shown by 
immunofluoresence techniques, ABCC4 is localized in the intracellular structures in 
platelets and plasma membranes in human monocytes (Ritter et al. 2005). ABCC4’s 
expression in these tissues might therefore play a role in therapeutic therapy by 
coordinating the intracellular accumulation of purine nucleosides. For example, the 
expression of ABCC4 has been shown at the apical (brush border) membrane of the 
human renal proximal tubules and may therefore explain the nephrotoxicity incurred 
by nucleotide analogue drugs by PMEA, adefovir and cidofovir (van Aubel et al. 2002; 
van Aubel et al. 2005). The differential polarization of ABCC4’s expression in various 
tissues is thus unique and the biological relevance of such ability to selectively 
localize either apically or basolaterally is unknown. 
The expression of ABCC5 mRNA/protein appears to be ubiquitous, with expression 
shown in many tissues. In a direct comparison between expression of ABCC4 and 
ABCC5, Kool et al., 1997 found that ABCC5 mRNA was detected in almost all 
common tissues tested and at much higher levels than ABCC4 using RNase protection 
assays (Kool et al. 1997). Belinsky et al., 1998, used RNA blot analysis to show 
expression of ABCC5 in skeletal muscle (highest), kidney, testis, heart and brain 
tissues (Belinsky et al. 1998). Spleen, thymus, pancreas, prostate, ovary, placenta, 
small intestine, colon peripheral blood lymphocytes (PBL), lung and liver also 
contained low levels of ABCC5 (Belinsky et al. 1998).  Localization of ABCC5 
protein in smooth muscle cells as well as endothelial cells of blood vessels in the 
genitourinary system and cardiomyocytes also suggests that ABCC5 plays a 
regulatory in role in the regulation of vascular smooth muscle tone and cardiac 
contractility via intracellular cyclic nucleotide concentration as well as in an alternate 
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mechanism of action for phosphodiesterase inhibitors such as sildenafil (Nies et al. 
2002; Dazert et al. 2003). 
Of worthy mention with respect to xenobiotic transport is the expression of ABCC4 
and ABCC5 on structural barriers within the human body which restrict entry of 
foreign materials into certain tissues and organs (Borst and Elferink 2002; Schinkel 
and Jonker 2003). The blood-brain barrier (BBB) formed by the brain capillary 
endothelial cells (BCEC) and the blood-cerebrospinal fluid barrier (BCSFB) formed 
by the choroid plexus form a very effective barrier to the transfer of xenobiotics into 
the brain (Graff and Pollack 2004).  
The presence of both ABCC4 and ABCC5 is demonstrated in brain microvessel 
endothelial cells that form the blood–brain barrier (BBB) (Zhang et al. 2000). Kool et 
al. 1997 also demonstrated a high level of ABCC5 expression in brain cell lines (Kool 
et al. 1997) and other studies have also found high levels of mRNA transcripts within 
cerebral cortex, cerebellum, and hippocampus (Belinsky et al. 1998; McAleer et al. 
1999). Besides endothelial cells, glial cells which consist of oligodendrocytes, 
astrocytes and microglias are also an important component of the blood-brain barrier 
and the Central Nervous System (CNS). As such, ABCC4 and ABCC5 transcriptional 
expression in glial cells may be important in elucidating the roles of these transporters 
in BBB physiology. Both ABCC4 and ABCC5 transcripts could be found in BCECs, 
glial cells, pericytes, capillary extract and grey matter extract (Berezowski et al. 2004). 
In sharp contrast to the absence of P-gp, the MRP homologue transporters ABCC1, 4, 
5, and 6 were detected in glial cells (Hirrlinger et al. 2002; Berezowski et al. 2004). 
As was also shown by Kool et al., 1997, ABCC4 mRNA transcription in these cells 
was much lower than ABCC5 (Kool et al. 1997; Berezowski et al. 2004). In addition, 
Dallas et al., 2004 showed that PMEA efflux from a microglia cell line was mediated 
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by ABCC4 and ABCC5 (Dallas et al. 2004). However, it was also shown that there is 
no involvement of glial cells or pericytes in the regulation of transcriptional 
expression of ABCC4 and ABCC5 transporters (Berezowski et al. 2004). With studies 
demonstrating ABCC4- and ABCC5- mediated resistance to antiviral nucleosides, one 
of the functions of ABCC4 and ABCC5 may be involved in nucleoside transport in the 
BBB. The low CNS penetration of dideoxynucleoside reverse transcriptase inhibitors, 
such as zidovudine (AZT), may be due in part to presence of efflux transporters 
including ABCC4 and ABCC5. The variability of effective therapy of HIV-associated 
neurodegenerative diseases such as dementia using reverse transcriptase inhibitors 
may thus be linked with expression of ABCC4 and ABCC5 transporters. In addition, a 
probenecid-sensitive efflux transport system for AZT, has been demonstrated in the 
BBB and this system may include the 2 probenecid-sensitive transporters (Takasawa 
et al. 1997). The localization of ABCC4 in the basolateral membrane of the choroid 
plexus epithelial cells and the apical membrane of brain capillary endothelial cells 
also adds weight to the argument that ABCC4 is perfectly poised to restrict brain 
penetration of topotecan and other substrates filtering from blood as well as 
preventing the accumulation of drug molecules in the cerebrospinal fluid (CSF) 
(Leggas et al. 2004). Endogenous anions such as taurocholate, 
dehydroepiandrosterone-3-sulfate, 2-estradiol-17β-glucuronide, and estrone sulfate as 
well as prostaglandins (which are produced by the choroids plexus) found in the brain 
are also ABCC4 substrates (Reid et al. 2003b; Zelcer et al. 2003). 
Like the BBB and BCSFB, the placental membrane represents a structural barrier that 
protects the developing and sensitive fetus from distribution of certain xenobiotics in 
the maternal circulation. ABCC5 is shown to be expressed in human placenta by RT-
PCR and Western blot analyses (Pascolo et al. 2003). Meyer et al., 2005 reported that 
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an increased amount of ABCC5 mRNA was detected in first and second trimester 
placentas in comparison with term placentas and MRP5 preferentially localizes in the 
basal membrane of syncytiotrophoblasts (Meyer Zu Schwabedissen et al. 2005; Ritter 
et al. 2005). A higher level of ABCC5 protein is also found in pre-term placentas 
(Meyer Zu Schwabedissen et al. 2005). The expression of this transporter in the 
membrane of syncytiotrophoblasts may indicate that the transporter may potentially 
regulate the intracellular concentration of the second messenger cGMP (and other 
cyclic nucleotides) and thereby partake in cGMP signaling. The extracellular level of 
cGMP is linked to cytotrophoblasts differentiation, control of fetoplacental vascular 
tone as well as NO-dependent placental angiogenesis. In addition, the presence of 
ABCC5 in placentas may influence nucleoside drug analogues and serve as a 
protective function against potential toxic agents. 
As ABCC4 and ABCC5 may be involved in the efflux of some antiretroviral drugs 
aimed at targeting the disease pathway of human immunodeficiency virus (HIV), the 
temporal changes in expression levels of these 2 transporters in human macrophages 
may be due to HIV infection. In uninfected monocyte-derived macrophages (MDM), 
the expression levels of ABCC4 and ABCC5 were low and stable. In MDM cultures 
infected with HIV-1/BA-L, HIV infection in vitro causes a significant but transient 
increase in ABCC4 expression, which was also correlated with TNP-α production 
(Jorajuria et al. 2004). In contrast, ABCC5 and ABCC1 transcription levels were 
sharply increased with HIV replication not correlated with the production of cytokines 
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2.4 Polymorphisms in coding regions of ABCC4 and ABCC5 gene loci 
There are two main sources of variation data available: published reports in peer-
reviewed journals and polymorphism/mutation databases. A few published reports 
have described polymorphisms in both the ABCC4 and ABCC5 gene loci (Table 5). 
Variations not strictly considered as SNPs like indels and repeats are nevertheless 
included in Table 5 and highlighted in grey. In 2002, Adachi et al. reviewed a 
selection of 10 ABCC4 variations and 5 ABCC5 variations by analyzing respective 
sequences in publicly available databases. One conservative substitution 1289 (Lys to 
Asn) reported by Lai et al., 2002 was not included. All these variants caused non-
synonymous changes in amino acids (Adachi et al. 2002). These variants were 
however not verified as true SNPs occurring in human samples and no frequencies 
were reported. Nearly all reported variations could not be found in the public SNP 
databases. The variation I18L was likely to be the SNP e1 -49C>T. In the same year, 
Saito et al., screened 48 Japanese individuals in eight genes of the ATP-binding 
cassette, subfamily C (ABCC/MRP/CFTR). Among the 779 genetic polymorphisms, 
230 are identified in ABCC4 and 85 in ABCC5. Within exons, a total of 11 ABCC4 
SNPs and 7 ABCC5 variations (including 1 repeat sequence) are listed. Only two 
ABCC4 SNPs and none of the ABCC5 SNPs were nonsynonymous. No allele 
frequencies were reported. All the SNPs in this report were also listed in the NCBI 
dbSNP database. 
More recently, Lockhart et al., 2003 reviewed polymorphisms in both nucleotide 
analogue transporters and listed a total of 10 ABCC4 and 10 ABCC5 variations 
(Lockhart et al. 2003). These variations were obtained by comparing various cDNA 
sequences of many sources in GenBank, including cell lines and across species e.g. 
mouse. Allele frequencies could not be obtained. 
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Only one report attempted to associate polymorphisms within the nucleotide analogue 
transporter genes with gene expression. Dazert et al., 2003 sequenced the ABCC5 
gene in 21 Caucasian individuals and identified 20 polymorphisms (Dazert et al. 
2003). Four exonic SNPs, all of which synonymous, were reported. They did not find 
any significant correlation between individual SNPs with ABCC5 mRNA expression, 
which could be a result of small sample size or the lack of power of association. 
Having a larger sample pool and using haplotypes instead of individual SNPs may 
have greater correlation power.   
The evolution of polymorphism/mutation databases has matched the rapid growth of 
SNP data. From several independent SNP databases, we tabulated a list of coding 
SNPs in ABCC4 and ABCC5 (Table 6). Several variations reported by the publications 
listed in Table 5 were not found within these databases. A total of 46 variants was 
found in ABCC4, surpassing the number found from polymorphism/mutation 
databases while the number of variants found in ABCC5 is remarkably small, 
especially when the transcript lengths of these two proteins are similar. Moreover, the 
ABCC4 protein carries far more variants that cause a nonsynonymous change in 
amino acid. Like the majority of the published reports for both gene loci, the 
variations detected via alignment of sequencing data e.g. from overlapping clones 
may be artifacts or cannot be traced at a detectable frequency in a human population 
(Marth et al. 2001; Barnes 2002). Only 6 ABCC4 variations and 3 ABCC5 variations 
possess a minor allele frequency of more than 10%.   
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Exon Function Amino Acid Change
Adachi et al., 2002 
(*Lai et al., 2002)
Saito et al., 
2002
Lockhart et al., 
2003
Dazert et al., 
2003
e1 -49C>T rs3751333 Yes e1 e1 67C/T
e1 52A>C rs11568681 e1 nonsynonymous Ile18Leu I18L *
e4 511G>T rs4148460 Yes e4 nonsynonymous Gly171Cys e4 205T/G T513G
e6 669C>T rs899494 Yes e6 synonymous Ile223Ile e6 48C/T T669C
e8 912T>G rs2274407 Yes e8 nonsynonymous Asn304Lys e8 1G/T G906T
e8 951G>A rs2274406 Yes e8 synonymous Arg317Arg e8 40G/A G951T
e8 969G>A rs2274405 Yes e8 synonymous Ser323Ser e8 58G/A G969A
e11 1497T>C rs1557070 Yes e11 synonymous Tyr499Tyr C1497T
e15 Unknown e15 nonsynonymous Glu637Gly E637G
e15 Unknown e15 nonsynonymous Ser664Phe S664F *
e15 Unknown e15 nonsynonymous Gln677Arg Q677R
e16 Unknown e16 nonsynonymous Ser703Asn S703N
e18 2269A>G rs3765534 Yes e18 nonsynonymous Lys757Glu e18 56G/A G2271A
e18 Unknown e18 nonsynonymous Gly757Glu G757E
e22 Unknown e21 nonsynonymous Gly893Glu G893E
e22 2712G>A rs1678339 Yes e22 synonymous Leu904Leu e22 26A/G A2712G
e23 2844C>T rs1189466 Yes e23 synonymous Phe948Phe e23 38C/T C2844T
e23 Unknown e23 nonsynonymous Lys1103Arg K1103R *
e26 3348A>G rs1751034 Yes e26 synonymous Lys1116Lys e26 138A/G A3348G
e27 Unknown e26 nonsynonymous Asn1139Lys N1139K *
e30 Unknown e30 nonsynonymous Ser1267Gly S1267G
e30 Unknown e30 nonsynonymous Lys1289Arg * 1289 (Lys to Arg)
e31 4016G>T rs3742106 Yes e31 e31 146G/T
ABCC5 SNPs
Exon SNP 







Exon Function Amino Acid Change Adachi et al., 2002
Saito et al., 
2002
Lockhart et al., 
2003
Dazert et al., 
2003
e3 Unknown e3 nonsynonymous Ala54Val A54V
e5 Unknown e5 nonsynonymous Pro176Arg P176R
* e5 GC527-8CG e5 nonsynonymous Arg176Pro GC527-8CG
e6 A723G e6 synonymous Ala241Ala A723G
e8 1145A>G Yes e8 synonymous Gln382Gln G1146A e8 36156A/G
e9 1185C>T rs1132776 Yes e9 synonymous Ala395Ala e9 38C/T C1185T e9 39270C/T
* e9 AGC1198-
200GGT e9 nonsynonymous Ser400Gly S400G
AGC1198-
200GGT
e9 1200 C>T Yes e9 synonymous Ser400Ser C1200T
e12 1743A>G Yes e12 nonsynonymous Ile581Val I584V A1741G e12 50138A/G
e12 1782C>T rs939336 Yes e12 synonymous Cys594Cys e12 21T/C T1782C
e25 3606 C>A Yes e25 nonsynonymous Tyr1202*
e25 3624C>T rs3749442 Yes e25 synonymous Leu1208Leu e25 120/T T3624C e25 75087T/C
e29 4148 C>A Yes e29 nonsynonymous Thr1383Asp N1383T C4148A
e30 4896G>A rs3749445 Yes e30 e30 684G/A
e30 5159 C>T Yes e30 e30 947C/T




e30 5557A>G rs562 Yes e30 e30 1345A/G
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Table 5.  Coding polymorphisms/mutations in ABCC4 and ABCC5 as reported from 
published reports. Adachi et al., 2002 reviewed ABCC4 sequences in 5 studies 
including Schuetz et al., 1999, Kruh et al., 2003, Lai et al., 2002, and van Aubel 2002 
for SNPs (Schuetz et al. 1999; Adachi et al. 2002; Lai and Tan 2002; van Aubel et al. 
2002; Kruh and Belinsky 2003), and ABCC5 sequences in another 5 studies from 
Suzuki et al., 1997, Belinsky et al., 1998, Wijnholds et al. 2000, McAleer et al. 1999, 
Jedlitchsky et al., 2000 (Belinsky et al. 1998; McAleer et al. 1999; Jedlitschky et al. 
2000; Suzuki et al. 2000; Wijnholds et al. 2000). By chance the polymorphism 
Lys1289Arg recorded by Lai et al., 2002 was not listed in Adachi’s review (marked 
by *). Lockhart, on the other hand reviewed ABCC4 polymorphisms in 2 studies from 
Saito et al., 2002 and Lee et al., 1998 (Lee et al. 1998; Saito et al. 2002a). Lockhart 
also reviewed ABCC5 polymorphisms from Belinsky et al., 1998, McAleer et al., 
1999, Wijnholds et al. 2000, and Suzuki et al., 2000 (Belinsky et al. 1998; McAleer et 
al. 1999; Suzuki et al. 2000; Wijnholds et al. 2000). However, he did not include 
ABCC5 SNPs recorded by Saito et al., 2002.  
 
More work is needed to characterize both ABCC4 and ABCC5 polymorphisms. There 
are certain concerns on the reliability of SNP information in public databases as well 
as comparative sequence data. Many of the variations reported as ‘SNPs’ in review 
publications and polymorphism/mutation databases were generated from comparative 
data of DNA sequences from overlapping clones and may therefore be mutations in 
cell lines used or sequencing errors, especially in small samples. The ‘false-positive’ 
variations may not be found in any human population at a detectable frequency 
(Marth et al. 2001; Barnes 2002). Re-genotyping may be required to verify these 
reported polymorphisms as true SNPs occurring in normal human populations and the 
International Hapmap Project is one major sequencing effort to yield data of verified 
SNPs. It remains elusive as to which of these ABCC4 and ABCC5 polymorphisms 
may have an impact on drug disposition or pharmacodynamics in vivo. In candidate 
gene-based studies such as this one, there are many more SNPs than can be 
investigated for every gene. A SNP selection strategy must be in place to permit a 
feasible list of SNPs to be investigated. Sources to look for variants include published 
reports and SNP databases. Sequencing pooled samples may also be a good 
complementary strategy. Validated SNPs are to be selected as well as common SNPs 
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that are known to exist at a frequency of more than 5-10% in the general population. 
SNPs that reside in exonic regions of the candidate genes especially those 
polymorphisms leading to a non-synonymous change in amino acid have a higher 
probability of association with a disease or drug response phenotype. SNPs residing at 
exon-intron junctions or at intron sites important for RNA stability (such as the 5’- 
and 3’- untranslated regions) may also be considered. Lastly SNPs within other 
intronic regions may be selected to achieve a high resolution sufficient for linkage 
disequilibrium analysis. 
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2.5 Clinical implications of ABCC4 and ABCC5 in drug efflux 
Based on substrate profiles of ABCC4 and ABCC5, clinical drugs with structural 
similarity to those used in experiments may also be potential substrates for 
ABCC4/ABCC5. These clinical drugs are mostly antitumour and antiviral agents. In 
association studies linking genotype to clinical drug response or disease, this selection 
of drugs in current clinical use may serve to be useful.  
 
1) Nucleotide and nucleoside analogues  
Nucleoside Reverse Transcriptase Inhibitors  
Treatment of nucleoside reverse transcriptase inhibitors (NRTIs) has been the 
cornerstone of HIV therapy since the first NRTI was introduced in 1987. With the 
availability of protease inhibitors (PIs) in 1997, NRTIs became the foundation of 
highly active antiretroviral therapy (HAART). With at least 7 NRTIs and NtRTIs on 
the market today, selection of these agents requires the careful and thoughtful 
consideration of efficacy, safety, resistance, and long-term tolerance profiles. 
NRTI/NtRTIs are structurally similar to the purine nucleosides adenosine and guanine, 
and the pyrimidine nucleosides thymidine and cytidine. They, however, lack the 
terminal 3'-OH group of the nucleoside. The mechanism of action of these 
NRTI/NtRTIs is by competitive inhibition. When these analogues are phosphorylated 
intracellularly and incorporated into the growing viral DNA chain, synthesis of DNA 
by reverse transcriptase (RT) is terminated. Viral RT mediates replication of viral 
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Hepatitis B antiviral agents 
Nucleoside/nucleotide analogues suppress HBV replication through inhibition of 
HBV DNA polymerase. A dideoxynucleoside reverse transcriptase inhibitor, 
lamivudine inhibits viral DNA replication. It is converted intracellularly to its active 
metabolite, b-L-3TC-triphosphate. Emerging treatment options include Adefovir, 
Dipivoxil and Entecavir. The adenine nucleotide analogue adefovir dipivoxil and the 
guanosine nucleoside analogue entecavir are oral antiviral drugs with activity against 
both wild-type and lamivudine-resistant HBV. Other experimental nucleoside 
analogue drugs include Telbivudine (LdT; Idenix; Phase III), Clevudine (L-FMAU; 
Gilead; Phase II), Elvucitabine (ACH 126,443; Acillon; Phase II), Valtorcitabine 
(Idenix; Phase II), Amdoxovir (DAPD, Triangle; Phase II), acivir (Pharmasset; Phase 
II), MCC478 (Elli Lilly; Phase I), MIV 210 (Medivir; Phase I), and Hepavir B 
(Ribapharm; Phase I). 
 
Hepatitis C antiviral agents 
Ribavirin [1-β-D-ribofuranosyl-1H-1,2,4-triazole-3-carboxamide] is a nucleoside 
analogue with antiviral activity used in combination therapy (primarily with interferon) 
for the treatment of hepatitis C. The U.S. Food and Drug Administration (FDA) in 
1998 approved Rebetron (combination of interferon alfa-2band ribavirin) for the 
treatment of individuals with chronic hepatitis C 
[http://www.fda.gov/cder/foi/label/2002/20903slr025_Rebetron_lbl.pdf] and on 24th 
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Antitumour Cytosine Analogues 
Gemcitabine (2',2'-difluorudeoxycytidine, dFdC) is an S-phase nucleoside cytidine 
analogue that is currently considered to be the single agent of choice in advanced 
pancreatic cancer and is being investigated in numerous trials as part of novel 
combination regimens [http://www.fda.gov/cder/foi/label/1998/20509lbl.pdf]. 
Gemcitabine has three mechanisms of action: it competes for incorporation into DNA, 
thereby inhibiting the synthesis of DNA; it prevents DNA repair by masked 
termination; and it undergoes self-potentiation. Gemcitabine primarily and 
irreversibly inhibits ribonucleotide reductase, the enzyme responsible for catalyzing 
the biosynthesis of deoxyribose nucleotides, which are essential for DNA replication. 
A drug recently abandoned in Phase II clinical trials is Tezacitabine [(E)-2'-deoxy-2'-
(fluoromethylene) cytidine (FMdC)] (designated orphan drug in 2005 by FDA), which 
acts similarly to gemcitabine. Also within this class is Troxacitabine (Troxatyl) 
(designated orphan drug in 2005 by FDA), a dioxolane nucleoside analogue of 
cytidine that is incorporated into DNA during replication, inhibiting DNA polymerase 
and DNA synthesis. Like gemcitabine it is intracellularly phosphorylated by 
deoxycytidine kinase to its active metabolite troxacitabine triphosphate. Unlike 
gemcitabine, however, it is not incorporated into RNA, it does not inhibit 
ribonucleotide reductase and it does not require nucleoside transporters, but enters 
cells by passive diffusion. Another pyrimidine nucleoside analogue of cytidine, 
Azacitidine (Vidaza, Pharmion Corporation, Boulder, CO) [4-amino-1-ß-D-
ribofuranosyl-s-triazin-2(1H)-one] is recently marketed in 2004 as an orphan drug for 
the use in myelodysplastic syndromes subtypes (MDS) 
[http://www.fda.gov/cder/foi/label/2004/050794lbl.pdf]. Known as the first of a new 
class of drugs known as DNA "hypomethylating" or "demethylating" agents, it is 
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thought to act by inhibiting DNA methyltransferase, the enzyme that is responsible for 
methylating newly synthesized DNA. Since methylation of DNA is a major 
mechanism regulating gene expression and increased DNA methylation can result in 
silencing of tumor suppressor genes, inhibition of methytransferase (“demethylation”) 
by azatidine may therefore restore the expression of genes silenced by methylation 
(Issa et al. 2005; Kaminskas et al. 2005a; Kaminskas et al. 2005b). 
 
2) Non-nucleotide and non-nucleoside analogues 
Nonsteroidal Anti-inflammatory Drugs (NSAIDs) 
Cellular efflux and vesicular uptake studies showed that both ABCC4 and ABCC5 are 
inhibited by physiological relevant concentrations of nonsteroidal anti-inflammatory 
drugs (NSAIDs) dipyramidole and indomethacin (Reid et al. 2003a; Reid et al. 2003b; 
Jedlitschky et al. 2004) (albeit by different degrees). Presence of ABCC4 and ABCC5 
in platelet membrane vesicles and granules as well as (porcine) coronary and 
pulmonary arteries also indicate a role of these two transporters in treatment of 
cardiovascular diseases including anticoagulant therapy. 
 
Uricosuric agents 
Reid et al., 2003 showed that two uricosuric agents, probenecid, and to a lesser extent 
sulfinpyrazone inhibit ABCC5 more than ABCC4. Both transporters are located in the 
kidney with ABCC4 protein expressed at the apical (brush border) membrane of the 
human renal proximal tubules. Uricosuric agents lower uric acid levels in patients 
with hyperuricemia and gout. Long term usage of uricosuric agents lowers uric acid 
levels and prevents the formation of uric acid crystals 
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PDE5 Inhibitors 
In 1988, FDA approved sildenafil citrate, a selective PDE5 inhibitor for the treatment 
of erectile dysfunction. By inhibiting the degradation of cGMP, PDE5 inhibitors 
prolong the activity of this cyclic nucleotide second messenger within the cavernous 
vasculature and smooth musculature, thus potentiating the erectile response. Two 
other drugs in this class are valdenafil and tadalafil.  
 
Leukotrienes Receptor Antagonists (LTRAs) 
The selective and competitive antagonist of leukotriene D4, MK571 is also a strong 
inhibitor of ABCC4- (Chen et al. 2002; Reid et al. 2003a), but not ABCC5-mediated 
cGMP transport (Jedlitschky et al. 2000; Klokouzas et al. 2003). There are three 
commercially available but structurally distinct drugs: montelukast and zafirlukast and 
pranlukast, which is available only in Asia. The LTRA drugs also known as 
leukotriene modifiers demonstrate both bronchodilator and anti-inflammatory 
properties and are used in the management of mild, persistent asthma. 
 
Topoisomerase I inhibitors  
Most inhibitors of type I topoisomerases are a new class of antineoplastic agents 
derived from campothecins. Camptothecins are alkaloids extracted from plants like 
Camptotheca acuminata. Drugs which are in clinical studies include 
natural/semisynthetic/synthetic derivatives of campthothecin: irinotecan [Camptosar, 
CPT-11]; topotecan [Hycamptin, TPT, 9-dimethyl-amino-methyl-10-
hydroxycamptothecin, 7-ethyl-10-[4-(1-piperidino)-1-
piperidino]carbonyloxycamptothecin], lurtotecan [NX211, OSI-211], exatecan [Ensiv, 
DX-8951f] and rubitecan [Orathecin, 9-nitrocamptothecin, 9NC, RFS 2000]. DNA 
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topoisomerases (types I and II) are enzymes in the cell nucleus that control DNA 
topology during nuclear processes such as replication, recombination, and repair. 
Type I DNA topoisomerase creates transient (reversible) single-stranded breaks in 
double-stranded DNA to relieve torsional strain inherent in supercoiled DNA double 
helix and binds covalently with the 3’-DNA terminus of the cleaved DNA strand, 
forming a complex. This complex can be cleaved and topoisomerase enzyme 
reanneals the broken DNA strands for transcription to proceed. Type I topoisomerase 
inhibitors are proposed to interact with the DNA-DNA topoisomerase cleavable 
complex during the S-phase of DNA synthesis. This interaction prevents the 
topoisomerase enzyme from religating the single-strand breaks. The accumulation of 
the ternary complex of DNA, topoisomerase type I inhibitor and DNA topoisomerase 
results in irreversible defects in DNA replication and subsequent cell cycle arrest and 
cell death. It was found that ABCC4, but not ABCC5 confers resistance to the 
topoisomerase inhibitor irinotecan and its active metabolite SN-38 in vitro (Norris et 
al. 2005). Remarkably the ABCC4-mediated resistance to irinotecan and SN-38 was 
relatively specific with less notable resistance to topotecan and camptothecin, even 
though all these drugs belong to the same class. 
The involvement of ABCC4 and ABCC5 transporters in drug resistance in clinical 
practice remains speculative but is supported by their substrate profiles and expression 
in specific tissues. Transport assays with recombinant ABCC4 or ABCC5 proteins 
may provide further evidence for the roles of ABCC4 and ABCC5 as transporters for 
the numerous drugs listed above. The identification of any polymorphisms within the 
ABCC4 or ABCC5 affecting any function may reveal the roles of both transporters as 
well as uncover new mechanisms of action of these drugs. Contrasting reports about 
substrate profiles of ABCC4 and ABCC5 have recently surfaced. In contrast to at least 
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two reports of both ABCC4 and ABCC5’s ability to transport cyclic nucleotides such 
cGMP with high affinity (Jedlitschky et al. 2000; Chen et al. 2001), Reid’s vesicular 
transport experiments showed low uptake of cGMP in ABCC4- or ABCC5-
overexpressing cells (Reid et al. 2003a). In addition, Reid also found that ABCC5 is 
insensitive to 3 inhibitors of cGMP-specific phosphodiesterase 5 (PDE5) (zaprinast, 
sildenafil, and trequinsin), while Jedlitschky reported a significant inhibition by the 
same substrates. These discrepancies could possibly be due to the use of different in 
vitro systems. The polymorphisms within the ABCC4 and ABCC5 cDNA 
independently isolated in different labs may also be another reason for these 
conflicting reports. An in-depth study of ABCC4 and ABCC5 polymorphisms is 
therefore needed to shed some light on these apparent discrepancies. 
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Chapter 3 Background and specific aims of studies 
 3.1 Workflow of studies 
To facilitate future association studies of the 2 nucleotide analogue transporters, 
ABCC4 and ABCC5 for future gene-based association studies, a step-by-step approach 
is devised from the development of a cost-effective SNP genotyping method to 
analyze multiple SNPs to characterizing the haplotype and linkage disequilibrium 
profiles of the 2 gene loci to finally achieving a manageable set of population-specific 
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Figure 5.  Overview of studies. 
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3.2 Genotyping assay development 
Responses to different drugs can vary widely among different individuals as a result 
of genetic variations in drug-metabolizing enzymes, transporters, receptors, and/or 
other cofactors. The multidrug resistance 1 (MDR1) transporter, a well-characterized 
member of the ATP-binding cassette superfamily, was shown to efflux a wide variety 
of structurally and functionally unrelated drugs, including anticancer, antiarrhythmic, 
antidepressant, antipsychotic, and antiviral agents. The pharmacogenetics of the 
MDR1 multidrug transporter have recently received much scientific attention. Several 
single nucleotide polymorphisms (SNPs) have been identified in the MDR1 gene; 
some occur only in specific ethnic groups, whereas others occur in all ethnic groups 
but at significantly different allele frequencies among the different races [see Ref. 
(Tang et al. 2002) and references therein]. Nonetheless, the functional significance of 
these SNPs remains unclear. Various functional associations, some paradoxical, have 
been observed between the synonymous SNP (exon 26 3435C>T) and MDR1 protein 
expression and plasma drug concentrations (Hoffmeyer et al. 2000; Hitzl et al. 2001; 
Kim et al. 2001; Sakaeda et al. 2001), drug-induced side effects (Roberts et al. 2002), 
and drug response (Fellay et al. 2002). The SNP exon 26 3435T allele has been 
associated with lower MDR1 expression in the duodenum (Hoffmeyer et al. 2000), 
leukocytes (Hitzl et al. 2001), and placental tissues (Tanabe et al. 2001), leading to 
lower rhodamine efflux (Hitzl et al. 2001) and increased plasma digoxin 
concentrations (Hoffmeyer et al. 2000). In addition, early-onset Parkinson patients 
have higher frequency of the SNP exon 26 3435T allele compared with late-onset 
patients or unaffected controls (Furuno et al. 2002). However, although this same 
allele has been associated with lower MDR1 expression in peripheral blood 
mononuclear cells and better response to HIV-1 drugs, it has also been associated 
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with lower plasma concentrations of nelfinavir (Fellay et al. 2002). Additionally, the 
SNP exon 26 3435T allele has been associated with an increased risk of nortriptyline-
induced postural hypertension, although blood concentrations of nortriptyline in these 
individuals were not significantly different from those in individuals carrying the C 
allele (Roberts et al. 2002). Furthermore, no association has been demonstrated 
between the SNP exon 26 3435C>T polymorphism and cyclosporin A efficacy in 
renal transplant patients (von Ahsen et al. 2001) or cyclosporin A pharmacokinetics 
(Min and Ellingrod 2002) in 14 healthy individuals. Together, these studies suggest 
that SNP exon 26 3435C>T itself may not be the causal variant producing these 
observed functional differences.  
Analyses of other SNPs within the MDR1 gene have revealed haplotype frequency 
differences among populations (Kim et al. 2001; Tang et al. 2002). The linkage 
disequilibrium (LD) spanning the 40 kb between SNPs exon 12 1236T>C and exon 
26 3435C>T was also found to differ among the Chinese, Malays, and Indians (Tang 
et al. 2002). Variations in LD blocks among different ethnic groups and the existence 
of ethnic-specific SNPs suggest that the current confusing association of SNP exon 26 
3435C>T with different functional changes may be attributable to strong LD between 
SNP exon 26 3435C>T and different, as yet unidentified, causal SNPs within the 
different LD blocks in the different study populations. Analyses of MDR1 haplotypes 
rather than genotypes may provide additional insights in determining associations 
with functional differences and may assist in discriminating between surrogate SNPs 
and causative variants. It would be useful to determine the haplotype structure of the 
entire 100-kb MDR1 gene in the different ethnic populations and to study the 
relationship between MDR1 haplotypes and drug response.  
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The primary aim is to first develop a rapid and robust assay to simultaneously 
genotype seven SNPs across the MDR1 gene. The seven SNPs span 100 kb of the 
gene and are located in five genomic regions that are potentially functional (promoter 
and exons 12, 21, 26, and 28). In this study, the principle of the genotyping assay is 
based on minisequencing or single-base extension (SBE) due to previous reports of its 
high accuracy (Syvanen 2001). Besides the ability to genotype multiple SNPs in a 
single reaction, the assay has to be scalable to 96 samples, sensitive to detect 
polymorphisms in small quantities of DNA and cost-effective. By coupling to an 
automated capillary electrophoretic platform, allelic discrimination of the different 
sizes of minisequencing products can be fast and efficient. Although this assay is first 
established using MDR1 as a candidate gene, it will be quickly modified and be the 
driving force for the haplotype and linkage disequilibrium studies of ABCC4 and 
ABCC5 gene loci. 
 
3.3 Genetic characterization of ABCC4 and ABCC5 gene loci 
More than one million SNPs have been validated in four human populations from the 
efforts of the International Hapmap Project [http://www.hapmap.org/] (2003). Such 
construction of high-density SNP maps has facilitated the testing of genetic variants 
of a potentially contributing gene in an association study through candidate gene 
studies. The candidate gene approach allows LD analyses and makes use of patterns 
of LD inherent in a gene region of interest to select a subset of tagging SNPs (tSNPs) 
to comprehensively describe common variations within the gene (Goldstein et al. 
2003). This significantly reduces genotyping effort with only a moderate loss of 
power (Johnson et al. 2001; Zhang et al. 2002). It has been estimated that at least 
400,000 tSNPs would still be required genome-wide (Carlson et al. 2004), and 
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genotyping this number of SNPs would still pose a major challenge in looking for 
causal gene loci. Recently the inference of natural selection as a strategy to look for 
functionally important variants has been of interest (Bamshad and Wooding 2003; 
Clark 2003). Under the influence of positive selective forces, a variant that increases 
the fitness of an individual to its environment undergoes fixation and leaves behind 
evolutionary footprints of low diversity and skewed allele frequency distribution 
(Altshuler and Clark 2005). These footprints are therefore trademarks of genes or loci 
that have undergone evolution under positive selection in recent history of humans 
due to adaptation of early humans as they dispersed out of Africa to specific 
geographical environments. Genes or loci that might underlie variation in disease 
resistance or drug transport can thus be identified through these changes (Bamshad 
and Wooding 2003) and there is increasing evidence of recent positive selective 
events on ABC drug transporters (Tang et al. 2004; Wang et al. 2005). 
Genetic variations in the MRP genes have been implicated in differences in drug 
response between individuals, and mutations in several genes have been identified in 
several human disorders, such as cystic fibrosis, sterol and bile salt transport 
deficiencies and retinal degeneration (Dean et al. 2001).  Hence, this study 
hypothesizes that single nucleotide polymorphisms (SNPs) within the ABCC4 or 
ABCC5 gene may potentially affect its expression and/or alter protein 
function/structure, leading to changes in the transport profiles and response to specific 
drugs and compounds.  At present, very little information is available underlying the 
ABCC4 and ABCC5 transporter polymorphisms resulting in inter-individual 
differences in drug response although it has been shown that there is large variability 
in ABCC4 expression in pediatric leukemias (Sampath et al. 2002) and a single study 
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of 21 Caucasian individuals found no statistically significant correlation between 
individual SNPs and mRNA expression of the ABCC5 gene (Dazert et al. 2003)..  
There is increasing interest in utilizing linkage disequilibrium (LD) and haplotype 
analyses for detecting associations between genes and complex traits.  The detailed 
characterization of haplotype and LD profiles in candidate genes in different ethnic 
populations may shed light on population history and ethnic differences that may 
confound association studies, but can also facilitate the identification of variants that 
are most likely to be the primary etiological determinants of complex diseases 
(Johnson et al. 2001; Reich et al. 2001).  Haplotype-based association studies have the 
advantage of not requiring the causal variant to be identified and tested directly and 
the potential of uncovering regions that harbor the trait variant (Judson and Stephens 
2001).  Such studies may provide more statistical power for detecting association with 
phenotype than association studies based on individual SNPs (Bader 2001).  By 
identifying a subset of highly informative tagging SNPs (tSNPs) representing the 
most common variations segregating at the gene locus, haplotype-based association 
studies can also be performed more efficiently (Johnson et al. 2001). 
This study postulates that both the ABCC4 and ABCC5 genes encoding widely 
distributed proteins with similarly unique transport profiles represent attractive 
candidate genes for linkage disequilibrium (LD) analysis and to test for signatures of 
local positive selection in preparation for future association studies. This study aims to 
derive population-specific haplotypes and generate tagging SNPs through 
comprehensive linkage disequilibrium analyses of ABCC4 and ABCC5 gene loci in 5 
ethnically unique and geographically distinct populations. These tSNPs should 
simplify future disease/trait association studies examining the roles of ABCC4 and 
ABCC5. It will further assess if positive selection can be a major cause for the genetic 
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diversity observed in different populations at specific loci of ABCC4 or ABCC5.  Loci 
exhibiting signatures of positive selection will be identified by a wide differentiation 
of allele frequency through two statistic measures, Fst and Pexcess (Akey et al. 2004; 
Bersaglieri et al. 2004), or the formation of a long-ranging haplotype within 
populations using a modified long-range haplotype test (LRH) (Sabeti et al. 2002; 
Tang et al. 2004).  
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II MATERIALS AND METHODS 
Chapter 4 Genotype assay development 
 4.1 Multiplex PCR amplification 
The multiplex minisequencing protocol is outlined in Figure 6. The five genomic 
segments containing the seven SNPs of MDR1 were amplified in a single multiplex 
PCR reaction. Twenty ng of genomic DNA was amplified in a T3 thermal cycler 
(Biometra) in a total volume of 10 µL containing 0.15 pmol/µL each of the 10 primers 
(Table 7A), 5 mM MgCl2, 200 µM each of the four deoxynucleotide triphosphates 
(dNTPs), and 0.75 U of HotStarTaq polymerase in the PCR buffer that was supplied 
(Qiagen). The reaction mixture was subjected to initial denaturation at 94 °C for 15 
min followed by 40 step-cycles of denaturation at 94 °C for 30 s, annealing at 56 °C 
for 30 s, and extension at 72 °C for 1 min. This was followed by a final extension at 
72 °C for 5 min. The expected PCR fragments and their sizes are shown in Figure 7A.  
 
 4.2 Multiplex minisequencing 
Unincorporated dNTPs and excess primers were inactivated and degraded in a single-
step reaction by the addition of 5 U of exonuclease I and 0.5 U of shrimp alkaline 
phosphatase (SAP; United States Biochemical), respectively, to 1.3 µL of the PCR 
product in a final volume of 2 µL. The reaction mixture was incubated at 37 °C for 15 
min, and the enzymes were subsequently inactivated at 80 °C for 15 min.  
The treated PCR products were then subjected to a multiplex minisequencing reaction 
to interrogate the seven SNP loci simultaneously. SNP-specific probing primers (or 
minisequencing primers) were designed to anneal to template DNA next to each SNP 
site such that extension by DNA polymerase added a single dideoxyribonucleoside 
triphosphate (ddNTP) complementary to the nucleotide at the polymorphic site 
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(Figure 7B). Each of the four ddNTPs was labeled with a spectrally distinct 
fluorophore i.e. ddATP was labeled with dR6G, ddCTP with dTAMRA™, ddGTP 
with dR110, and ddTTP with dROX™. To facilitate the examination of the seven 
SNPs simultaneously, each SNP-specific primer was designed to be a different length 
by the addition of variable lengths of nonhomologous d(GACT) polynucleotide tails 
to the 5' end of the primer. This enabled differentiation of the SNP loci based on 
length of the different ddNTP-extended primers (Figure 7B). The addition of 
nonhomologous tails simplified the standardization of annealing temperatures for all 
primers regardless of their total primer lengths. Minisequencing primers longer than 
40 bases were purified by HPLC to remove incomplete primer synthesis products. 
Table 7B details the sequences of the minisequencing primers and their concentrations 
in the final minisequencing reaction mixture.  
The multiplex minisequencing reaction contained the treated multiplex PCR product 
(2 µL), various concentrations of minisequencing primers, and 1.3 µL of SNaPshotTM 
Multiplex Ready Reaction Mix (Applied Biosystems) in a total reaction volume of 5 
µL. The reaction mixture was subjected to 25 single-base extension cycles of 
denaturation at 96 °C for 10 s, primer annealing at 53 °C for 5 s, and primer extension 
at 60 °C for 30 s. Thereafter, unincorporated fluorescent ddNTPs were inactivated 
enzymatically with 0.5 U of SAP at 37 °C for 1 h, followed by SAP deactivation at 80 
°C for 15 min.  
 
 4.3 Capillary electrophoresis and data analysis 
The multiplex minisequencing products (0.8 µL) were then mixed with 9 µL of 
HiDiTM formamide and 0.5 µL of GeneScan-120 LIZ size standard (Applied 
Biosystems), and resolved by automated capillary electrophoresis for 25 min on an 
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ABI PRISM 3100® Genetic Analyzer (Applied Biosystems). GeneScan-120 LIZ size 
standard was a 5th dye-labeled internal size standard. Analyses were performed with 
the GeneScanTM 3.7 application software (Applied Biosystems). The relative position 
of each primer peak indicated the SNP locus, whereas the peak color(s) specified the 
genotype. The colors of the analyzed peaks were green for ddATP, black for ddCTP, 
blue for ddGTP, and red for ddTTP. Figure 7C provides a diagrammatic depiction of 
the various colored peaks denoting the alleles at the various SNP loci and their 
positions relative to one another.  
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Figure 6.  Schematic illustration of multiplex minisequencing protocol.  
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Figure 7.  Multiplex PCR for the seven MDR1 SNPs. 
Panel A agarose gel electrophoresis of the multiplex PCR products from five 
representative samples. A 2-µL aliquot of each reaction product was resolved on a 2% 
agarose gel. UTR, untranslated region.  
Panel B, schematic diagram showing relative positions of the minisequencing primers 
and SNP sites within the MDR1 gene. Only exons are shown in the diagram except 
for the promoter region, where SNP -41AG resides within an intron. Minisequencing 
primers were designed to anneal next to each SNP site. Each minisequencing primer 
differed in length from the next by the inclusion of 5' nonhomologous tails of various 
lengths.  
Panel C, schematic illustration of the expected allele peaks of the seven SNP loci and 
their relative migration patterns on the GeneScan electropherogram. The position of 
the ddNTP-extended primer peak specifies the SNP locus, whereas the peak 
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Chapter 5 Genetic structure characterization 
5.1 DNA samples 
Human genomic DNA was derived from 2 sources.  Blood samples were collected 
from discarded umbilical cords of normal, healthy and unrelated neonates delivered in 
the National University Hospital, Singapore.  Genomic DNA was isolated from 288 
samples.  These samples were previously archived genomic DNAs extracted from 
cord blood samples discarded after clinical newborn screening for glucose-6-
phosphate dehydrogenase deficiency.  The samples had been completely anonymized 
by removal of all identifiers immediately after G6PD testing and prior to DNA 
extraction.  These samples belonged to each of three ethnic Asian populations 
representing various geographical locations including East Asia (Chinese) (96 
samples), Southeast Asia (Malay) (96 samples) and South Asia (Indians) (96 samples).  
The Chinese and Indian populations were mainly descendents of migrants from South 
China and India respectively, while the Malays are indigenous inhabitants. Only sex 
and race of the sample are retained which are insufficient to determine identity.  
Ethnicity was categorized based on the mother's self-report and verified by the nurse. 
Individuals were considered to be of a given ethnic group if both parents were of the 
same ethnicity as the child. For example, the cord blood from a child of known mixed 
parentage would be assigned under ‘Others’ during childbirth and its cord blood 
would not be selected for DNA extraction. No database containing identifiable 
information exists for these samples, and there is thus no possibility of tracing their 
identity.  These studies do not utilize prospectively collected venous blood samples. 
While efforts have been made to ensure careful handling during sample collection, 
there exists a small possibility that cord blood may be contaminated with maternal 
cells and thereby interfere with subsequent genotyping results. Nevertheless, 
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genotyping of microsatellites and the triallelic MDR1 SNP e26 2677G>T/A 
conducted on these same samples did not yield results of more than 2 alleles in any 
sample. This gives us confidence that any maternal DNA contamination is minimal 
among the samples. These studies fall within the guidelines as spelt out in the IRB 
guidelines (NUS_IRB guidelines (IRB-GUIDE-006 #4 and OHRP Guidelines 45 CFR 
46.101) and the Human Tissue Research report of the Bioethics Advisory Committee 
(Part IV, Section 8, para 8.10) and exemption from IRB review was thus obtained 
from the National University of Singapore (NUS-IRB Reference Code #04-126E). All 
original identifiers of each sample were discarded with the exceptions of ethnicity and 
sex.   
Genomic DNA samples were also obtained from the respective Human Variation 
Collections in the National Institute of General Medical Sciences (NIGMS) Human 
Genetic Cell Repository (The Coriell Institute for Medical Research, Camden, NJ).  
These consisted of 100 European Americans and 100 African Americans.  
These populations were chosen with a view to directly compare against populations 
with similar ancestry used by the International Hapmap Project 
[http://www.hapmap.org/].  Hence the Chinese, European American and African 
American population data would be compared against data derived from the Han 
Chinese in Beijing (HCB), CEPH/UTAH (CEU) and Yoruba in Ibadan (YRI) 
respectively.  The Malay and Indian populations were included to study whether 
results from one population could be transferable to other populations. 
 
5.2 SNP selection 
Selection of SNPs was initially based on three criteria: location at which a SNP could 
exert a functional change, high reported minimum allele frequency (>5%) for 
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adequate haplotype characterization and that consecutive SNPs were well-spaced 
apart throughout the ABCC4 locus for comprehensive coverage.  Exonic SNPs are 
likely to cause functional changes, so all exonic SNPs that have a reported minor 
allele frequency of 5% were selected to maximize chances that these SNPs would be 
observed in the studied samples.  SNPs in the 5’ flanking region might alter promoter 
activity so these were studied as well.  Intronic SNPs were selected purely to ensure 
an even SNP density throughout the gene locus and therefore a reported high minor 
allele frequency in intronic SNPs would be advantageous.   
The ABCC4 gene (NT_009952) spans approximately 280 kb (Figure 8).  In all, 
twenty-eight SNPs were selected from published reports (Saito et al. 2002a) and 
public databases (Figure 8).  These SNPs lie within 1500 bp 5’ from the transcription 
starting site to 1500 bp 3’ downstream from the last exon of the gene.  The distances 
between pairs of consecutive SNPs vary from 57 bp to 35.9 kb. 
Twenty-one SNPs occurring in the exons, introns and flanking regions and spanning 
~100 kb of the ABCC5 gene (NT_022959) were selected from previously published 
reports (Saito et al. 2002a; Dazert et al. 2003) or public databases (Figure 9).  All 
reported SNPs residing in potentially functionally regions (i.e. exons and 5’ flanking 
regions) were genotyped in at least one population.  SNPs that were monomorphic in 
that population (e.g. exon 9 1200C>T; exon 25 3606C>A; exon 29 4148C>A; e30 
5159C>T) were excluded from the final panel of SNPs that was genotyped in the 5 
populations.  The distances between 2 consecutive SNPs varied from 15 bp to 25 kb.  
In addition, 1163 bp upstream of the transcription start site was sequenced in more 
than 30 random Asian genomic samples (Figure 9) to identify additional novel SNPs 
in this very important putative promoter region.  Three novel SNPs was identified in  
this region (Figure 9). 
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5.3 Nomenclature of SNPs 
The nomenclature for the SNPs used is as follows:  For the 5’ flanking SNPs - 
Region-number of nucleotides upstream the transcriptional starting site-Allele 
1>Allele 2.  Since these SNPs occur in the intronic region upstream exon 1, Region is 
denoted as intron -1 and allele numbers carry a negative sign.  For the coding SNPs – 
Region-number of nucleotides downstream of transcriptional starting site using cDNA 
sequence-Allele 1>Allele 2.  Region refers to the exon that the SNP resides.  For 3’ 
flanking SNPs – Region-sum of the length of the cDNA sequence plus number of 
nucleotides after the cDNA sequence-Allele 1>Allele 2.  Since these SNPs occur in 
the intronic region after exon 30, Region is denoted as intron 30.  For intronic SNPs – 
Region-number of nucleotides downstream the respective intron-exon junction-Allele 
1>Allele 2. Region denotes the intron that the SNP resides (Gwee et al. 2005). 
 
5.4 Genotyping strategy 
Eight different minisequencing panels were set up, each genotyping 4-10 different 
ABCC4 and ABCC5 SNPs.  Specific PCR primers and minisequencing probes were 
designed for the amplification of fragments containing these SNPs and the multiplex 
reactions respectively.  Information on the PCR and minisequencing primers as well 
as the conditions of reaction are tabulated in the Tables 7 and 8.  All primers ordered 
were normal oligonucleotides. Minisequencing primers that were greater than 45 bp in 
length were HPLC purified to reduce background and increase signal-to-noise ratio. 
Genotyping was carried out using multiplex PCR amplification and multiplex 
minisequencing as previously described (Gwee et al. 2003).  For each minisequencing 
panel, one to ten different genomic segments containing the SNPs of ABCC4 and 
ABCC5 were amplified in a single multiplex PCR reaction.  PCR was performed 
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using either Qiagen Multiplex PCR Master Mix (containing HotStarTaq DNA 
Polymerase), or using standard HotStarTaq DNA polymerase in an otherwise identical 
reaction mixture.  Ten ng of genomic DNA was amplified in a T3 thermal cycler 
(Biometra) in a total volume of 5 µL containing 0.10 – 0.25 pmol/µL each of the PCR 
primers (Table 7A), 1.25 - 5 mM MgCl2, 100 – 200 µM each of the four 
deoxynucleotide triphosphates (dNTPs), and 0.25 - 0.75 U of HotStarTaq polymerase 
in the PCR buffer that was supplied (Qiagen).  It was possible to substitute 
HotStarTaq polymerase directly with 2x Qiagen Multiplex PCR Master Mix (no 
additional buffer required).  Multiplex assays could be tedious and time-consuming to 
establish. Some form of optimization was usually required, such as adjusting primer 
concentrations, and Mg2+ concentration.  The Qiagen Multiplex PCR Kit combined 
the benefits of a highly stringent hot start with a unique PCR buffer specifically 
developed for multiplex reactions and made customization of multiplex PCR assays 
faster.  For Panel C of Table 8 (ABCC4) and Panel of B of Table 9 (ABCC5), the high 
GC content (>65%) of the 5’ and 3’ flanking regions required the addition of betaine 
for successful amplification. First, the reaction mixture was subjected to initial 
denaturation at 95 °C for 15 min followed by 40 step-cycles of denaturation at 95 °C 
for 45 - 60s, annealing at 56 – 64 °C for 30 - 45s, and extension at 72 °C for 1 - 2 min. 
This was followed by a final extension at 72 °C for 10 min. To ensure that the 
multiplex amplification was successful, the amplicons were analyzed by 
polyacrylamide (10-15%) or agarose gel (1.5 - 2%) electrophoresis for at least 25% of 
the samples of each panel. The expected PCR fragments and their sizes are tabulated 
in Tables 7 and 8. 
The direct addition of 2 U of exonuclease I and 0.2 U of shrimp alkaline phosphatase 
(SAP; United States Biochemical) to 0.5 µL of the PCR product in a final volume of 
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0.8 µL inactivated and degraded unincorporated dNTPs and excess primers 
respectively in a single-step reaction. The reaction mixture was incubated at 37 °C for 
30 min, and the enzymes were subsequently inactivated at 80 °C for 15 min.  
After treatment with ExoI and SAP, the PCR products were subjected to a multiplex 
minisequencing reaction. Each of the SNP-specific probing primers (or 
minisequencing primers) was designed to anneal to template DNA next to the 
respective SNP site so that DNA polymerase extended a single dideoxyribonucleoside 
triphosphate (ddNTP) complementary to the nucleotide at the polymorphic site.  
Incorporation occurred only at a single site and the addition of ddNTPs terminated 
further extension. Each of the four possible dye labeled terminators in the 
minisequencing reaction was labeled with a different fluorescent dye, which allowed 
the labeled primer extension products to be detected and analyzed.  The addition of 
variable lengths of nonhomologous d(GACT) polynucleotide tails to the 5' end of 
each SNP-specific primer enabled differentiation of the SNP loci based on length of 
the different ddNTP-extended primers. The sequences of the minisequencing primers 
and their concentrations in the final minisequencing reaction mixture were tabulated 
in Tables 7 and 8 for ABCC4 and ABCC5 respectively.  To 0.8 µL of treated multiplex 
PCR products, various concentrations of minisequencing primers and 0.28 µL of 
SNaPshotTM Multiplex Ready Reaction Mix (Applied Biosystems) to a total reaction 
volume of 1.5 µL.  The multiplex minisequencing reaction consisted of 25 single-base 
extension cycles of denaturation at 96 °C for 10 s, primer annealing at 53 °C for 5 s, 
and primer extension at 60 °C for 30 s. To inactivate unincorporated fluorescent 
ddNTPs enzymatically, 0.5 U of SAP was added to the tube. The entire solution was 
incubated at 37 °C for 30 min, followed by enzyme deactivation at 80 °C for 15 min. 
Before being resolved by automated capillary electrophoresis for 25 min on an ABI 
 80
Genetic Characterization of Nucleotide Analogue Transporters ABCC4 and ABCC5 Gene Loci 
PRISM 3100® Genetic Analyzer (Applied Biosystems), 0.8 µL of the multiplex 
minisequencing products were added to 9 µL of HiDiTM formamide and 0.15 µL of 
GeneScan-120 LIZ size standard (Applied Biosystems). Analyses of the 
electropherogram were performed with the GeneScanTM 3.7 application software 
(Applied Biosystems). For SNP loci in every panel of minisequencing, several 
samples from each ethnic population were randomly selected for dideoxy sequencing 
to ascertain the accuracy of genotyping and several samples were chosen to be 
regenotyped to ensure consistency of results obtained.  
While the general steps of the genotyping strategies followed the original protocol 
used for haplotype analyses of MDR1 SNPs, several improvements had been made. 
These include the use of less DNA as starting material for amplification, reduction of 
volumes of reagents such as SNaPshotTM Multiplex Ready Reaction Mix (Applied 
Biosystems) as well as the reduction of time for amplification and minisequencing. 
This highlighted the flexibility and robustness of the genotyping strategy introduced. 
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5.5 Data analysis 
The allele frequencies for each SNP were calculated and determined if these 
frequencies vary significantly among 5 populations using Fisher’s exact test. Any 
deviation of the SNP allele frequency from Hardy-Weinberg equilibrium was also 
tested using Bonferroni correction for multiple locus testing.   
All SNPs polymorphic in all populations were used for the inference of haplotypes 
from the genotypic data, removing SNPs that were monomorphic in any population.  
Only samples in which all loci can be genotyped were included in the haplotype 
frequency estimation. To reconstruct possible haplotypes and estimate haplotype 
frequencies from genotype data, the expectation-maximization (EM) algorithm 
(Slatkin and Excoffier 1996) within SNPHAP version 1.3 program [http://www-
gene.cimr.cam.ac.uk/clayton/software/snphap.txt] was utilized. This program has the 
advantage of managing potentially large number of haplotypes generated from a large 
number of SNP loci. Fisher’s exact test was used to detect any differences in 
haplotype frequencies within populations.    
To summarize pair-wise LD, 2 common measures of LD, Lewontin’s coefficient, |D’| 
(Lewontin and Krakauer 1973; Ardlie et al. 2002), and Pearson’s correlation, r2 
(Pritchard and Przeworski 2001; Ardlie et al. 2002) were used.  Fisher’s exact test was 
utilized to determine whether pairs of SNP markers were in significant LD.  From the 
negative correlation of LD and genetic distance, a LD decay trend line was obtained 
with the equation: D = Do(1-α)t (Schulze et al. 2002).  Half-LD (LD0.5) is defined as 
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5.6 Identification of tagging SNPs 
Tagging SNPs (tSNPs) at the both the ABCC4 and ABCC5 gene locus were identified 
using the “TagIT” program [http://popgen.biol.ucl.ac.uk/software.html] based on 
weighted-average haplotype r2 (Weale et al. 2003).  The smallest ‘best-performing’ 
sets of tagging SNPs in every population as well as for all 5 populations were chosen.  
 
5.7 Scanning for evidence of positive selection 
Two measures, Fst and Pexcess based on the quantitation of the variation in SNP allele 
frequencies between populations were used to identify signatures of natural selection. 
To examine variations in allele frequencies, distribution of Fst values was constructed 
for all genotyped SNPs for 5 populations. The fixation index, Fst, was calculated with 
Nei’s correction for sample size (Akey et al. 2002).  In cases where estimates of Fst 
values are negative, they are assumed to be zero (Akey et al. 2002). Based on the 
comparison of simulated and empirical genome-wide distribution of Fst performed by 
Akey et al (Akey et al. 2002), a threshold of 0.45 or greater was applied in this study 
to be indicative of selective forces acting on that allele. 
Besides Fst, a novel test based on Pexcess was applied. This test calculates the 
probability P which represents the extent at which a haplotype is over-represented in 
the affected sample, and equates to Pexcess = (Ptest - Preference)/(1 - Preference), 
where Ptest and Preference denote allele frequency in chromosomes of population 
under study and ancestral population, respectively. Taking the African American 
allele frequency as representative of the ancestral allele frequency (Preference), the 
21% European admixture was not corrected (Parra et al. 1998; Bersaglieri et al. 2004).  
As a final strategy to look for signatures of recent positive selection at both the 
nucleotide analogue transporters, this study also adopted the long range haplotype 
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(LRH) test described first by Sabeti et al., 2002 and modified it for individual SNP 
markers.  The Haplotype Branching Diagrams (HBDs) were illustrated using an 
algorithm that was programmed using the VBA language in Microsoft Excel. The 
algorithm was capable of analyzing both biallelic and triallelic SNPs.  The Haplotype 
Branching Diagram (HBD) allowed the profile of LD decay to be represented 
pictorially across the entire ABCC4 or ABCC5 gene locus and helped the visualization 
of the presence of a strong and extensive haplotype, signified by a strong thick branch. 
The root of each diagram begins from a core SNP locus from which branches appear.  
The thickness of each branch corresponds to the proportion of chromosomes with the 
haplotype.   
To quantitatively assess the LD decay of each allele (for every test SNP site) over a 
stretch of genomic distance, a statistical measure called the extended haplotype 
homozygosity (EHH) was used. EHH at a distance x from the test variant (either a 
single SNP allele or a core haplotype) is defined as the probability that two randomly 
chosen chromosomes containing the tested variant are homozygous at all loci for the 
entire length of x. Relative EHH (rEHH) is then expressed as the ratio of EHH of the 
tested allele against the EHH of the other alleles at the same locus (Sabeti et al. 2002). 
A high relative rEHH given a certain allele frequency is usually indicative of recent 
positive selection.  The extended haplotype homozygosity (EHH) of each tested SNP 
allele was first calculated to capture those with unusually high rEHH. The rEHH 
values of these alleles were then tested against simulated data. 
 
5.8 Coalescent simulations 
An allele with long flanking haplotype may be under evolutionary processes other 
than recent positive selection. To test the hypothesis of positive selection, coalescent 
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simulations were performed (Hudson 2002). Representing different evolutionary 
processes, four different population models including those of constant size, 
expansion, extreme bottleneck and highly structured population were simulated. The 
parameters for the four tested models were defined as follows. A population size of 
10,000 was assumed for the constant-sized model. The expansion model assumed a 
sudden population expansion from 104 to 107 occurring 200 generations ago. The 
bottleneck model assumed sudden reduction in population size from 10,000 to 800 
occurring 800 generations ago which recovered to 10,000 at the 640th generation. 
Two equal subpopulations with a constant size of 5000 and with a compound term 
signifying a constant migration rate 4Neμ=0.1 was assumed for the structured 
population, where μ is the mutation rate. 
Within each model, simulations were performed with three different recombination 
rates, 0.65 cM Mb–1, 1.3 cM Mb–1 and 2.6 cM Mb–1. These values reflect the large 
variations of recombination rates observed in the human genome (Nachman 2002). 
Three mutation rates, 0.5x10–8 site–1 generation–1, 1.0x10–8 site–1 generation–1 and 
2.0x10–8 site–1 generation–1, were first tested for the constant-size model with 
recombination rate of 1.3 cM Mb–1. The distribution of mutation sites were expected 
to be independent of genealogy, since these mutation sites were assigned after 
simulation of genealogy. The resulting data distribution was found to be consistent 
despite different mutation rates. Thus, a constant mutation rate of 1.0x10–8 site–1 
generation–1 was utilized for all models. Only recombination rates would be variable 
for each of the 4 models.  
A chromosomal sequence of 300 kb was simulated. Datasets matching the observed 
data to within ±12.5% of the allele frequency and EHH, and within ±3 kb in distance 
for all downstream loci were first selected. The anchor locus was chosen to be within 
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±3 kb of the tested locus for the selected datasets. Each simulation was iterated at 
least 10,000 times to achieve 20,000 – 50,000 data points for each of the five 
populations.  
Plots of allele frequency versus relative EHH for the simulated data points were 
obtained and compared with the observed data of alleles of the test SNP locus. 
Probability lines of 95%, 75% and 50% were obtained by binning the simulated data 
by allele frequency into 20 bins of equal size with intervals of 5%. P-values were 
computed by ranking the relative EHH of the observed SNP of interest with that of all 
of the simulated data points that lie within a ±0.25 allele frequency window of that 
SNP. SNPs of high rEHH were selected as candidates for ranking against simulated 
data points containing SNPs of the matching allele frequency.  SNP markers with 
empirical P value < 0.05 were deemed to show evidence of recent positive selection. 
 
5.9 Prediction of transcription factor binding sites 
To assess whether the identified polymorphisms in 5’ flanking region (ABCC4 SNP -1 
-1015G>A) affected binding to putative transcription factors, a genomic sequence of 
1500 bp 5’ from the transcription starting site containing each of the alternative alleles 
of SNPs within this sequence was submitted to three web-based algorithms.  These 
three webtools were MatInspector 
[http://www.genomatix.de/products/MatInspector/index.html] (Quandt et al. 1995), 
TESS (Transcription Element Search System) [http://www.cbil.upenn.edu/tess] 
(Schug and Overton 1997) and Alibaba2.1 [http://www.alibaba2.com/] (Grabe 2002). 
The MatInspector algorithm was set with the default optimized matrix similarity 
threshold and produced the most number of results.  The TESS algorithm was set at 
these default parameters: maximum allowable string mismatch % (tmm) = 10; 
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minimum log-likelihood ratio score (ts-a): = 12; minimum string length (tw) = 6; 
secondary lg-likelihood deficit = 3; count significance threshold = 1.0e-2; minimum 
core similarity = 0.75; and minimum matrix similarity = 0.85.  These parameters were 
set for the Alibaba2.1 algorithm: pair-wise similarity of sequence to known binding 
sites = 50; matrix width in bp = 10; minimum number of sites in matrix = 4; average 
matrix conservation = 75%; Similarity of sequence to matrix = 1%; and factor class 
level = 4. 
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III RESULTS 
Chapter 6 Genotyping assay development 
The aim of this study was to use the MDR1 gene as a candidate for the development 
of a genotyping assay to be used for haplotype analysis and this study will serve as a 
foundation for the genetic characterization of the nucleotide analogue transporters 
ABCC4 and ABCC5, the subjects of this thesis. 
A multiplex PCR strategy was employed to simultaneously amplify 5 different 
genomic regions in the MDR1 gene for subsequent genotyping of the 7 SNPs in the 
MDR1 gene.  Under the PCR conditions described, 5 distinct bands of different sizes 
representing the 5 genomic regions were observed (Figure 7). 
The multiplexed PCR products were then purified to inactivate and remove 
unincorporated dNTPs and excess primers before multiplex minisequencing was 
performed.  After multiplex minisequencing, unincorporated fluorescent ddNTPs 
were enzymatically inactivated before the resultant products were resolved by 
capillary electrophoresis.   
As illustrated in Figure 10, this assay was able to unambiguously genotype different 
DNA samples at the seven MDR1 SNP loci. Each SNP locus was identified based on 
differences in primer length, and hence migration speeds through the capillary, as well 
as peak color from incorporation of one of 4 different fluorescent ddNTPs by the 
SNP-specific primer.  For example, the SNP-specific primer of SNP Intron -1/-
41A>G is shorter, and thus migrates faster, than the SNP 26 3435C>T primer.  In 
samples homozygous at a particular SNP locus, either of the alternative dye-
terminators attached to the SNP-specific primer, producing a single primer peak at 
that site on the electropherogram. Samples heterozygous for a particular locus had two 
different dye-terminators attach to the minisequencing primer, producing two, 
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different-colored peaks. Migration of this same minisequencing primer differed 
depending on the molecular weight differences of the nucleotide–fluorescent ddNTP 
combinations. For example, the A-allele peak of SNP exon 21 2677GT>A migrated 
more slowly than the G-allele peak, so that SNP exon 21 2677GA heterozygous 
samples displayed two allele peaks with minimal overlap (Figure 10f). However, the 
T-allele peak did not migrate very differently from the A-allele peak; hence SNP exon 
21 2677TA heterozygous sample displayed overlapping allele peaks (Figure 10d). 
Peak heights of the different alleles could also differ significantly because of 
differences in the fluorescence intensities of the different fluorophores (Figure 10). 
Accurate genotypes were obtained from all 100 genotype type-known samples at all 
seven loci that were tested (data not shown).  
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Figure 10.  Genotyping results for the seven MDR1 SNPs. 
GeneScan 3.7 analysis of multiplex-minisequencing products. Electropherograms of 
representative samples with different genotypes at the seven SNP sites are shown. 
Each SNP allele displays a characteristic peak color, position, and height relative to 
the other allele peak 
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Chapter 7 Genetic characterization of ABCC4 gene locus 
7.1 Large variability in SNP frequencies amongst populations 
Within ABCC4, 28 SNPs were genotyped in 4 multiplex minisequencing panels (as 
shown in Table 8).  These SNPs included 12 exonic SNPs, 11 intronic SNPs, 4 SNPs 
in the 5’ flanking region and 1 in the 3’ flanking region, all of which were either 
reported in the public databases or publications (Table 10). SNP i-1 –644C>T and 
SNP e4 511T>G were monomorphic in all 5 populations while SNP e11 1497C>T 
was only polymorphic in the African American population.  SNP e11 1497C>T may 
therefore be an ancient variant which was lost after the diversification of the ancient 
African population into other subpopulations.  Only 3 SNPs including the exonic SNP 
e18 2269G>A possessed a minor allele frequency of less than 5%.  The rest of the 
SNPs were highly polymorphic. 
In addition, results also showed allele frequencies to vary widely amongst different 
populations. Unlike previous studies on MDR1 and ABCC5, the Chinese and Malay 
populations did not share as much similarity in allele frequencies (Tang et al. 2004; 
Gwee et al. 2005). Previous similar relationship between the Indian and European 
American populations was also not seen here.  However, the African American 
population remained the most different in terms of allele frequencies.  An example 
could be seen in the C allele of the SNP i19 10304C>A. In the African American 
population, the C allele occupied an allele frequency of 25.5% and this frequency rose 
to a range of 66.0-78.5% in the non-African populations.  
Positional information of the SNP loci is presented in Table 10 and Figure 8.  Ten of 
140 different SNP locus/population combinations showed deviations from HWE at 
α=0.05. Genotyping error was ruled out by rechecking minisequencing 
electropherograms, sequencing random samples as well as samples in which 
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genotypes were too difficult to call. These deviations may therefore be due to other 
violations of assumptions inherent to Hardy-Weinberg such as close linkage to areas 
under selection. Most of these deviations were also observed to occur in the African 
American population. Although its ancestry is predominantly African, it may be 
difficult to rule out admixture from European and Native American founding 
populations (Parra et al., 1988; Kittles et al., 2002). Upon Bonferroni adjustment for 
multiple-loci testing, no significant evidence for deviation from Hardy-Weinberg 
equilibrium (HWE) was found in all SNPs.  
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7.2 Rapidly declining LD profile across ABCC4 gene locus 
The LD between all pairs of genotyped SNP loci was investigated and the data 
presented in Figure 11.  Two traditional measures of LD, D’ and r2, were used to 
estimate recombination rates and strength of association respectively.  Pair-wise LD 
in Figure 11 showed that general pattern of LD across all 5 populations was similar.  
SNPs in close proximity showed more intense LD between them than those apart e.g. 
SNPs e22 2712A>G and e23 2844C>T.  SNP e18 2269G>A showed erroneously high 
measures of LD with all other SNPs in the European American and African American 
populations, due to its low minor allele frequency of less than 2%.  Since SNP e11 
1497C>T only occurred in the African American population, LD values were not 
calculated for the rest of the populations (highlighted in grey in Figure 11).  
LD measures against genomic distance were correlated, restricting values from SNPs 
with minor allele frequency >5%. The common LD decay pattern existed in all 
populations, although the negative correlation between LD measures and distance was 
poor (Figure 11A). Half-length LD of the Chinese, Malay, Indian, European 
American and African American populations were 54.4 kb, 50.6kb, 57.8kb, 58.2 kb 
and 48.0kb, with correlation coefficient R2 at 0.240, 0.184, 0.091, 0.208, 0.130 
respectively (Figure 11B).   In addition, useful r2 values greater than 0.3 were 
estimated to be 77.42 kb in both Chinese and Malays, 59.03 kb in both Indians and 
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7.3 High variability in profiles of common haplotypes amongst 
populations 
The overall LD across the ABCC4 gene was rather weak. Consequently, the number 
of haplotypes for the gene was likely to be large.  Only a short stretch between SNPs 
e18 2269G>A and i27 7469G>A showed discernibly tight linkage in all populations. 
The number of haplotypes was inferred, based on estimates derived using the EM 
algorithm from the genotypic data of 25 polymorphic SNPs in all 5 populations.   
EM estimated that there were 104, 100, 116, 117, and 151 haplotypes in the Chinese, 
Malay, Indian, European American and African American populations respectively.  
In total, 536 unique haplotypes could be found for all samples.  None of the estimated 
haplotypes was shared by all 5 populations and only 10 haplotypes were shared by 
more than 2 populations.  These numbers of EM-estimated haplotypes were compared 
to those derived from a simulated population of the same sample size and observed 
allele frequency assuming random association among the 25 analyzed SNPs.  Under 
random association, 185.95±0.23, 191.88±0.34, 187.61±0.62, 199.31±0.86, and 
199.68±0.57 haplotypes were predicted to exist in the Chinese, Malay, Indian, 
European American and African American populations respectively.  The reduction in 
predicted haplotype number (~ 52.1 - 75.6%) represented a small but significant 
amount of recombination that has taken place in this locus.  
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Figure 12.  Haplotype profiles of SNPs at the ABCC4 gene locus.  Haplotype 
frequencies were inferred from genotype data of the 25 highly polymorphic SNPs at 
the ABCC4 gene locus using Expectation-Maximization algorithm.  A total of 536 
unique haplotypes occur in at least one population, of which 104, 100, 116, 117, and 
151 were found in the Chinese, Malay, Indian, European American and African 
American populations, respectively.  Only haplotypes occurring at >2% are presented 
in this figure and those with frequencies >2.5% are labeled as MH1-MH25.  
Haplotype profiles are represented as horizontal arrays of black or white boxes with 
the allele specified.  Each column of boxes represents a SNP locus.  Each row of 
boxes represents a haplotype, with the estimated frequencies expressed as a 
percentage shown in the adjacent table as well as portrayed in a bar graph. (CH: 
Chinese; ML: Malay; IN: Indian; CAU: European American; AA: African American). 
 
 
In Figure 12, 25 haplotypes with frequency of at least 2.5% in any 1 population are 
identified as “major haplotypes” (MH).  The highest haplotype frequencies observed 
are 4.62% (MH10 in Chinese), 8.85% (MH4 in Malays), 7.28% (MH20 in Indians), 
11.92% (MH5 in European Americans) and 3.00% (MH15 in African Americans).  
Since the haplotype distribution profiles of the populations differed widely, it would 
be important to find out if the differences observed were significant.  Applying 
Fisher’s Exact test to the haplotype frequencies showed that the African American 
population was significantly different from the rest of the 5 populations (p<0.05), with 
the exception of the Indian population.  No significant differences could be observed 
in other pair-wise population differentiation.  
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7.4 Population-specific tagging SNP sets  
The presence of low-grade LD across the ABCC4 gene signified that there were 
considerably large sets of haplotypes.  However this study still attempted to reduce 
the complexity of the haplotypes by calculating the smallest tagging-SNP (tSNPs) sets 
sufficient to represent all the haplotypes for each population (Table 11).   A total of at 
least 7 tSNPs was required to obtain the weighted-average haplotype r2 values of at 
least 90% of maximum value in non-African populations whereas a minimum of 9 
tSNPs was required for African Americans.   Table 11 shows that the identity of the 
SNPs which may be most suitable for use as tSNPs for the association studies. None 
of the sets were the same for any 2 populations, which was an indication that specific 
sets of tSNPs need to be discovered for individual populations studied for the use of 
association studies. However, it also calculated that 10 tSNPs would be enough to 
obtain 90% coverage if the chromosomes in all of the 5 populations were studied. 
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H=6 177100 CH 2 7 11 17 18 24 0.88365
2 7 12 17 18 24
ML 2 7 11 16 22 24 0.84056
2 7 12 16 22 24
IN 3 12 13 15 16 25 0.81913
CAU 2 7 12 16 23 25 0.82871
AA 2 5 7 12 21 24 0.69116
3 5 7 12 21 24
H=7 480700 CH 2 7 11 15 16 18 24 0.9366
2 7 12 15 16 18 24
ML 2 6 11 13 17 23 25 0.90665
2 6 12 13 17 23 25
IN 3 5 11 13 15 16 25 0.90159
CAU 3 7 12 15 16 21 25 0.90911
AA 1 2 5 7 12 18 25 0.79806
1 3 5 7 12 18 25
H=8 1081575 CH 2 7 8 11 15 16 18 24 0.95847
2 7 8 12 15 16 18 24
ML 2 6 8 11 15 16 20 24 0.94894
2 6 8 12 15 16 20 24
IN 3 5 7 11 13 15 17 25 0.95638
CAU 2 5 7 11 15 16 23 24 0.94767
2 5 7 11 15 16 23 25
2 5 7 11 15 17 23 24
2 5 7 11 15 17 23 25
2 5 7 11 15 16 23 24
2 5 7 11 15 16 23 25
2 5 7 11 15 17 23 24
2 5 7 11 15 17 23 25
AA 1 5 7 8 15 18 23 25 0.88311
ALL 2 5 7 12 15 16 23 25 0.81991
H=9 2042975 AA 2 5 7 8 11 16 18 23 24 0.9348
3 5 7 8 11 16 18 23 24
ALL 2 5 7 12 15 16 19 23 25 0.87956
H=10 3268760 ALL 1 3 5 7 12 15 16 18 23 25 0.9224
 
Table 11.  Combinations of tagging SNPs (tSNPs) at the ABCC4 gene locus. (CH: 
Chinese; ML: Malay; IN: Indian; CAU: European American; AA: African American; 
ALL: all 5 populations). 
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 7.5 Scanning for evidence of positive selection by Fst and Pexcess 
To assess the degree of population structure present among the five studied 
populations, the traditional index of allele frequency differentiation Fst was first 
applied to each SNP locus (Table 10 and Figure 13). Fst values ranges from 0 (no 
differentiation amongst populations) to unity (complete differentiation amongst 
populations). The use of the statistic Pexcess was further explored. As explained in 
Bersaglieri et al 2004, the rationale of using Pexcess was to detect a marker within 
particularly long haplotype that rapidly rose in frequency. The change in allele 
frequency from Preference, prior to the event of selection to Ptest, during selection 
could therefore be a measure of selection. To observe the distribution of Fst and 
Pexcess values around the ABCC4 genomic region, these sets of values were plotted 
against genomic distance across ABCC4 using the genotype data from 25 polymorphic 
SNP markers (Figure 13).  
As can be seen from the graph in Figure 13, there was no obvious region within the 
ABCC4 gene that showed a consistent elevation of Fst and Pexcess values across 
multiple markers. Two different sets of Fst, one derived from 3 of the 5 populations 
(African American, European American and Chinese) (Fst3pop) and the other derived 
from 5 populations (Fst5pop) were compared. The 2 sets of Fst did not seem to show 
any difference – peaks and troughs of each set mirrored each other closely. The mean 
global Fst values for 25 polymorphic SNPs were 0.061±0.061 for 3 populations and 
0.052±0.041 for 5 populations. Several SNPs e.g. i-1 -1015G>A (Fst3pop=0.13), i-1 -
527C>G (Fst3pop=0.13), i19 10304C>A (Fst3pop=0.28) and i20 6594G>A 
(Fst3pop=0.12) were observed to have relatively higher Fst values.  These Fst values at 
these SNPs might be indicative of weak positive selection driving the skewness in 
allele frequencies in certain individual populations. The pair-wise Fst values between 
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populations for all polymorphic SNPs were also calculated to elicit population-
specific differentiation (Table 10). The African American population consistently 
showed higher Fst values with other populations at SNPs i-1 -1015G>A, i-1 -527C>G, 
i19 10304C>A, i20 6594G>A and i27 7469G>A. At certain pairings e.g. between 
African Americans and Chinese or Malays at SNP i19 10304C>A or between African 
Americans and Indians at SNP i20 6594G>A, Fst values were greater than 0.40 
although these were not significantly different from genome-wide Fst values 
(0.123±0.131) especially after multiple-test correction for P-values (Akey et al. 2002).  
The average Pexcess value for 25 polymorphic SNPs was 0.333±0.236. SNPs with 
high Fst values did not necessarily correspond to SNPs with high Pexcess values and 
the reverse was true. The sporadically distributed markers that showed unusually high 
Pexcess values were SNPs i-1 -1393G>A (0.70), i1 34530T>C (0.92), and i20 
32573T>C (0.69). There were 7 SNP loci with above-average Fst and Pexcess values: 
i-1 -1015G>A, i-1 -527C>G, i1 34530T>C, e8 951G>A, i19 10304C>A, i20 
6594G>A and i20 32573A>C. They represented candidate loci for assessment of 
recent positive selection using a more powerful long-range haplotype method. 
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7.6 Revelation of recent positive selection at 5’ flanking region by 
long-range haplotype method 
With 125 different SNP locus/population combinations, this study sought to reduce 
the number of test loci for the long-range haplotype method LRH test. To achieve 
enough power to test for positive selection, SNP loci with above-average Fst and 
Pexcess values as well as those core alleles with high relative EHH for the longest 
distance possible were pre-selected for analysis.  HBDs were derived, using each of 
these selected polymorphic SNPs as the core locus to check for evidence of a long-
ranging haplotype (Figure 14). Out of all the diagrams derived, four HBDs using 
SNPs i-1 -1393G>A, i-1 -1015G>A, i-1 -527C>G, and i31 1454C>T as core loci, 
were selected to be shown here. Diagrams with core SNPs i-1 -1393G>A and i31 
1454C>T represented the proximal and distal ends of the ABCC4 gene while diagrams 
with core SNPs i-1 -1015G>A, and i-1 -527C>G showed potential positive selection 
as shown in Figure 13. Compared with other four ethnic groups, the African 
Americans showed more number of branches and slightly thinner branches as a result 
of their rapid decay. As can be seen in HBDs (Figure 14), the major alleles of the 
markers i-1 -1015G>A, i-1 -527C>G, and i31 1454C>T in the European American 
population seemed to reside in a long-ranging haplotype across the ABCC4 gene locus 
whereas the minor alleles are on a short-ranging haplotype. This was not observed in 
other populations, especially that of the African American population. Utilizing a 
modified long-range haplotype method proposed by Sabeti et al, the relative EHH 
were plotted against their respective allele frequencies to test for evidence of recent 
positive selection at ABCC4 gene locus (Figure 15). P-values were calculated by 
comparing relative EHH values against the simulated data at the observed allele 
frequencies. Based on the HBDs, the core alleles in i-1 -1393G>A, i-1 -1015G>A, i-1 
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-527C>G, e8 951G>A and i31 1454C>T were selected, all with high relative EHH 
covering certain distance. The distances from these SNP alleles to the furthest SNP 
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Figure 14.  Haplotype Branching Diagrams at 4 selected SNP loci.  Haplotype 
branching diagrams with SNPs i-1 -1393G>A, i-1 -1015G>A, i-1 -527C>G, and i31 
1454C>T selected as the roots or core marker locus are presented. SNPs i-1 -
1393G>A and i31 1454C>T were selected as the 5’ and 3’ ends of the ABCC4 gene 
locus. HBDs using each root locus for each population are arranged horizontally. 
Each root or core marker locus is denoted by a black dot.  The position of each locus 
along the X-axis is scaled to the physical distance between each locus.  Each SNP 
locus upstream or downstream of the root locus is denoted as a node specified by a 
black dot.  Grey lines are drawn between nodes to represent the specific haplotypes. 
LD decay is portrayed progressively with increasing distance away from the test locus. 
Branching depends on the presence of alternative alleles at the next consecutive node.  
The thickness of the branches corresponds to haplotype frequency while the size of 
the black dots corresponds to allele frequency. HBDs of these SNPs i-1 -1015G>A, i-
1 -527C>G, and i31 1454C>T in the European American population are potential 
candidates for the LRH tests and are therefore highlighted. (CH: Chinese; ML: Malay; 
IN: Indian; CAU: European American; AA: African American). 
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Figure 15.  Extended haplotype homozygosity (EHH) and relative EHH (rEHH) plots 
of SNPs i-1 -1015G>A and i31 1454C>T. First vertical panel:  EHH values at varying 
distances from SNPs i-1 -1015G>A and i31 1454C>T are plotted for all 5 populations. 
Second and third vertical panel: Relative EHH values at a most distant locus were 
plotted against allele frequency for each alternative allele of SNPs i-1 -1015G>A and 
i31 1454C>T respectively (represented as a black diamond), and compared against 
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simulated data (gray dots) under the structured population model with a 
recombination rate of 1.3 cM Mb-1. The curved lines in each rEHH plot signify the 
95th, 75th and 50th percentiles of the distribution of simulated alleles. (CH: Chinese; 
ML: Malay; IN: Indian; CAU: European American; AA: African American). 
 
The relative EHH value of SNP i-1 -1015 allele A of the European American 
population was 2.31 (Figure 15). Under the long-range haplotype test, this allele also 
demonstrated significant departure from evolutionary neutrality under four different 
population model assumptions and three different recombination rate assumptions 
(P<0.05) (Table 12). At another proximal SNP i-1 -527C>G which also displayed 
high LD scores with i-1 -1015G>A, the allele C showed a relative EHH value of 2.61. 
This allele in the European American population also showed significant evidence of 
positive selection under all tested population models and recombination rate 
assumptions except the structure model with the recombination rate 2.6 cM Mb–1 (p = 
0.06) (Table 12).  The C allele of the SNP in the 3’ UTR region, i31 1454C>T had a 
high relative EHH value of 2.00. In the European American population, evidence of 
positive selection was also found for this allele under all tested models and 
assumptions.  There were other SNP alleles showing high values of rEHH, but they 
failed to depart from all tested population models and recombination rate assumptions 
(data not shown). The Bonferroni adjustment was not applied to the test critical value 
despite using 25 polymorphic loci as the correction was too conservative for the LRH 
test and using an independent set of results, significant conclusions at the 5’ flanking 
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Mindful that one of the SNPs, SNP i13/90G>A in the European American population 
deviated from HWE without Bonferroni correction and that prediction of different sets 
of haplotypes might lead to a false conclusion of positive selection, haplotypes 
previously generated were compared against those inferred from the set of 25 
polymorphic markers sans SNP i13 90G>A. A total of 104 haplotypes were obtained 
for the latter set. The 2 most common haplotypes of both sets were congruent. 
Evidence of positive selection using the LRH test was reapplied on this newly inferred 
set of haplotypes. The SNP i-1 -1015G>A was tested. The relative EHH value of SNP 
i-1 -1015 allele A of the European American population was recalculated as 2.61 and 
using the LRH test, this allele seemed to appear on a single haplotype which again 
demonstrated significant departure from evolutionary neutrality under four different 
population model assumptions and three different recombination rate assumptions 
(P<0.05). The LRH test was therefore robust in detecting the evidence of positive 
selection in these cases. 
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Figure 16.  Pair-wise linkage disequilibrium profile of CEPH population in 
International Hapmap Project. Panel A. Pair-wise |D’| and r2 values for highly 
polymorphic SNPs were summarized into tables.  Panel B: |D’| between pairs of 
single SNPs was plotted against physical distance.  Panel C:  r2 between pairs of 
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The International Hapmap Project [http://www.hapmap.org/] is a large resource for 
studying verified SNPs in populations of different ethnicity. With genotype data from 
the CEPH (CEU), Han Chinese (HCB) and Yoruban (YRI) samples listed, 
comparative data could be obtained against those from this study (using populations 
of similar ancestry). Therefore CEPH population will be compared against the 
European American population, HCB against the Chinese population and finally YRI 
against the African Americans.  Using the data set available publicly from the 
International HapMap Project, genotype data were obtained from 30 sets of CEPH 
trios (Utah residents with ancestry from northern and western Europe). Because of the 
similarity in ancestry between the CEPH trios and the European American population 
used in this study, analysis of the CEPH trios makes an interesting proposition. From 
the CEPH genotype data, the LD profile of 58 polymorphic SNPs surrounding the 
entire ABCC4 (from SNP i-1 -1393G>A (rs868853) to SNP i31 1454C>T 
(rs1059762)) showed that there were some differences from this study’s own data 
(Figure 16).  The half-length LD block and useful LD (r2≥0.3) were estimated to be 
87.7 kb and 76.65 kb respectively. The discrepancy in LD measures between the 2 
sets of data could be attributed to the large number of data points from the CEPH 
population, leading to a poorer correlation (R2=0.135) in LD against genomic distance 
(as compared to a correlation factor of R2=0.208 in the European American 
population from this study’s data). 
Due to the large number of the SNP markers listed in the International Hapmap 
Project, 29 polymorphic SNPs spanning approximately 140 kb from the 5’ of ABCC4 
were short-listed for haplotype analysis. Of these 29 SNPs, it was found that the G 
allele of the SNP rs869951 (SNP -1 -527C>G) possessed a high rEHH value of 2.74 
at a frequency of 0.58. This SNP was subjected to the long range haplotype test and 
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demonstrated significant departure from evolutionary neutrality under all four 
different population model assumptions and three different recombination rate 
assumptions (P<0.05) (Figure 17A). This SNP lies in the 5’ promoter region which is 
in high LD (r2 = 0.92 see Figure 11) and is 488 bps away from i-1 -1015G>A 
(genotype data not available in CEPH data set), which was shown to pass the long 
range haplotype test in this study’s data set. This simultaneous discovery of proximal 
SNPs showing positive selection in populations of similar ancestry is evident of 
genetic hitchhiking. When selection of one allele from either SNP occurs, the adjacent 
segment of DNA is passively selected with it, only later becoming separated by rare 
recombination. This gives rise to the tight linkage disequilibrium within the 5’ region 
of ABCC4, which means that alleles may appear to be associated with variation in a 
phenotype without themselves causing that variation. As such this additional finding 
from the CEPH data gave greater confidence that the causal variant might be within 
the 5’ region of ABCC4 gene locus.  
Similarly for the 3’end of the gene locus, 29 polymorphic SNPs from the International 
Hapmap Project spanning approximately 160 kb upstream of SNP i31 1454C>T 
(rs1059762) were analyzed.  The major allele C of the SNP i31 1454C>T (rs1059762) 
was calculated to have a rEHH value of 1.00 at an allele frequency of 0.58.  Here the 
p-value for a single structure model with recombination rate set at 1.3 cM Mb–1 is 
shown in Figure 17.  Since no significant deviation was obtained for this model, no 
further analysis was performed. This discrepancy from the data used in this study was 
not surprising due to the fact that the HBD in the CEPH data showed a diffuse 
branching pattern at both alleles was too diffuse (Figure 17C). 
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Chapter 8 Genetic characterization of ABCC5 gene locus 
8.1 Diversity of ABCC5 SNP allele frequencies amongst different 
populations 
A ~1.2 kb fragment flanking the 5’ end of ABCC5, which potentially contains the 
ABCC5 promoter, was sequenced from 30 individuals representing the three Asian 
ethnicities.  Three novel SNPs (i-1 -889T>C; i-1 -177C>T and i-1 -115A>C) were 
identified and their frequencies determined in these populations (Table 13).  However, 
each SNP was monomorphic in two of the three populations examined and present at 
very low frequency in the remaining population.  These SNPs were excluded from 
further analysis. 
Of 17 ABCC5 SNPs selected either from SNP databases or published reports that were 
genotyped in the 5 ethnic populations, 16 had high minor allele frequencies of >5% in 
all 5 populations (Table 13).  Only intron 1 SNP 628G>C was monomorphic in 
European Americans and displayed low minor allele frequencies in Chinese (4.5%), 
Malays (2.9%), Indians and African Americans (both ~0.5%).  The allele and 
genotype frequency distributions of all polymorphic SNPs were consistent with the 
Hardy-Weinberg equilibrium assumption (P>0.05) in at least four of the five 
populations examined (Table 13).  When Bonferonni correction for multiple-locus 
testing was applied, no significant departure from Hardy-Weinberg equilibrium was 
detected for all genotyped SNPs in all populations. 
The allele frequencies of most of the SNPs in the European American population that 
was genotyped were similar to frequencies of SNPs in another cohort of Caucasian 
population that was previously reported (Dazert et al. 2003) except for SNPs in exons 
12 and 25.  The differences in allele frequencies observed for SNPs in exons 12 and 
25 could be due to stochastic variation as a result of the relatively small number of 
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samples genotyped (100 in this study and 20 in the previous study).  It could also be 
due to differences in the population studied since the European American population 
this study examined was from the United States of America while those reported 
previously were probably German Caucasians (Dazert et al. 2003). 
Allele frequencies at all SNP loci were similar between Chinese and Malays, and 
between European Americans and Indians (P>0.05).  In sharp contrast, African 
American allele frequencies differed significantly from the non-African populations at 
most SNP loci (P<0.05; Table 13). 
The significance of the variation in SNP allele frequencies between populations were 
evaluated using the Fst statistic (Akey et al. 2002).  As shown in Table 13, the Fst 
values for all the 20 SNPs range from 0.02 to 0.14 with a mean value of 0.078.  These 
values are all below the threshold of 0.45 suggesting that it is unlikely that any of the 
tested SNPs at this gene locus are under positive selection pressures. 
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8.2 Strong LD at the ABCC5 gene locus in all five populations 
Linkage disequilibrium across the 100 kb ABCC5 genomic region was examined in 
the five ethnic populations for all possible SNP pairs.  Only the 16 SNPs, with minor 
allele frequency of >5% in all populations were included in this analysis.  The two 
common LD statistics, |D’| and r2, which measure recombination rate and associative 
power, respectively, were determined (Shifman et al. 2003). 
All five populations showed generally strong LD across the entire gene locus with 
high |D’| and r2 values between the fourth (intron -1 -1205C>T) and last (intron 30 
7161G>A) SNPs (p<0.05) (Figure 18).  Similar to observations at other gene loci 
(Johnson et al. 2001; Tang et al. 2004), LD at the ABCC5 gene locus generally 
decreased with physical distance although the correlation was weak (R2<0.32) (Figure 
18B).  Half-length LD (LD0.5) was shortest in African Americans (106 kb), followed 
by the Malays (144 kb), Chinese (165 kb), European Americans (266 kb), and Indians 
(293 kb).  When r2≥0.3 was utilized as a threshold for useful LD in association 
studies (Pritchard and Przeworski 2001), useful LD was found to extend beyond the 
entire 100 kb ABCC5 gene locus in all five populations (Figure 18C). 
As illustrated in Figure 19, less intensive branching is seen in the 4 non-African 
populations compared to the African American population, indicating that LD decay 
across the ABCC5 gene is more pronounced in the African American population.  
Interestingly, the Chinese and Malay ABCC5 genes share very similar branching 
patterns, while the European Americans and Indians share a similar pattern.  These 
results indicate that LD decay is similar between Chinese and Malays and between 
European Americans and Indians. 
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8.3 Low but varied ABCC5 haplotype diversity among the five 
populations 
Assuming maximum random association between the 16 polymorphic ABCC5 SNPs, 
the number of haplotypes predicted based on the tested sample size and observed 
allele frequencies in a simulated population iterated 1,000 times was found to be 
164.57 ± 1.63, 168.93 ± 1.68, 179.98 ± 1.29, 197.41 ± 1.61 and 177.77 ± 3.53 in the 
Chinese, Malay, Indian, European American, and African American populations, 
respectively.  If no recombination occurs, the number of possible haplotypes would be 
decreased to 17.  In this study, 35, 28, 32, 26 and 55 haplotypes were observed in the 
Chinese, Malay, Indian, European American, and African American populations, 
respectively.  Hence, the observed number of haplotypes in the Chinese, Malay, 
Indian, European American, and African American groups constituted only 21.27%, 
16.57%, 17.78%, 13.17%, and 30.94% of expected haplotypes, simulated under 
maximum random association, respectively.  These results suggest that only limited 
recombination has occurred between SNP pairs at this locus.  The greatest haplotype 
diversity was observed in the African American population (Figure 20). 
In total, 130 different ABCC5 haplotypes were observed from these five populations.  
Several of the haplotypes are specific to the Chinese (22 haplotypes), Malay (10), 
Indian (17), European American (16) and African American (40) populations. 
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Figure 20.  Haplotype profiles of SNPs at the ABCC5 gene locus.  Expectation-
Maximization algorithm was utilized to infer haplotype frequencies from genotype 
data of the 16 highly polymorphic SNPs at the ABCC5 gene locus.  A total of 130 
haplotypes occur in at least one population, of which 35, 28, 32, 26 and 55 were found 
in the Chinese, Malay, Indian, European American and African American groups, 
respectively.  Only haplotypes occurring at >1% are presented in this figure and those 
with frequencies >5% are labeled as MH1-MH9.  Haplotype profiles are represented 
as horizontal arrays of black or white boxes with the allele specified.  Each column of 
boxes represents a SNP locus.  Each row of boxes represents a haplotype, with the 
estimated frequencies expressed as a percentage shown in the adjacent table as well as 
portrayed in a bar graph. (CH: Chinese; ML: Malay; IN: Indian; CAU: European 
American; AA: African American). 
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Figure 20 shows the haplotypes that occur at higher than 1% frequency in at least one 
population.  While the most common haplotype accounts for 27-40% of total alleles in 
each 4 non-African population, the most common haplotype in the African American 
population accounts for only 22.9%.  Of the five major haplotypes that occur in all 
five populations, four show similarities in frequency distribution between the Chinese 
and Malay and between the Indians and European Americans.  Fisher’s Exact Test 
showed no significant difference in haplotype frequencies between Indians and 
European Americans (p=0.14456), as well as between Chinese and Malays 
(p=0.06915), but highly significant difference for all other pair-wise comparisons 
between populations (p<0.00001). 
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8.4 Tagging SNPs at the ABCC5 gene locus 
The above results suggest that the entire 100 kb of the ABCC5 gene locus may reside 
within a region of strong LD.  To reduce genotyping costs and effort in future 
association studies, it would be useful to identify tSNPs that represent the majority of 
observed haplotypes but with minimal reduction in power to detect associations.  The 
“Tag-IT” program (Weale et al. 2003) was utilized to identify tSNPs at the ABCC5 
gene locus.  In the non-African populations, a minimum of 4 tSNPs were sufficient to 
generate haplotype r2 values of ~0.9 and thus account for ~90% of the observed 
haplotypes in each population (Table 14).  However, the panel of 4 tSNP 
combinations with haplotype r2 values of ~0.9 differed among the four populations, 
suggesting that the panel of tSNPs identified in one population may not be suitable for 
use in other populations without a reduction of power (Table 14).  Nonetheless, more 
than 40 different combinations of 4 tSNPs with haplotype r2 values >0.9 could be 
utilized for association studies in any of the non-African populations.  In the African 
American population, at least six tSNPs are required to represent 90% of all the 
observed haplotypes (Table 14). 
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Table 14.  Tagging SNPs at the ABCC5 gene locus in 5 ethnic populations. 
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8.5 Evidence of positive selection not apparent at the ABCC5 gene 
locus 
Utilizing a modified long-range haplotype method proposed by Sabeti et al, the 
relative EHH were calculated for their respective allele frequencies to test for 
evidence of recent positive selection at ABCC5 gene locus (Table 15).  The 
observation that ABCC5 SNPs with high rEHH and low allele frequencies (as 
compared to ABCC4 SNPs) runs contrary to the premise of recent positive selection.  
We were also unable to obtain enough simulated data for comparison as the entire 
ABCC5 gene locus is in a region of strong linkage disequilibrium and the genomic 
distance covering all the SNPs in ABCC5 gene locus was too small. Only the first and 
last SNPs could be effectively tested.  
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SNP
Allele Frequency rEHH Allele Frequency rEHH Allele Frequency rEHH Allele Frequency rEHH Allele Frequency rEHH
i-1 -1990G>A
A 0.244 1.210 0.250 1.340 0.291 3.304 0.320 1.833 0.050 4.244
G 0.756 0.826 0.750 0.746 0.709 0.303 0.680 0.546 0.950 0.236
i-1 -1821T>C
C 0.250 1.138 0.250 1.340 0.297 3.136 0.320 1.833 0.050 4.244
T 0.750 0.879 0.750 0.746 0.703 0.319 0.680 0.546 0.950 0.236
i-1 -1679T>A
T 0.673 0.222 0.605 0.189 0.863 0.297 0.900 0.472 0.600 0.276
A 0.327 4.504 0.395 5.305 0.137 3.372 0.100 2.118 0.400 3.617
i-1 -1205C>T
C 0.250 0.918 0.192 1.457 0.571 0.532 0.480 0.568 0.775 0.343
T 0.750 1.089 0.808 0.686 0.429 1.880 0.520 1.761 0.225 2.917
i-1 -793C>A
C 0.667 0.243 0.605 0.189 0.863 0.300 0.900 0.472 0.930 0.617
A 0.333 4.115 0.395 5.283 0.137 3.332 0.100 2.118 0.070 1.621
i1 1834C>T
C 0.881 0.372 0.843 0.475 0.599 0.444 0.560 0.323 0.715 0.580
T 0.119 2.692 0.157 2.105 0.401 2.253 0.440 3.097 0.285 1.724
i2 7980C>T
C 0.685 0.208 0.616 0.179 0.863 0.308 0.890 0.575 0.870 0.431
T 0.315 4.803 0.384 5.601 0.137 3.248 0.110 1.739 0.130 2.319
i5 374C>T
C 0.554 1.431 0.599 1.951 0.582 0.878 0.625 0.926 0.740 0.549
T 0.446 0.699 0.401 0.513 0.418 1.139 0.375 1.080 0.260 1.821
e8 145A>G
A 0.542 1.639 0.587 0.985 0.582 0.869 0.625 0.926 0.745 0.546
G 0.458 0.610 0.413 1.015 0.418 1.151 0.375 1.080 0.255 1.833
e9 1185C>T
C 0.875 0.421 0.855 0.487 0.621 0.414 0.570 0.321 0.725 0.642
T 0.125 2.373 0.145 2.054 0.379 2.414 0.430 3.120 0.275 1.557
e12 1782C>T
C 0.881 0.429 0.860 0.399 0.643 0.291 0.545 0.461 0.765 0.467
T 0.119 2.332 0.140 2.505 0.357 3.431 0.455 2.168 0.235 2.140
e25 3624C>T
C 0.554 0.625 0.547 0.450 0.802 0.717 0.825 0.960 0.785 1.022
T 0.446 1.600 0.453 2.223 0.198 1.395 0.175 1.041 0.215 0.978
e30 4896G>A
G 0.506 0.738 0.419 0.607 0.484 0.774 0.480 0.678 0.220 0.656
A 0.494 1.356 0.581 1.647 0.516 1.292 0.520 1.475 0.780 1.525
e30 5557A>G
A 0.506 0.738 0.390 0.687 0.516 1.280 0.505 1.660 0.345 1.161
G 0.494 1.356 0.610 1.455 0.484 0.781 0.495 0.602 0.655 0.861
i30 6272A>G
G 0.512 1.244 0.581 1.881 0.505 0.779 0.465 0.649 0.235 0.558
A 0.488 0.804 0.419 0.532 0.495 1.283 0.535 1.542 0.765 1.794
i30 7161G>A
G 0.869 0.420 0.866 0.361 0.626 0.364 0.570 0.312 0.790 0.258
A 0.131 2.379 0.134 2.771 0.374 2.749 0.430 3.201 0.210 3.874
CAU AACH INML
 
Table 15.  ABCC5 SNPs and their respective rEHH values. rEHH values above 2.0 
were highlighted in bold and grey.  (CH: Chinese; ML: Malay; IN: Indian; CAU: 
European American; AA: African American). 
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IV INFERENCES 
Chapter 9 Simultaneous Genotyping of Seven Single Nucleotide 
Polymorphisms (SNPs) of the MDR1 gene by Single-Tube 
Multiplex Minisequencing 
The MDR1 multidrug transporter plays an important role in protecting the body 
against xenobiotics.  Its expression in the cells of luminal epithelium of the gut, the 
blood-brain barrier and blood-germ cell/fetal barrier suggest that polymorphisms that 
alter the function of this transporter may have an impact on the absorption, 
distribution and elimination of drugs, potential toxic substances and metabolites as 
well as contribute to susceptibility of certain diseases such as Parkinsons (Furuno et al. 
2002).  In fact, exon 26 3435C>T SNP in the MDR1 transporter has been associated 
with differences in drug side effects as well as efficacy of a variety of drugs in 
different individuals (Hoffmeyer et al. 2000; Hitzl et al. 2001; Kim et al. 2001; 
Sakaeda et al. 2001; Fellay et al. 2002; Roberts et al. 2002).  However, this SNP does 
not result in an amino acid change, and some paradoxical associations have been 
observed between this SNP and MDR1 protein expression and plasma drug 
concentration, drug-induced side effects, and drug response, suggesting that this SNP 
may not be the causal SNP.  Haplotype analyses of SNP 26 3435C>T and 2 other 
SNPs in the MDR1 gene reveal different LD block lengths in different ethnic 
populations raising the possibility that SNP 26 3435C>T may be linked to different 
unobserved causal SNPs in different study populations.  It has been suggested that 
analyses of MDR1 SNP haplotypes rather than individual SNP genotypes would be 
more useful for association studies of drug response or disease susceptibility. 
Thus far, the major technologies employed for genotyping SNPs in the MDR1 gene 
have been resequencing (Kim et al. 2001; Saito et al. 2002b), or indirect gel-based 
 138
Genetic Characterization of Nucleotide Analogue Transporters ABCC4 and ABCC5 Gene Loci 
methodologies like PCR-single strand conformation polymorphism (SSCP) (Ito et al. 
2001; Kim et al. 2001; Tanabe et al. 2001) and PCR-restriction fragment length 
polymorphisms (RFLP) (Ameyaw et al. 2001; Cascorbi et al. 2001; Roberts et al. 
2002; Tang et al. 2002), with one report of SNP 26 3435C>T genotyping using 
fluorogenic hybridization probes (Nauck et al. 2000).  Except for the fluorogenic 
hybridization probe method, these methods, although effective, are relatively slow and 
expensive.  The indirect gel-based methods of PCR-SSCP and PCR-RFLP also 
require subjective interpretation of gels that may contribute to an additional source of 
error.  In addition, although the fluorogenic hybridization probe method is potentially 
capable of limited multiplex interrogation of 2-3 SNPs, multiplexing to interrogate 
more than 4 SNPs simultaneously is currently not possible with any the above 
methods.  This report describes a method that multiplexes both the PCR as well as 
minisequencing steps to achieve the simultaneous genotyping of 7 SNPs across 100 
kb of the MDR1 gene.  This method is potentially capable of genotyping 13 or more 
SNPs simultaneously (Krone et al. 2002). 
A major advantage of this multiplex minisequencing method of genotype 
determination is its cost-effectiveness. By reducing the volumes and multiplexing 
both the PCR and the minisequencing steps, reproducible results for the seven SNPs 
spanning 100 kb of the MDR1 gene could be achieved, starting with only 20 ng of 
genomic DNA and one-fourth of the recommended SNaPshot Mix, reducing the cost 
per reaction to approximately US $2 or less than 30 cents per SNP. Additionally, the 
multiplex PCR and minisequencing assay as described here is relatively rapid, with 
results for 96 DNA samples obtained within a single day.  
In conclusion, the ability of this assay to rapidly and efficiently genotype 7 different 
SNPs across 100 kb of the MDR1 simultaneously in a single reaction should simplify 
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medium to high throughput multiple SNP genotyping of this gene for population-
based haplotype and LD studies, as well as for studies correlating MDR1 haplotypes 
with drug response and/or disease.  The robustness and flexibility of this genotyping 
assay allow it to be quickly modified for the haplotype studies of other genes as well.  
This thesis will demonstrate the usefulness of this genotyping assay in achieving its 
objective of characterizing the genetic structures of nucleotide analogue transporters 
ABCC4 and ABCC5, two genes belonging to the same ATP-Binding Cassette 
superfamily as MDR1. 
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Chapter 10 Inference of Positive Selection on a Polymorphism in the 5’ 
Flanking Region of the Nucleotide Analogue Transporter 
ABCC4/MRP4 
Much attention has been focused on ABCC4, which was the first transporter shown to 
efflux nucleoside monophosphate analogues. Some clinical drugs are also substrates 
of this transporter. As a first step in establishing useful associations between 
variations in the ABCC4 gene and drug responses, the aim was to establish the 
haplotype and linkage disequilibrium profiles in different populations. The results 
from the investigation of selected polymorphisms in ABCC4 gene showed 
discrepancies of allele frequencies amongst different populations.  
 
10.1 Variability in allele frequencies in ABCC4 SNPs amongst 
populations 
Here the attention is focused on using linkage disequilibrium of haplotypes to 
facilitate more power in detecting association between genotype and phenotype 
studies of ABCC4.  Haplotypes and LD measurements were generated from genotypes 
of SNP data in 5 ethnically unique populations containing 100 each of Chinese (CH), 
Malay (ML), Indian (IN), European American (CAU) and African American (AA).  
The majority of the biallelic SNPs studied were intronic.  A total of 49 exonic SNPs 
were found in the public databases (dbSNP, TSC and JSNP as of 5th October 2002) 
but the reported minor allele frequencies for the non-genotyped SNPs are lower than 
7.5%.  The observation that allele frequencies of individual SNPs vary amongst 
different ethnic groups has been reported in many genes, including ABC transporters.  
Unlike previous findings in MDR1 and ABCC5 (see Chapters 8 and 11), there were no 
similarities between any 2 populations with regards to allele frequencies. The SNP 
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e11 1497C>T was only polymorphic in the African American population. The T allele 
was completely absent from the rest of the populations of non-African ancestry. As a 
potentially functionally relevant SNP, this SNP would be a good candidate for African 
American populations or populations with African ancestry. Similarly, allele 
frequencies in other SNPs including SNPs i-1 -1015G>A, i-1 -527C>G, i19 
10304C>A, i20 6594G>A, and i27 7469G>A, varied between the non-African 
populations and the African population. 
The amount of variation in allele frequencies also seemed to vary among gene loci.  
The variance in allele frequencies was measured using the measurement Fst.  The 
range of Fst values for 5 populations was from 0.00 to 0.14, with a global mean of 
0.052±0.041 (25 SNPs). In particular, SNPs i19 10304C>A and i20 6594G>A in 
ABCC4 had unusual high Fst values.  
 
 10.2 A rapidly declining LD profile of ABCC4 
Linkage disequilibrium profile of ABCC4 was disperse, signified by the pale 
coloration in Figure 11.  The suggestion that the human genome consists of ‘blocks’ 
of LD (30-100kb) interspersed with short segments of recombination hotspots might 
be oversimplistic.  Although a segment of strong LD from SNPs i20 6594G>A and 
i31 1454C>T could be found, it was clearly difficult to demarcate regions of LD as 
‘blocks’.  There were a very small number of SNP pairs in significant LD (4 out of 
352 informative pairs in the African American population, using the LD statistic r2). 
The pair-wise comparisons were suggestive of variable high and low levels of LD, 
signified by the diffuse coloration in Table.  Both the half-length LD statistics (48.0-
58.2 kb) and useful r2 values (37.23-77.42 kb) in all 5 populations also confirmed this.  
Although ABCC4, ABCC5 and MDR1 belong to the ATP-Binding Cassette 
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superfamily and appear to be closely related in sharing predicted structural topology, 
having diverse tissue distribution and possessing the ability to transporting molecules 
of diverse structures out of the cell, this study clearly showed that there are genetic 
differences amongst these transporters.  The diverse and complex genetic structure 
found in ABCC4 contrasts sharply against the ABCC5 and MDR1 genetic structures of 
strong linkage disequilibrium (Tang et al. 2002; Tang et al. 2004; Gwee et al. 2005).  
The half-length LD of ABCC4 ranges from 48.0 kb to 58.2 kb. This is comparatively 
shorter than both the MDR1 (Tang et al. 2002; Tang et al. 2004) and ABCC5 (see 
Chapters 8 and 11) (Gwee et al. 2005).  In ABCC5, the entire gene studied is in a 
strong LD, with half-length LD of more than 144 kb while in MDR1, the half-length 
LD is measured to be 110 – 150 kb (Tang et al. 2002; Tang et al. 2004).  It is also 
noted that the half-length LD of MRP1, another ABC transporter that is structurally 
different from ABCC4, ABCC5 or MDR1 is measured to be 23 – 48 kb (Wang et al. 
2005).  
 
 10.3 Population-specific tSNPs are required 
From the International Hapmap Project, validated SNP maps of well-characterized 
genetic markers have emerged for the majority of the human chromosomes (Ke et al. 
2004) In genomic regions of high LD (e.g. haploblocks), it is possible to identify 
tSNPs in four global populations, in order to facilitate LD mapping of common 
diseases. Haplotype tagging is a means of selecting a set of non-redundant markers 
(tSNPs) from an initial given set of densely spaced SNPs to retain the most 
information about the dense map, yet reduce genotyping cost and scale. However 
several groups have reported that sets of tSNPs differ across different populations 
(Weale et al. 2003; Gwee et al. 2005). In studying specific genes that may be involved 
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in predisposition to complex disease or aberrant drug response, LD patterns need to be 
defined at a finer scale in order to obtain accuracy in candidate gene associations 
studies (Tishkoff and Verrelli 2003). These suggest that additional studies in specific 
ethnically diverse populations and individual candidate genes are still necessary. 
Differing sets of tSNPs were found for all 5 populations in this study of ABCC4 
(Table 11). None of the tSNPs were shared by all the populations. Despite the general 
low LD exhibited, there was still a 72% reduction in number of SNPs genotyped in 
non-African populations and 64% reduction in African American population 
respectively, to achieve at least 90% coverage.  Consistent with the high level of r2 
observed between the 2 SNPs i-1 -1015G>A and i-1 -527C>G as well as the stretch of 
genomic sequence across the 4 SNPs from i19 33474C>T to e26 3348A>G, any one 
of the SNPs could represent the respective regions of tight linkage and be included in 
disease or drug response association studies. 
 
10.4 LRH test identifies signature of positive selection in a 5’ flanking 
SNP of ABCC4 
To increase power in identifying functional variants, all the polymorphisms in the 
ABCC4 gene were further screened for signatures of local positive selection. The 
dispersal of early humans out of the African continent infers that different selective 
pressures acted on human populations and positive selected genetic variants would 
increase the fitness (and hence survival) of specific population. Traditional tests 
screening for evidence of selection in candidate genes rely on degree of differentiation 
in polymorphic loci in different populations. Any large allele frequency differences 
amongst populations infer the effects of selection acting upon one or more 
populations but not the rest. These tests include the Wright’s Fixation Index, Fst and 
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Pexcess.  The Wright’s Fixation Index Fst is essentially a measure of population 
subdivision and can be used to indicate the presence of selection events.  The test 
based on Pexcess calculates the extent at which a haplotype is over-represented in a 
population under study as compared to an ancestral population. The average allele 
frequencies of the ancestral population were estimated from the African American 
population. Both the Fst and Pexcess tests are therefore dependent on the assumptions 
of all allele frequency differentiation measures. In addition, using allele frequency of 
the African American or East Asian population as the ancestral allele frequency may 
be erroneous, even though Bersaglieri et al., 2002 showed that their results did not 
defer significantly whether or not a 21% European admixture in the African American 
population was accounted for (Bersaglieri et al. 2004). The long range haplotype test 
relied on the length of linkage disequilibrium on one haplotype in relation to the 
frequency of that haplotype, and had been showed to be more powerful than tests 
dependent on measuring the degree of skewness in allele frequency distribution 
(Sabeti et al. 2002).  Both the Fst and Pexcess measures on all 25 polymorphic 
markers were therefore utilized to obtain a smaller set of candidate polymorphisms for 
assessment using the more computationally intensive long range haplotype test. 
Despite the finding of low grade LD, the major alleles of the SNPs i-1 -1015G>A, i-1 
-527C>G, and i31 1454C>T in the European American population appeared to reside 
in a long-ranging haplotype across the ABCC4 gene locus and with the exception of 
SNP i-1 -527C>G, showed significant departures from neutrality. The SNP i-1 -
527C>G managed to show significant departures from 11 out of 12 simulated 
population models. The C allele of SNP i-1 -527C>G was also assessed and verified 
to show significant evidence of recent positive selection by using the genotype data 
from a panel of 30 trios from the CEPH collection (U.S. Utah residents with ancestry 
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from northern and western Europe) in the International Hapmap Project.  This 
enhanced confidence that these 2 SNPs (SNPs i-1 -1015G>A and i-1 -527C>G) or 
other nearby SNPs within the putative promoter region and in LD with i-1 -1015G>A 
could be a functional variant. Using web-based transcription-binding prediction tools 
(listed in Materials and Methods), it was predicted that the G allele of the SNP i-1 -
1015G>A resides in a binding site of the homeobox protein engrailed (En1), a 
conserved sequence abolished if an A allele is present.  Localized at chromosome 
2q13-q21, the human engrailed homolog 1 encodes a homeodomain-containing 
protein and may be important for the development of the central nervous system 
especially that of the mesencaphalic dopaminergic neurons (Smidt et al. 2003; Simon 
et al. 2004).  The presence of ABCC4 is demonstrated in brain microvessel endothelial 
cells that form the blood–brain barrier (BBB) (Zhang et al. 2000) as well as the lumen 
of brain capillaries and in the basolateral membrane in the choroid plexus epithelium 
(Leggas et al. 2004). Recent studies demonstrating ABCC4- and ABCC5- mediated 
resistance to antiviral nucleosides suggest that one of the functions of ABCC4 may be 
involved in nucleoside transport in the blood brain barrier. Hence it would be 
interesting to find out if the expression of ABCC4 could be influenced by the SNP i-1 
-1015G>A which dictates the presence of En1 transcription factor binding site.  
In summary, the strategy employed here using ABCC4 gene locus has identified SNP 
i-1 -1015G>A as displaying evidence of positive selection and uncovered a short 
region within the 5’ flanking region as functionally important. It would be 
advantageous to include SNP i-1 -1015G>A in the tagging set obtained above for it 
could be either functional important or in linkage disequilibrium with another nearby 
SNP which is functional important. It is postulated that the functionally important 
SNP could be involved in the interindividual variability of nucleoside transport.  
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Chapter 11 Strong Linkage Disequilibrium at the Nucleotide Analogue 
Transporter ABCC5 Gene Locus 
The ABCC5 protein transports nucleotides, cyclic-nucleotides, nucleotide analogues 
and certain heavy metal compounds (McAleer et al. 1999; Jedlitschky et al. 2000; 
Wijnholds et al. 2000; Wijnholds 2002; Wielinga et al. 2003). Akin to the function of 
the MDR1 transporter, ABCC5 may play a role in regulating the bioavailability of 
these compounds within cells.  Several clinically important antiviral and thiopurine 
anticancer drugs are transported by the ABCC5 gene product (Wijnholds et al. 2000; 
Wijnholds 2002), and individual differences in response to these drugs may be due to 
cryptic differences in their gene sequences.  The LD and haplotype structure of the 
classical ABC transporter, MDR1, was previously characterized in five different 
populations (Tang et al. 2002; Tang et al. 2004).  A detailed haplotype and LD 
structure characterization of the ABCC5 gene was now performed in these same five 
populations.  This will enable more powerful haplotype-based association studies of 
functional differences compared with single SNP association analyses (Judson and 
Stephens 2001). 
 
11.1 Similarities and differences in SNP, haplotype and LD profiles 
between populations 
The ABCC5 SNP profiles were found to be similar between the Chinese and Malays, 
and between the Indians and European Americans, there being no statistical difference 
(P>0.05) in observed allele frequencies at all SNP loci examined (Table 13).  There 
was also no evidence of significant departures from evolutionary neutrality when the 
Fst statistic (Akey et al. 2002) was utilized to quantitate the variation in SNP allele 
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frequencies between populations as the Fst values for all the SNPs at the ABCC5 gene 
locus were below the threshold of 0.45 (Table 1). 
Similarities in haplotype profiles were also observed between the Chinese and Malays 
(P=0.06915); and between the European Americans and Indians (P=0.14456) (Figure 
20).  In contrast, the African American ABCC5 haplotype profile differed significantly 
from the non-African populations (P<0.00001) (Figure 20).  Consistent with the 
hypothesis that all modern populations are derived from a common African ancestral 
population, all but one of the major haplotypes (i.e. with >5% frequency) present in 
the non-African populations were also represented in the African American 
population (Figure 20).  The African Americans were also observed to have the 
highest number of unique as well as total haplotypes, and the lowest LD of the five 
populations (Figures 18 and 20).  Likewise, long-range LD breakdown as represented 
diagrammatically by the HBD (Figure 19) revealed similarities in LD decay profiles 
between the Chinese and Malays and between the Indians and European Americans, 
while the African American profile was distinct. 
Thus, similar to observations made at the MDR1 gene locus (Tang et al. 2004), these 
current results are consistent with the “Out-of-Africa” hypothesis (Hammer 1995; 
Krings et al. 1997; Ingman et al. 2000) of a common non-African ancestor arising 
from an ancestral African population.  This ancestor subsequently populated Europe / 
South Asia, and East / Southeast Asia. 
 
11.2 Haplotype diversity and LD at the ABCC5 gene locus 
One notable difference between the ABCC5 and MDR1 genes is that the former 
resides in a genomic region of low haplotype diversity and strong LD.  Given the 
observed SNP allele frequencies and under an assumption of linkage equilibrium, the 
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expected number of haplotypes of the 16 high frequency SNPs in the non-African and 
African American populations should be 165 - 197 and 178, respectively.  Yet only 13 
- 21% and 31%, respectively, of the predicted number of haplotypes were actually 
observed.  In contrast, the number of observed haplotypes at the MDR1 gene locus 
constituted 42 – 47% and 65% of the predicted number of haplotypes in the non-
African and African American populations, respectively, under complete linkage 
equilibrium.  These data suggests that haplotype diversity at the ABCC5 gene locus is 
lower than that at the MDR1 gene locus.  The lower number of observed haplotypes 
in the non-African populations supports the “Out-of-Africa” model of human 
evolution which suggests that the former are the descendents of small founding 
subgroups from Africa. 
Pair-wise LD profiling using the |D’| statistic revealed that in all five ethnic groups, 
statistically significant strong LD exists between SNPs intron -1 -1205C>T and intron 
30 7161G>A, which lie >100 kb apart.  The half-length LD (LD0.5) was estimated to 
extend beyond the size of the gene, with the African Americans displaying the 
shortest LD0.5 (106 kb) followed by the Malays (144 kb), Chinese (165 kb), European 
Americans (266 kb) and Indians (293 kb) (Figure 18).  In the MDR1 gene locus, LD0.5 
ranged from only 105 kb in the Malays to a maximum of 150 kb in European 
Americans (Tang et al. 2004).  More striking differences were observed when the 
Pearson correlation (r2) statistic was evaluated.  This statistic models association 
power and is thus of great utility in disease association studies.  When r2≥0.3 was 
utilized as the threshold for useful LD in association studies, useful LD extended 
beyond the 100 kb extent of the ABCC5 gene (Figure 18).  This observation suggests 
that the entire ABCC5 gene resides within a region of strong LD and that all SNPs 
within the ABCC5 gene have high associative power.  This is in contrast to the 200 kb 
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MDR1 gene locus, where useful LD extended only from 35 kb in the Chinese and 
Malay populations to a maximum of 82 kb in the Indian population (Tang et al. 2004). 
Strong LD has also been reported in two other cancer susceptibility gene loci, ATM 
(140 kb) and BRCA1 (200 kb) (Bonnen et al. 2002).  The observation of strong LD 
extending across the entire ABCC5 gene has implications for association studies.  On 
the one hand, it implies that fewer SNPs need to be examined in association studies.  
However, it also implies that once an association is made between a surrogate SNP 
and any functional difference, a greater region of DNA will have to be sequenced to 
identify the causative SNP. 
 
11.3 Tagging SNPs at the ABCC5 gene locus 
To facilitate association studies, the “TagIT” program (Weale et al. 2003) was utilized 
to identify a subset of highly informative tSNPs in the ABCC5 gene that would 
represent the majority of haplotypes segregating at this locus in the different 
populations.  For each non-African population, only 4 tSNPs were sufficient to 
represent the majority of ABCC5 haplotypes, with ~10% reduction in power to detect 
associations compared to direct assays of all 16 high minor allele frequency (>5%) 
SNPs (Table 14).  However, the panel of 4-tSNPs that generate the maximum 
haplotype r2 value in one non-African population generated lower haplotype r2 value 
in other populations.  Hence, common panels of 4-tSNPs for all the 4 non-African 
populations would result in ~10% loss in associative power (Table 14).  In order to 
have a tSNP panel useful for all 5 populations with less than 10% loss of associative 
power, 6 tSNPs were necessary (Table 14).  This requirement is also partly due to the 
fact that for the African American population, a minimum of 6 tSNPs are necessary to 
achieve >90% associative power.  The identification of tagging SNPs is a useful tool 
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in association studies, potentially reducing genotyping effort by 50-70% and avoiding 
repeated testing of individual loci for association, which may lead to problems related 
to multiple testing and reduction of overall power if all ten SNPs were genotyped 
simultaneously.  The results of 4-6 tSNPs at the ABCC5 gene locus in the different 
ethnic groups is consistent with previously reported number of tSNPs required at 
other gene loci in other populations (Johnson et al. 2001; Weale et al. 2003).   
 
 151
Genetic Characterization of Nucleotide Analogue Transporters ABCC4 and ABCC5 Gene Loci 
V GENERAL DISCUSSION 
Chapter 12 Concluding remarks and perspectives 
12.1 ABCC4 and ABCC5: partners in crime or chalk and cheese? 
There is a strong genetic component in how humans respond to drugs and xenobiotics. 
The interplay between drugs and the human genome (or pharmacogenomics) is 
therefore of immense interest in the fields of medicine and science. Single nucleotide 
polymorphisms, (SNPs) occurring randomly throughout the genome, may contribute 
to the genetic differences between individuals that influence the pharmacokinetics of 
drugs and hence inter-individual response to drugs. These polymorphisms affect not 
only metabolic enzymes such as phase I enzymes (cytochrome P450 isoenzymes) and 
phase II enzymes (N-acetyltransferase (NAT), glutathione S-transferase (GST) etc.) 
but also drug transporters as well. The MDR1 represent the classical representative of 
the ATP-Binding Cassette superfamily of transporters. Based on structural homology, 
the ABCC4/MRP4 and ABCC5/MRP5 share a P-glycoprotein-like core with MDR1 
i.e. two nucleotide-binding domains (NBDs) and two membrane spanning domains 
(MSDs).  Like MDR1, ABCC4 and ABCC5 are ubiquitously expressed in different 
cell types and tissues. For example, all three transporters are expressed in brain 
microvessel endothelial cells that form the blood–brain barrier (BBB) (Zhang et al. 
2000).  If polymorphisms within the MDR1 gene have been associated with 
variability in protein expression, plasma drug concentrations, drug-induced side 
effects, and drug response (Hoffmeyer et al. 2000; Hitzl et al. 2001; Kim et al. 2001; 
Sakaeda et al. 2001), it is reasonable to assume that polymorphisms within ABCC4 
and ABCC5 may also play an equivalent role in accounting for functional differences. 
ABCC4 and ABCC5, the subjects of this thesis, stand out from the rest of the ABC 
transporters in having a common ability to confer resistance to cyclic nucleotides 
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adenosine 3',5'-cyclic monophosphate (cAMP) and guanosine 3',5'-cyclic 
monophosphate (cGMP) as well as several nucleotide analogues.  These findings 
suggest that ABCC4 and ABCC5 as membrane transporters may be involved in the 
cellular homeostasis of natural nucleotides as well as having a protective function 
against the assault of nucleoside analogues.  The initial studies demonstrating efflux 
of nucleoside monophosphate analogues such as 9-(2-
phosphonylmethoxyethyl)adenine (PMEA), 6-mercaptopurine and thioguanine in 
cells overexpressing ABCC4 and ABCC5 proteins postulated that other structurally 
similar antiviral and antineoplastic nucleoside analogues in clinical use were likely 
substrates.  In particular, 6-mercaptopurine and thioguanine, two thiopurine analogues 
of the naturally occurring bases hypoxanthine and guanine, are cytotoxic agents 
important in the treatment of childhood leukaemias and there is cross-resistance 
between them.  Other therapeutic agents in clinical use have also been shown to be 
substrates or inhibitors of these 2 drug transporters (Table 16).  These two transporters 
may therefore work in tandem to actively extrude these drugs out of the cell. Some 
publications have reported upregulation and wide interindividual variability in ABCC4 
and ABCC5 mRNA and protein expression in various pathological states such as 
ischemic (ICM)/dilated (DCM) cardiomyopathy; small (SCLC)/non-small cell lung 
cancers (NSCLC); progressive familial intrahepatic cholestasis (PFIC); neuroblastoma; 
paediatric leukaemias and ductal pancreatic carcinoma (Sampath et al. 2002; Dazert et 
al. 2003; Savaraj et al. 2003; Keitel et al. 2005; Konig et al. 2005; Norris et al. 2005) 
with low expression in control/normal tissues.  These findings have importance in the 
clinical treatment of leukaemias, human immunodeficiency virus 1 infection, hepatitis 
B viral infection, erectile dysfunction, just to name a few.   
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With their unique substrate profiles and ubiquitous expression, these two transporters 
therefore represent good candidate genes for association studies.  It is not known 
whether the similarities between ABCC4 and ABCC5 are also extended to the genetic 
structures as well. This thesis therefore devised a series of studies that make use of 
polymorphisms to characterize the genetic profiles of these two genes for future 
association studies as well as compare the population genetics governing the 
architectures that underlie the genomic region surrounding these 2 genes. 
Using a new multiplex minisequencing technique developed for the following studies, 
selected polymorphic markers were genotyped across the genetic loci of ABCC4 and 
ABCC5. Linkage disequilibrium was assessed between pairs of genetic loci using two 
measures of LD, D’ and r2. At the ABCC5 gene locus, the half-length LD blocks 
(LD0.5) of populations of non-African ancestry were between 144 – 293 kb with that 
of African Americans at 106 kb (Table 17). At the ABCC4 gene locus, the half-length 
LD blocks of populations of non-African and African ancestry were half those at 
ABCC5, measuring 51 – 58 kb and 48 kb respectively. This is in spite of the fact that 
the genetic length of the ABCC4 locus (282 kb) assessed is more than twice that of 
ABCC5 locus (103 kb).  Since D’ is an indicator of recombination rates, ABCC5 must 
reside in a sequence of much lower recombination rate than ABCC4. When r2≥0.3 
was utilized as a threshold for useful LD in association studies, useful LD was found 
to extend beyond the entire 100 kb of the ABCC5 gene locus in all five populations 
while it was limited to 37 - 77 kb in ABCC4 locus (Table 17). Associative power 
would therefore be greater studying SNPs in ABCC5 than in ABCC4.  On the other 
hand, demonstration of association would refine a smaller region likely to harbor the 
disease or functional variant within the ABCC4 gene loci because linkage 
disequilibrium extends for shorter distances compared to the ABCC5 gene. Although 
 154
Genetic Characterization of Nucleotide Analogue Transporters ABCC4 and ABCC5 Gene Loci 
it is possible to use pair-wise measures such as r2 in regions of strong LD such as 
ABCC5 for association analysis, multi-locus haplotype analysis is expected to be a 
more powerful strategy for regions of low LD such as ABCC4. 
From the above observations, it is apparent that ABCC5 gene locus is in a region of 
strong LD while ABCC4 gene locus has a weak LD profile. This conclusion is also 
extended to the haplotype profiles of the 2 transporters. In terms of number of 
haplotypes which were inferred from 16 SNPs in the ABCC5 gene locus, 26 – 35 and 
55 haplotypes were found in populations of non-African and African descent 
respectively. This indicates that a small degree of recombination has taken place. In 
total 130 unique ABCC5 haplotypes were obtained. In contrast, 100 - 151 haplotypes 
were inferred from 25 ABCC4 SNP markers in the non-African and African American 
populations respectively, with a total of 536 unique haplotypes in all populations 
(Table 16). While it was difficult to assess the degree of recombination between the 
two regions, the percentage of these observed haplotypes inferred was compared 
against expected haplotypes, simulated from a simulated population of the same 
sample size and observed allele frequency under maximum random association. Not 
surprisingly, the reduction in predicted haplotype number in the ABCC4 gene locus 
(52.1 - 75.6%) was less aggressive than in ABCC5 gene locus (13.2 - 30.9%). The 
most common haplotype in ABCC5 accounted for 27 - 40% of total alleles in each 4 
non-African population and 22.9% in the African American population while the 
highest haplotype frequencies of each of the 4 non-African population and African 
population at the ABCC4 gene locus accounted for only 4.6 – 11.9% and 3% 
respectively. 
Due to the greater haplotype diversity derived from the variable LD pattern in ABCC4 
gene locus, more tagging SNPs (tSNPs) were needed to account for the majority of 
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the diversity observed in ABCC4 than in ABCC5. Compared to 6-10 tSNPs needed for 
ABCC4, just 4-6 tSNPs were required to represent 90% of all the observed haplotypes 
in ABCC5.  
These results allow one to conclude that the underlying LD and haplotype structures 
of ABCC4 and ABCC5 are extremely different.  Indeed, current evidence indicates 
that the biological functions of ABCC4 and ABCC5 are probably unique to one 
another.  ABCC4 gene maps to 13q32 and covers a large genomic region of 282 kb. 
ABCC5, in contrast, maps to 3q27 and its gene locus of 103 kb is less than half the 
size of ABCC4.  Despite sharing a similar protein structure, the ABCC4 protein is only 
36% identical with the ABCC5 protein.  The relationship between ABCC4 and ABCC5 
is akin to that of MDR1 and ABCC1/MRP1: drug transporters with considerable 
overlap in their substrate specificities, but retaining individual differences in substrate 
affinities and profiles.  For example, the ABCC5 protein has a higher affinity for 
cGMP than the ABCC4 protein (Jedlitschky et al. 2000) while irinotecan and 
methotrexate are substrates of ABCC4 but not ABCC5  (Rius et al. 2003; Norris et al. 
2005).  The level of ABCC5 mRNA expression in most tissues was also shown to be 
much higher than ABCC4 (Kool et al. 1997).  
Currently, there are few published studies on the evaluation of polymorphisms with 
regards to functional activities of ABCC4 and ABCC5 and it is likely that future 
studies will be directed towards using polymorphic markers to determine association 
to drug response, especially those of nucleotide analogues.  With the tools developed 
through this thesis, it is hoped that more information can be gained through 
associating ABCC4/ABCC5 haplotypes with drug response, and thereby play a 
supportive role in revealing the similar-yet-different biological functions of these two 
transporters.   
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Substrate Therapeutic Use Substrate Therapeutic Use
  Nonsteroidal Anti-inflammatory Drugs (NSAIDs)   Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
Dipyridamole Platelet Aggregation Inhibition Dipyridamole Platelet Aggregation Inhibition
Indomethacin
Ankylosing Spondylitis, Bursitis, Gout,
Osteoarthritis, Rheumatoid Arthritis,





Osteoarthritis, Pain, Rheumatoid Arthritis
Flurbiprofen Osteoarthritis, Rheumatoid Arthritis












Postoperative Pain, Rheumatoid Arthritis;
Vioxx (MSD) - Withdrawn
  Prostaglandins and Thromboxanes
Prostaglandin PGE1
Alprostadil, the naturally occurring
prostaglandin E1, is a vasodilating agent
and a platelet-aggregation inhibitor.
Erectile Dysfunction, Ductus Arteriosus-
dependent Congenital Heart Disease
(Neonatal)
  Estradiols, analogues and derivatives
E217betaG
As Estradiol: Advanced Prostatic
Carcinoma, Atrophic Vaginitis associated
with Menopause, Female
Hypogonadism, Hypoestrogenism Due
To Bilateral Oophorectomy, Metastatic
Breast Carcinoma, Post-Menopausal
Osteoporosis Prevention, Primary
Ovarian Failure, Primary Ovarian Failure,
Prostatic Carcinoma, Vasomotor
Symptoms associated with Menopause
Leucovorin
Bone Marrow Suppression due to Folic
Acid Antagonism, Colorectal Carcinoma,
Megaloblastic Anemia, Metastatic
Colorectal Cancer, Methotrexate Toxicity,
Pyrimethamine Toxicity, Trimethoprim
Toxicity
Folic acid Folate Deficiency, Folic Acid DeficientMegaloblastic Anemia
ABCC 4 ABCC 5
 
 




Genetic Characterization of Nucleotide Analogue Transporters ABCC4 and ABCC5 Gene Loci 
Substrate Therapeutic Use Substrate Therapeutic Use
  Nucleoside analogues  Nucleoside analogues
Ganciclovir
CMV Retinitis in AIDS Patients, CMV
Retinitis in Immunocompromised
Patients, Prevention of CMV Disease
After Organ Transplant, Prevention of
CMV Disease in Advanced HIV Patients
AZT
HIV Infection, Maternal-Fetal
Transmission of HIV Prevention; Retrovir
(GSK)
3TC Chronic Hepatitis B, HIV Infection; Epivir(GSK)
Ribavirin Treatment of chronic hepatitis B(Schering-Plough)
Adefovir Chronic Hepatitis B; Hepsera (Gilead)
Abacavir HIV Infection
Cladribine Hairy Cell Leukemia
Gemcitabine Non-Small Cell Lung Cancer, PancreaticCarcinoma; Gemzar (Eli Lilly)
Cytarabine
Acute Lymphocytic Leukemia, Acute


















6-Thioguanine Acute Myeloid Leukemia (GSK) 6-Thioguanine Acute Myeloid Leukemia (GSK)
Methotrexate (MTX)
Acute Lymphocytic Leukemia, Breast
Carcinoma, Diffuse Large B-Cell
Lymphoma, Head and Neck Carcinoma,
Juvenile Rheumatoid Arthritis, Lung 
  Uricosuric agents   Uricosuric agents
Probenecid Gouty Arthritis, Hyperuricemia, InhibitRenal Drug Excretion Probenecid
Gouty Arthritis, Hyperuricemia, Inhibit
Renal Drug Excretion
Sulfinpyrazone Chronic Gouty Arthritis, Hyperuricemia Sulfinpyrazone Chronic Gouty Arthritis, Hyperuricemia
  Phosphodiesterase 5 (PDE5) Inhibitors   Phosphodiesterase 5 (PDE5) Inhibitors
Sildenafil Erectile Dysfunction; Viagra (Pfizer) Sildenafil Erectile Dysfunction; Viagra (Pfizer)
  Topoisomerase Inhibitors
Irinotecan Colorectal Carcinoma, MetastaticColorectal Cancer; Camptosar (Pfizer)
Topotecan Ovarian Carcinoma, Small Cell Lung 
ABCC 4 ABCC 5
 
Table 16  (continued). 
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12.2 So, will the real functional variant please stand up? 
Many new challenges and opportunities lie in the wake of the completion of genomic 
sequence of the human race. With information on the position and specific sequence 
of every gene on any chromosome now available, it is now possible to look at a 
multitude of genes and investigate levels of interactions amongst sets of different 
genes simultaneously, instead of being limited to individual genes. The greater power 
of resolution has also enabled molecular biologists and geneticists to perform analysis 
of genome-wide scale investigations. Furthermore, as a drive to study the 
interindividual variation in different human populations, different polymorphisms and 
different transcripts of each gene can now be compared and scrutinized. As a result, 
the next major challenge is the analysis of these huge volumes of information in ways 
that allow interpretation and conclusion.  
 
Identifying sites of functional significance 
The objective of pharmacogenetics is to identify potential sites of functional 
significance in drug response. To help achieve this objective, this thesis outlined a 
series of strategies from development of a genotyping assay to linkage disequilibrium 
and haplotype analyses to detection of recent positive selection. The strategies were 
designed with a view to reduce redundancy as well as enhance power and efficiency 
for association studies. Association studies examine candidate marker loci or genes 
among affected individuals and unrelated unaffected control subjects and are therefore 
one of the easiest way of testing for potential sites of functional significance. The real 
question is how to obtain at least a suitably small subset of marker loci amongst the 
huge number of reported polymorphic SNPs, many of which are neutral and 
redundant, for association studies without losing resolution. The strategies used in this 
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thesis to drive the search of functional variants within two members of the human 
ATP-Binding Cassette (ABC) transporter superfamily of transporters, ABCC4 and 
ABCC5 are summarized here. 
 
Developing a robust genotyping assay 
Pharmacogenetics and genetic association studies require the analysis of multiple 
DNA segregating sites in large human sample pools. The work in this thesis is purely 
focused on profiling of single nucleotide polymorphisms (SNPs) and genetic 
characterization in and around candidate gene loci through the establishment of 
linkage disequilibrium and haplotype structures in different ethnic populations. In 
anticipation of such demands, the choice of having an appropriate genotyping method 
of sufficient throughput and affordability for a small laboratory is crucial. 
The candidate gene chosen for the development of such a genotyping assay was 
multidrug resistance 1 (MDR1) gene, the most well-known member of the ATP-
binding cassette superfamily. Encoding P-glycoprotein which has been shown to 
efflux a wide array of xenobiotics and drug molecules, the MDR1 gene contains 
several polymorphisms. Differences in SNP allele and haplotype frequencies amongst 
populations had been reported (Kim et al. 2001; Tang et al. 2002). Moreover, there 
were conflicting observations of associations linking individual SNP alleles with 
MDR1 expression profiles and drug concentration. A robust and rapid multiplex 
genotyping assay was developed to facilitate the establishment of MDR1 haplotypes 
(see Chapters 6 and 9). As was discussed in Chapter 1, minisequencing or SBE is a 
robust assay that allowed the flexibility of genotyping multiple SNP loci 
simultaneously. The cost effectiveness of this multiplex minisequencing technique 
was particularly attractive. Simultaneously amplifying multiple target sites using 5-20 
 161
Genetic Characterization of Nucleotide Analogue Transporters ABCC4 and ABCC5 Gene Loci 
ng of genomic DNA, multiplexing the minisequencing SNP detection step and 
reducing reaction volumes, seven MDR1 SNP loci were successfully and 
unambiguously genotyped (see Chapters 6 and 9). All probes used in this method 
were normal or HPLC purified oligos. No expensive labeled probes were needed. 
Allelic differentiation of minisequencing products was performed by capillary 
electrophoresis, on a highly-efficient and automated platform which was additionally 
capable of dideoxy sequencing. Further cost savings could be achieved through whole 
genome amplification (Hawkins et al. 2002) and DNA sample pooling. The 
application of this genotyping assay for haplotype analysis has been extended from 
MDR1 (Gwee et al. 2003; Lee et al. 2004a; Tan et al. 2004; Tang et al. 2004), to 
several other members of the ATP-Binding Cassette family, ABCC1/MRP1 (Wang et 
al. 2005), ABCC4/MRP4 (see Chapters 7 and 10), and ABCC5/MRP5 (see Chapters 8 
and 11) (Gwee et al. 2005). This genotyping assay is uniquely positioned for future 
association studies of ABCC4 and ABCC5. A maximum of 10 tagging SNPs was 
found through LD and haplotype analyses of both genes. With the genotyping assay’s 
ability to handle at least 10 SNPs (Tables 8 and 9), a single panel can be designed to 
probe these tSNPs in both case and control populations.  Furthermore, many of the 
PCR and minisequencing primers designed for previous panels can be reused in this 
new panel. 
Like all genotyping methods, the assay developed here is not without its limitations. 
Primer design is of importance.  Interaction amongst multiple PCR primers should be 
minimized using various primer design programs available such as Vector NTI primer 
design program used in this thesis. Short amplicons reduce the possibility of 
nonspecific binding and reduce time for amplification. On the other hand, PCR of a 
single amplicon of relatively long size (~2 kb) is preferable to the amplification of 
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many short fragments.  Amplicons with high GC content are best amplified separately 
from the amplicons with moderate or low GC content. It is, however, possible to 
amplify multiple GC-rich fragments in a single tube, with additives facilitating DNA 
denaturation. Amplification takes the most amount of time in this genotyping assay – 
40 cycles of thermal cycling was required for almost all genotyping panels and 
random samples were monitored by gel electrophoresis.  The design of the 
minisequencing primer is fixed by the position of the polymorphic site investigated. 
There are 2 directions at which the 3’ end of primer probe can anneal and the one that 
produces less secondary structures usually gives better results. The length of the 
minisequencing probe can be altered by the addition of non-homologous tails which 
are predicted to have minimal secondary structures. The addition of poly (dGACT) 
tails was standardized in studies conducted in this thesis, although poly (dT), poly 
(dA), and poly (dC) worked just as well. The use of 5’ poly (dT) tails is not 
recommended as they may interfere with the addition of 3’ ddATP.  The mobility of 
an oligonucleotide in capillary electrophoresis is determined by its size, nucleotide 
composition, and dye.  While a difference of 4–6 nucleotides between minisequencing 
primer lengths is recommended as a guideline, it is difficult to predict the exact time 
at which the minisequencing products will be eluted.  For an example, the genotyping 
results showed that the time lapse between products from short minisequencing 
primers of say, 20 bp and 24 bp appeared to be much quicker in the electropherogram 
than the time lapse between products from long minisequencing probes of 40 bp and 
44 bp. As such the difference in lengths of shorter minisequencing primers were 
usually designed to be greater than the difference between longer minisequencing 
probes (Tables 8 and 9). The dye-labeled ddNTPs are of different molecular weight 
and therefore products coupled with different ddNTPs migrate differently. When 2 
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primer lengths are designed too closely and there may be a serious overlap of peaks, 
confusion may arise as to the identity of SNP locus especially in the case of 
heterozygous samples. Better results were also achieved when the melting 
temperatures of the longer minisequencing probes were designed to be higher than 
those of the shorter ones. 
Capillary electrophoresis is sensitive to contaminants inside the reaction mix. When 
normal oligos of lengths greater than 45 bp were used, the background noise increased. 
Aside from cost, the preparation of minisequencing primers to be purified by HPLC 
took a longer time.  Throughout the course of genotyping ABCC4 and ABCC5 SNPs, 
it was found that there was wide variability in the concentrations of minisequencing 
probes needed to achieve similar peak heights in the electropherogram, as the 
annealing efficiencies of the individual probes differed.  Peak height correlated with 
amount of minisequencing probes used. Amounts of probes therefore had to be 
carefully titrated in each panel to achieve peaks of similar intensity. 
While this method is potentially capable of genotyping 13 or more SNPs 
simultaneously (Krone et al. 2002) and this study has achieved the genotyping of 10 
ABCC4 SNPs in a single panel (Table 9), genotyping beyond 10 SNPs in a single 
panel gets increasingly difficult. Optimizing multiplex PCR can be time-consuming 
and arduous.  Moreover the addition of every SNP locus to be investigated often 
means re-optimizing the proportions of minisequencing probes. In this thesis, nearly 
500 samples were analyzed for every genotyping panel.  Any concerns of 
contamination from other samples, operator mistakes and false calling had to be 
addressed by re-sequencing random samples.  Some form of automation such as the 
use of robotic arms could eliminate some of these concerns and increase overall 
efficiency but these instruments are too expensive for the average laboratory. 
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For a truly high throughput setting required for the simultaneous survey of even larger 
number of SNPs within multiple genes or across large genomic regions, there is a 
need to scale up from a 96-well liquid-based format to a multiplexed, microarray 
based platform. The use of high-density oligonucleotide arrays containing thousands 
of oligonucleotide tags based on the principle of minisequencing has been published 
in several publications (Fan et al. 2000; King et al. 2004) and the study of population-
specific haplotypes using such arrays has also been reported to be successful (Raitio et 
al. 2001; Jain et al. 2003).  While there is certainly a disparity in terms of throughput 
capabilities between industrial companies and small academic laboratories, the 
average small academic laboratory should be flexible and creative in finding 
innovative ways to adopt the existing large-scale genotyping methods.  
 
Identifying a subset of SNPs useful for association studies 
Association studies offer a potentially powerful approach to identify genetic variants 
that influence susceptibility to common disease or response to drugs. The traditional 
candidate gene approach has been based on attempts to detect associations between 
single polymorphisms within various candidate genes and phenotypes of interest. 
Unfortunately, many of these studies failed to find any association or are not 
consistently reproducible. One possible reason for the low power to detect significant 
associations and irreproducible results is that the approach in single polymorphism 
analysis adopted in such studies is oversimplistic. An alternative approach in using 
haplotypes or the specific combinations of alleles on an individual chromosome 
(Hoehe 2003) takes into account the interaction of alleles especially when the 
polymorphisms are in close proximity. Haplotype analysis therefore entails the 
simultaneous study of multiple polymorphisms within one gene, as opposed to the 
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study of individual SNPs. The property of alleles at two different genetic polymorphic 
loci having various degrees of association or linkage disequilibrium (LD) can be used 
to identify causative variants adjacent to a set of surrogate markers in LD if the region 
is associated with functional significance such as variable protein expression. Sets of 
SNP loci as surrogate markers in candidate gene regions are chosen such as those of 
ABCC4 and ABCC5 studied here can be used to narrow the location of functional 
variants through linkage disequilibrium analysis. In measuring the strength of linkage 
disequilibrium, it is important to select well-spaced SNPs with relatively high allele 
frequency so that these selected SNPs can be observed in the test populations used. In 
this thesis, the choice of surrogate SNP markers was based on the location at which 
they are likely to exert a functional change, reported allele frequency (if available in 
the public databases at point of investigation) and coverage of the whole gene region. 
This would ensure a greater confidence that any functional variant is likely to be 
within this set of selected SNPs or at least in close proximity and hence high LD with 
any of the markers of this set.  In total, 25 and 16 polymorphic markers were chosen 
to cover the genetic loci of ABCC4 and ABCC5, a genomic distance of 282 kb and 
103 kb respectively. From the genotype allele frequencies, haplotypes were estimated 
using EM algorithm and pair-wise LD measures amongst SNPs were calculated.  
When haplotypes within a region of strong linkage disequilibrium are inferred, a large 
proportion of the diversity of haplotypes can be explained by a few common 
haplotypes and many others with rare haplotype frequencies. As such the majority of 
the diversity within a region can be captured by only genotyping SNPs shared 
amongst the common haplotypes. In contrast, a region of low linkage disequilibrium 
implies that there are numerous haplotypes of low frequencies and will therefore 
require more tagging SNPs (tSNPs). 
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The juxtaposition of contrasting genetic profiles is clearly demonstrated here in this 
thesis. ABCC4 gene locus lies in a genomic region marked by rapidly decaying LD 
amongst SNPs and large numbers of haplotypes while ABCC5 gene locus is in a 
region of strong linkage disequilibrium characterized with few haplotypes.  These 
findings have strong implications for haplotype association studies involving these 2 
drug transporter genes. A genomic sequence or gene locus in investigation such as 
ABCC5 that has a strong LD pattern would require very few surrogate marker loci to 
represent the region, but it requires additional finer mapping to look for the functional 
variant.  This proved to be true in the LD and haplotype analyses of ABCC5 as 
intensive pair-wise LD between ABCC5 SNPs meant that only 4-6 tagging SNPs were 
required to adequately describe the majority of the haplotype diversity with the gene 
locus. Genotyping fewer tagging SNPs for ABCC5 compared to ABCC4 can reduce 
overall time and costs of association studies. In the event that association between any 
of these tagging SNPs and complex trait is to be found, then the genomic region 
surrounding this surrogate marker that has to be re-sequenced for the presence of the 
real functional variant in LD with the marker locus is likely to be large.  These 
additional as-yet-unknown sequence variants will require further investigation. On the 
other hand, ABCC4 with a weak LD pattern requires more surrogate marker loci to 
describe adequately the genomic region, but the functional variant should be in close 
proximity to any marker loci that may show association with a phenotypic change. 
The rapidly declining linkage disequilibrium profile of ABCC4 required more tagging 
SNPs than ABCC5 to explain 90% of the complexity within the gene locus. However, 
this implied that one only needs to search within a shorter genomic region for a 
functional variant if any association with disease / drug phenotype was to be observed 
as compared to the strong LD profile of ABCC5 gene locus.  
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Identifying functional variants though signatures of positive selection 
A lot of effort has been focused at detecting the presence of positive selection during 
the evolution of a gene (Fay et al. 2001; Akey et al. 2004; Altshuler and Clark 2005). 
With the increasing amount of DNA polymorphism data in human and primate 
populations, there is a renewed interest in assessing the neutral theory of evolution. 
Genes such as those of drug enzymes and transporters may confer an evolutionary 
advantage for the organism or certain human populations to adapt to a different 
environment or physiological requirement. Therefore it can be reasonably assumed 
that the drive to attain evolutionary ‘fitness’ in these genes may be positive selection.  
As past selective events may affect the flanking haplotypes of the functional or 
disease variant, the Long-Range Haplotype test (Sabeti et al. 2002) was modified to 
analyze SNPs within the candidate genes. Five human populations were subjected to 
assessment of positive selection to identify population-specific SNPs which may be 
crucial in dictating evolutionary events at the ABCC4 and ABCC5 transporter loci. 
Using the inherent LD underlying a long-ranging haplotype, a polymorphic marker 
SNP i-1 -1015G>A within the 5’ flanking region of ABCC4 gene locus was 
successfully identified, showing significant departures from neutrality. This 5’ 
flanking region could potentially be within the promoter of ABCC4 and of functional 
significance. Importantly the observation of high haplotype homozygosity (2.31) in 
the A allele of SNP -1 -1015G>A was limited to the European American population 
but not four other populations studied (Chinese, Malay, Indian, and African 
American). When subjected to the LRH test, this allele in the European American 
population demonstrated significant departure from neutrality under all four different 
population models and three different recombination rate assumptions (P<0.05). Just 
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as importantly, there was also supportive evidence of recent positive selection using 
an independent population of similar ethnic background. Genotype data were obtained 
from 30 sets of CEPH trios (Utah residents with ancestry from northern and western 
Europe) and it was hypothesized that some evidence of a long-ranging haplotype 
surrounding the A allele of SNP -1 -1015G>A could be detected in nearby SNPs. This 
effort uncovered a SNP that was located 488 bp away and had high associative power 
with SNP -1 -1015G>A (r2 = 0.92 for European American population). The G allele 
of the SNP rs869951 (SNP -1 -527C>G) possessed a high rEHH value and also 
showed significant departures from neutrality. It can be proposed that this SNP is 
under the influence of genetic hitchhiking from the SNP -1 -1015G>A. When 
selective forces acted on the A allele of SNP -1 -1015G>A, the adjacent G allele of 
SNP rs869951 (SNP -1 -527C>G) was in tight linkage disequilibrium with this allele 
and there was insufficient time for recombination. Hence evidence of recent positive 
selection could be demonstrated for this short stretch of genomic region found within 
the putative promoter of ABCC4. 
The web-based transcription binding tool MatInspector 
[http://www.genomatix.de/products/MatInspector/index.html] predicted that the G 
allele of the SNP i-1 -1015G>A resided in a putative binding site of homeobox 
protein engrailed (En1), a conserved sequence that would be abolished if the 
alternative A allele was present. Regarded as developmental genes, the engrailed-1 
(En1) and its other paralog En2 are expressed in the central nervous system from early 
in development to adulthood (Smidt et al. 2003; Simon et al. 2004). They are involved 
in the pattern formation of the mid/hindbrain as well as neurogenesis, neuronal 
differentiation, regulation of apoptosis of mesencephalic dopaminergic (mesDA) 
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neurons (Alberi et al. 2004; Simon et al. 2004). They are therefore implicated in 
neurological disorders such as Parkinson's disease. 
Given this, it is not inconceivable that the transcription factor En1 may directly 
influence the expression of the ABCC4 in the brain and brain capillaries, thereby 
regulating the uptake of neurotoxic xenobiotics and maintaining the integrity of the 
central nervous system. This may also suggest a mechanism for the etiology of 
neurological disorders, interindividual variability in drug responses and adverse 
events of clinically relevant drugs that are ABCC4 substrates. 
This polymorphism SNP -1 -1015G>A within the putative promoter region could 
therefore be of functional importance and warrants further investigation. Inclusion of 
this SNP within the tSNP set of European American population established in these 















Genetic Characterization of Nucleotide Analogue Transporters ABCC4 and ABCC5 Gene Loci 
12.3 Sources of complexity to LD and haplotype studies 
There are several major contributors that may add to the complexity in studying 
linkage equilibrium and haplotype patterns. 
Population diversity  
While most populations share common SNP variants and haplotype patterns inherited 
from the common ancestor population, frequencies of these SNP variants and 
haplotype patterns may be similar or different amongst populations. The greater 
extensive LD and lower number of observed haplotypes in the non-African 
populations at both ABCC4 and ABCC5 supports the “Out-of-Africa” model of human 
evolution which suggests that the former are the descendents of small founding 
subgroups from Africa. With greater haplotype diversity, more tSNPs were needed to 
provide coverage in the African American populations at both loci. Comparing 
amongst the populations of non-African descent was not as simple. As was discussed 
in ABCC5, using Fisher’s exact test and pair-wise Fst tests, the Chinese and Malay 
populations as well as the Indian and European American populations typically 
showed more similarities in allele frequencies between them. This similarity was also 
extended to haplotypes inferred and their haplotype frequencies. This trend was not 
replicated at the ABCC4 gene locus where it seemed that each of the non-African 
population possessed its specific set of haplotypes with varying frequencies. 
Moreover, while similar sets of tSNPs could be found for all non-African populations, 
each population had its own best performing set of tSNPs i.e. with the highest 
haplotype r2.  
The results in this thesis underscore to need to study haplotypes in specific 
populations. In regions of low haplotype diversity and high LD such as that 
surrounding the ABCC5 gene locus where common haplotypes representing diverse 
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human populations are expressed, one could extrapolate findings to another 
population. For example, the data in Malay population closely parallels that in the 
Chinese population so it might seem a good idea to base any results in association 
studies with ABCC5 in one population to the other. All ABCC5 haplotypes in 
populations of non-African descent could be found in the African American 
population, alluding to the possibility of using African American haplotypes to predict 
genotypes of other ethnic background (Evans et al. 2004). On the other hand, very few 
similar haplotypes were shared across populations at the ABCC4 gene locus. 
Predictably, using the haplotype information from the African American population to 
map functional variants for another population would be inaccurate. Therefore at a 
region of variable LD and high haplotype diversity such as that of ABCC4, more 
efforts to include a high-definition LD mapping are needed for each studied 
population in order to obtain any power in association studies.  
 
Genotyping errors and deviation of Hardy-Weinberg equilibrium 
Another issue concerning the application of linkage disequilibrium (LD) and 
haplotype analysis is genotyping errors. Genotyping errors may produce Type I 
results especially if there is a systematic error in calling one genotype over another. In 
familial studies, genotyping errors can appear as Mendelian inconsistency and these 
cases of Mendelian inconsistency can be resolved by either retyping or setting as 
missing data. However such error checks cannot be performed in unrelated 
individuals. To minimize this error, the genotypes should be ensured to be in Hardy-
Weinberg proportions and sample sizes should not be too small. On the other hand, 
SNPs showing deviation from Hardy-Weinberg should not be discarded immediately. 
In cases the violation from HWE is expected for variants close to a susceptibility 
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locus. Nevertheless, the genotyping protocol has to be reviewed and SNPs deviating 
from HWE should preferably be genotyped using a different method to ensure correct 
calling. In this thesis the allele and genotype frequency distributions of several 
polymorphic SNPs deviated from HWE prior to Bonferonni correction for multiple-
locus testing.  Population substructure was ruled out as there was no consistent 
deviation from HWE of genotype data in a single population.  Nevertheless all 
minisequencing electropherograms were rechecked and recalled independently.  
Sequencing random samples as well as samples in which genotypes were too difficult 
to call did not show that there were gross inaccuracies in the genotype data initially 
obtained. 
Additionally this thesis also followed the recommendation in implementing haplotype 
inference programs such as those based on Expectation-Maximization algorithm 
(Arlequin, SNPHAP and TAGIT) that were not as sensitive to deviations of HWE for 
the genetic characterization of ABCC4 and ABCC5 (Niu et al. 2002; Niu 2004) even 
though it must be stated that HWE is one of the assumptions of EM.   
 
 12.4 Future perspectives 
There are many polymorphisms besides nonsynonymous SNPs which are potentially 
functionally important.  Polymorphisms may introduce stop codons and cause a 
premature truncation of protein or be located in splice sites may lead to aberrant 
splicing or cause a complete frameshift (Crawford et al. 2005). Alternatively spliced 
variants have been reported for both ABCC4 and ABCC5.  Lamba et al detected an 
ABCC4 cDNA that contained two additional exons within intron 1.  The inclusion of 
either one or both of these 2 exons produced a frame shift and a premature termination 
codon (PTC).  Of the three major variants, one of them with an additional single exon 
 173
Genetic Characterization of Nucleotide Analogue Transporters ABCC4 and ABCC5 Gene Loci 
1b was a predominant transcript.  Lamba proposed that these conserved PTC exons 
may facilitate translational re-initiation and lead to protein diversity (Lamba et al. 
2003).  
A short transcript, SMRP had been reported by Suzuki et al (Suzuki et al. 1997; 
Suzuki et al. 2000).  First cloned from a cisplatin-resistant human lung 
adenocarcinoma cell line, this transcript corresponds to the 3’ end of the full-length 
transcript of ABCC5 and translates to a protein of only 946 amino acids (instead of 
1437 amino acids from the full transcript of ABCC5/MRP5) and Northern blot 
analysis showed its expression in various tissues (Suzuki et al. 1997).  Low levels of 
SMRP mRNA had been successfully detected in human auricular and ventricular 
tissue samples by real-time PCR (Dazert et al. 2003).  Significant increase of this 
transcript was also observed in samples of patients suffering from ischemic 
cardiomyopathy (ICM) over levels in samples from patients with dilated 
cardiomyopathy (DCM) or nonfailing heart tissues.  Increased levels of expression of 
both ABCC5 and SMRP were detected by real-time PCR in a human nonsmall cell 
lung cancer line after induction of adriamycin and increased mRNA expression was 
also observed in adriamycin-resistant cell lines using RNase protection assay and 
Northern blotting analysis (Yoshida et al. 2001). In another report using Taqman real-
time PCR, no significant correlation could be found between expression of both MRP 
and SMRP in 53 children with de novo acute myeloid leukemia (AML) with overall 
survival or remission rate (Steinbach et al. 2003a). Likewise, this same technique also 
showed no significant association of both ABCC5 and SMRP in 103 children 
diagnosed with previously untreated acute lymphoblastic leukemia (ALL) with poor 
response to chemotherapy and poor prognosis (Steinbach et al. 2003b).  It is unknown 
whether other splice variant forms of ABCC5 exist. 
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Some of these spliced forms of ABCC4 and ABCC5 may give rise to truncated 
proteins that retain the reading frame but have lost parts of functional domains.  There 
are two challenges to this area of study. One is to detect the presence of these alternate 
splice products and investigate whether these proteins are functional or affect normal 
function of the two nucleotide analogue transporters.  The second challenge is to 
elucidate if the polymorphisms can affect the splicing mechanism of ABCC4 and 
ABCC5.  Intronic and synonymous SNPs can be potentially functionally important 
and influence either splicing accuracy or efficiency (Cartegni et al. 2002).  For 
example, it was found that a translationally silent synonymous SNP can result in 
inefficient inclusion of an exon leading to an unstable, inactive protein (Cartegni and 
Krainer 2002). It would be of interest to find out if a polymorphism within ABCC4 or 
ABCC5 causes the alteration of correct splicing patterns and thereby introduces 
phenotypic variability. 
Polymorphisms that reside within the regulatory regions of the genes are also 
important.  SNPs in the promoter can alter the expression of the gene by affecting 
transcription binding while SNPs in the untranslated regions (5’UTR and 3’UTR) can 
affect mRNA stability, translation or transport.  In the putative promoter region of 
ABCC4, this thesis identified one SNP -1 -1015G>A within a long range haplotype 
that is under the influence of recent positive selection and alters a putative binding site 
of a transcription factor.  In the putative promoter region of ABCC5, three novel low-
frequency SNPs were discovered.  The promoters of both the ABCC4 and ABCC5 
genes are not yet characterized and this presents a unique opportunity for research.   
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 12.5 Conclusions 
In the context of candidate gene analysis, this thesis describes a model in which a 
series of strategies designed to facilitate future genetic association studies can be 
adopted. Instead of conventional analysis using single polymorphic variants, the 
objective was to harness information from the dependencies amongst SNPs using 
haplotype association analysis. The establishment of a multiplex minisequencing 
genotyping technique allowed the rapid and robust investigation of multiple 
polymorphic markers around the loci of two nucleotide analogue transporters ABCC4 
and ABCC5. These two genes encode for transporters demonstrated to efflux 
nucleotide analogues useful for antiretroviral therapy and chemotherapy as well as 
other clinically relevant drug molecules. By carefully selecting polymorphic markers 
based on distance and functionality, the LD and haplotype architectures around 
ABCC4 and ABCC5 gene loci were further characterized in five different populations, 
including Chinese, Malay, Indian, European American and African American. The 
two loci exhibited contrasting genetic structures; whereas LD decayed rapidly across 
282 kb of ABCC4, it remained constantly strong across 103 kb of ABCC5 gene. A 
modest number of population-specific tagging SNP sets that best described the 
underlying haplotype structure useful for these genes were also defined. These results 
also demonstrate the capabilities of the algorithms chosen to analyze large number of 
genotype data and across large genomic distances.  
Transporter genes such as ABCC4 and ABCC5 that are involved in xenobiotic efflux 
may be under selective pressures as the migration of early modern humans out of 
Africa to other continents exposed them to new environments, new pathogens and 
new diets. One of the signatures of recent positive selection is the occurrence of a 
haplotype with long range LD given its frequency. The final strategy to detect 
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evidence of recent positive selection singularized the allele A of SNP i-1 -1015G>A 
within the putative promoter region of ABCC4 in an European American population, 
but not other populations. The discovery that selective forces occur in transporter 
genes that may affect drug response in vivo such as MDR1 (Tang et al. 2004), 
ABCC1/MRP (Wang et al. 2005) and ABCC4/MRP4 (Chapters 7 and 10) is also 
important for the study of human evolution and adaptation.  
The flexible model described in this thesis can easily be adopted for haplotype 
association studies of other candidate genes in addition to those involved in drug 
response or human diseases and would therefore augment efforts in disclosing the 
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